Differential Metallothionein Isoform Expression as Biomarkers of Cadmium Exposure in Human Urothelium by McNeill, Rhiannon Victoria
Differential Metallothionein Isoform Expression as 
Biomarkers of Cadmium Exposure in Human 
Urothelium 
 
 
 
Rhiannon McNeill 
 
 
 
Doctor of Philosophy 
 
University of York 
Biology 
June 2017 
 
 
 
 
 
 
 
 
Abstract 
2 
Abstract 
The metallothionein (MT) superfamily consists of 11 genes whose proteins bind to and 
sequester metals within cells. Although the presence of so many isoforms raises the 
possibility of differing metal specificities and functions, they have rarely been 
discriminated in the literature. This thesis investigated the expression and inducibility of 
MT isoforms in normal human urothelium with the aim of determining whether specific 
MT isoforms represent discriminatory biomarkers of cadmium exposure, which has been 
increasingly linked to the development of urothelial cancer (UC) in recent years. 
Specialised techniques already established were used for the cell, tissue and organ culture 
of normal human urothelium. These cultures were exposed to cadmium concentrations 
reflective of in vivo human exposure and analysed using isoform-specific primers and 
antibodies. The results revealed the extent of differential expression of the MT isoforms, 
including preferential metal activation; for example, zinc could highly induce MT-1G 
transcript expression but could only cause minimal transcript induction of MT-1M. This 
demonstrates the importance of distinguishing between all known isoforms when 
determining MT expression. The discriminatory approach used in this thesis allowed the 
identification of two MT-1 isoforms, MT-1A and MT-1M, whose protein induction was 
highly specific to cadmium exposure. Although isoform transcript induction was 
observed to be transient, the protein expression of MT-1A persisted for at least 6 weeks 
post exposure, consistent with a metal sequestration role. Investigation using 
spectroscopic techniques additionally suggested that cadmium could penetrate the 
protective urothelial barrier and enter the underlying urothelial cells, where it may be 
sequestered by MT within these long-lived cells, thus serving as a long-term source for 
chronic exposure. Overall the results suggest that MT-1 isoforms may be useful as 
urothelial biomarkers of cadmium exposure, potentially allowing the identification of 
individuals ‘at risk’ of developing UC and additionally, stratifying a subset of cadmium-
induced UC. 
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Chapter 1: Introduction 
1.1 The Urothelium 
1.1.2 Structure and Organisation 
The transitional epithelial lining of the mammalian urinary bladder is known as the 
urothelium (Hicks, 1975). This specialised epithelium also lines the rest of the urinary 
tract, including the renal pelvis and ureters, and functions to protect the underlying 
tissues. The urothelium has a stratified organisation and comprises 3 distinct cell zones; 
basal, intermediate and superficial cells (Jost et al., 1989; see Figure 1). Superficial cells 
are generally thought of as possessing a highly differentiated phenotype, whereas 
intermediate and basal cells are associated with a less-differentiated phenotype  (Varley 
et al., 2004). A basement membrane separates the urothelium from the underlying 
supportive stromal tissue, whose function is to maintain normal urothelial growth, 
differentiation and maturation (Howlett et al., 1986).  
 
 
Figure 1: Illustrated image of the urothelium. The image shows haemotoxylin and eosin 
staining of a section of ureter, demonstrating the urothelium. The superficial, intermediate and 
basal cell layers are annotated, along with the underlying basement membrane and stromal 
tissue. Scale bar: 25 µm. 
 
Normal urothelium is generally considered to have a low turnover rate and remain in a 
largely quiescent state, with the average urothelial cell reportedly undergoing mitosis 
only 1 - 2 times per year (Marceau, 1990). It is also thought that a small fraction of cycling 
cells exists within the urothelium in order to satisfy any minor renewal requirements. 
Chapter 1: Introduction 
24 
However, quiescent cells are capable of re-entering the cell cycle and proliferating rapidly 
when required, for example upon injury. Evidence has suggested that these cells regulate 
their proliferation and migration via an epidermal growth factor receptor (EGFR)-
mediated autocrine signalling loop in order to close gaps (Varley et al., 2004), supporting 
the observation that the urothelium possesses a high regenerative capacity (Hicks, 1975; 
Jost, 1986).  
 The existence of progenitor cells that are responsible for homeostasis of the human 
urothelium has not been confirmed, but it has been hypothesised that two distinct 
progenitor cell populations are responsible for generation of basal/intermediate cells and 
superficial cells separately (Castillo-Martin et al., 2010). Indeed, tracking of urothelial 
cells using age-related mitochondrial DNA changes demonstrated clonal units spanning 
all cell layers. These clonal cells had the same lineage and included several basal cells, 
leading to the proposal these basal cells may be urothelial stem cells; although it was 
acknowledged that a definitive stem cell marker would be needed for confirmation (Gaisa 
et al., 2011). This is supported by another study that observed the presence of a 
subpopulation of basal cells, characterised by cytokeratin (CK) 14 expression, that 
possessed regenerative properties and could give rise to all cell types of the urothelium 
(Papafotiou et al., 2016). 
 Alternatively, it has been proposed that cells from all layers of the urothelium are able to 
enter the cell cycle and proliferate (Hicks, 1975). Upon injury of the urothelium by 
uropathogenic Escherichia coli (UPEC), proliferation was observed to occur within both 
the superficial and intermediate cell zones, and approximately double the number of 
intermediate urothelial cells proliferated compared to basal (Colopy et al., 2014). 
Additionally, injury has been found to increase transcription of the proliferation-
associated SRY-Box 9 (SOX9) gene in all three urothelial cell zones, coinciding with 
urothelial repair (Ling et al., 2011). It has been suggested that the type of injury to the 
urothelium may also play a role in determining which cellular zone proliferates in 
response, suggesting that the urothelium is not solely populated from a basal stem cell 
population (Balsara and Li, 2017). A recent study has demonstrated that both basal and 
suprabasal normal human urothelial cells are capable of proliferation in vitro, despite 
their origin in the urothelium in vivo (Wezel et al., 2014). Further, both cell groups could 
be stimulated to differentiate and recapitulate a functional urothelium consisting of all 
urothelial cell types. These results suggest that urothelial cell differentiation is determined 
by cellular localisation or niche, rather than being pre-programmed from specific stem or 
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progenitor cell populations, and are further supported by the lack of a clear anatomical 
stem cell niche within the urothelium (Balsara and Li, 2017). 
1.1.3 Barrier Function 
One of the main functions of the urothelium is to accommodate changes in urine volume 
for storage, whilst maintaining a low pressure in the bladder. To achieve this, during 
bladder filling the urothelium ‘unfolds’ and superficial cells are thought to alter their 
morphology in order to accommodate increased urine volume, returning to their cuboidal 
morphology upon bladder emptying (Minsky and Chlapowski, 1978). Other important 
functions of the urothelium include control of permeability, cell-cell communication and 
immune response (Lazzeri, 2006). The urothelium is also essential for the protection and 
defence of the underlying tissue from exposure to urine and pathogens (Zeidel, 1996; 
Negrete et al., 1996; Dozmorov et al., 2007). The urinary tract is one of the main excretory 
routes for the body, and thus a number of potentially harmful compounds are contained 
within the urine (Caldwell et al., 1995). These compounds are filtered out of the blood 
via the kidneys and become concentrated in the urine, which is retained in the bladder 
until such a time that it may be excreted (Krause et al., 2015). Consequently, the 
urothelium can be exposed to toxic substances at high concentrations for prolonged time 
periods (National Research Council US Subcommittee on Biologic Markers in Urinary 
Toxicology, 1995). Thus, it is essential that the urothelium acts as a barrier to prevent 
these toxins from re-entering the body.  
 The urothelium is thought to form one of the tightest epithelial barriers in the body 
(reviewed by Kreft et al., 2010), preventing any trans- or para-cellular passage of toxic 
constituents from the urine into underlying tissue. The urothelium achieves this tight 
barrier via the expression of specific differentiation-associated features comprising 
asymmetric unit membranes (AUM) plaques and tight junctions (TJ), with TJs primarily 
responsible for barrier tightness and acting as a ‘seal’ between cells (Farquhar and Palade, 
1963) . AUM plaques exist on the apical surface of the superficial layer of cells, covering 
around 70 - 90 % of the apical cell membrane. These plaques are composed of integral 
membrane proteins termed uroplakins (UPK), of which there are four major UPK proteins 
and one minor (reviewed by Wu et al., 2009). As AUM plaques exist only on superficial 
urothelial cells they can therefore be used as biomarkers of differentiation and are 
indicative of a functioning urothelial barrier (Sun et al., 1999). Tight junctions exist on 
the most apical part of the lateral membrane of superficial cells and develop during 
Chapter 1: Introduction 
26 
urothelial cell differentiation  (Varley et al., 2006). They consist of proteins including 
occludins and claudins, a number of which are expressed prior to differentiation, but re-
localise during the process. These proteins differ in their kinetics for relocalisation, with 
some proteins relocating before others, which appears to reflect the differentiation 
progression stages in situ. Claudin 3 and zona occludens (ZO)-1 protein expression have 
been identified as the last proteins to localise to their final position at the terminal 
junctions of superficial cells (the ‘kissing point’), and their expression here is therefore 
particularly linked with development of a functional barrier (Smith et al., 2015). 
However, both ZO-1 and ZO-2 are thought to be critical to tight junction development, 
having been implicated in the timing and positioning of claudin polymerisation at tight 
junction strands (Umeda et al., 2006). Urothelial barrier function can be measured using 
transepithelial electrical resistance (TER) in accordance with Ohm’s Law. TER is a 
measure of ionic permeability and accounts for both trans- and paracellular pathways, but 
particularly transcellular solute movement. A reading >500Ω.cm2 is arbitrarily taken as 
the cut-off for a ‘tight’ epithelial barrier, whereas a reading <500Ω.cm2 is suggestive of a 
‘leaky’ epithelia, where urine constituents may reach underlying tissues and cause 
conditions such as vesical ischemia (Frömter and Diamond, 1972; Hohlbrugger, 1996).  
1.1.4 In Vitro Models of Human Urothelium 
Prior to the use of human-derived urothelial cells, animal models were regularly used to 
investigate the urothelium. Although these proved useful in understanding basic 
physiology and the development of cancer (Cohen et al., 1983; Owens, Wei, & Smart, 
1999), there are inherent species differences which mean that animal models are not ideal 
for studying human bladder carcinogenesis (reviewed by Crallan et al., 2006). 
Researchers therefore began to establish human urothelial cell lines. A number of human 
urothelial cancer cell lines exist which can be used to study tumour cell behaviour, as 
compared by Masters et al. (1986) and Nickerson et al. (2016). To understand the initial 
events leading to carcinogenesis, normal human urothelial cell lines have also been 
developed from normal human urothelium. However, a number of these cell lines have 
been genetically modified to become immortalised; for example, the UROtsa cell line 
was immortalised using a SV40 large T-antigen construct (Petzoldt et al., 1995), which 
disables both the p53 and Rb tumour suppressor proteins (Kao et al., 1993). Therefore, 
although immortalised cell lines are readily available and useful for maintaining long-
term culture, they are no longer genetically ‘normal’. This presents a problem in that the 
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early genetic changes responsible for initiating carcinogenesis may already be altered due 
to the process of immortalisation, and regular cellular processes, such as growth 
suppressing feedback loops, already altered. For example, immortalisation of normal 
human urothelial cells with human telomerase reverse transcriptase (hTERT) results in 
compromised differentiation ability and functional capacity, possibly due to inhibited p16 
expression (Georgopoulos et al., 2011). To investigate early carcinogenic events it is 
therefore important to use urothelial cells that have not been genetically manipulated, and 
that reflect in vivo cells as closely as possible (reviewed by Crallan et al., 2006).  
 For this thesis, finite normal human urothelial (NHU) cell lines were utilised. NHU cells 
are non-immortalised, ex vivo cells that are obtained via isolation from surgical biopsies 
and grown in culture (Southgate et al., 1994). Once in culture, the cells adopt a 
proliferative phenotype and can be serially passaged with a finite lifespan of between 20-
30 population doublings (Chapman et al., 2006). Cultures are grown in low calcium, 
keratinocyte serum-free medium (KSFM) completed with bovine pituitary extract and 
epidermal growth factor, and supplemented with cholera toxin (Southgate et al., 1994; 
Southgate et al., 2002). Proliferating NHU cells lack protein markers associated with 
differentiation, but express markers associated with basal and intermediate cells such as 
cytokeratin (CK) 5 (Southgate et al., 1994). Stratification of NHU cells can be induced 
by raising the exogenous calcium concentration, whereupon the cells begin to form layers 
3-4 cells thick and decrease proliferation; however, this is not sufficient to induce 
terminal differentiation as shown by the absence of CK20 and AUM plaques (Southgate 
et al., 1994) and the absence of a functional barrier (Cross et al., 2005).  
 NHU cells can be stimulated to differentiate by the addition of adult bovine serum and 
increasing the exogenous calcium concentration to physiological conditions, resulting in 
inhibition of proliferation and formation of a cell sheet with a ‘tight’ urothelial barrier. 
(Cross et al., 2005). This “biomimetic” model is comprised of 3-7 cell layers, including 
superficial ‘umbrella’ cells (so-called due to their ability to contract and expand; section 
1.1.3), and subsequently displays differentiation-associated protein markers such as 
CK20 and claudin (CLDN) 7 (Cross et al., 2005). 
1.1.5 Organ Culture 
Although the use of NHU cells is preferable to the use of genetically altered, immortalised 
cell lines, the in vitro approach is still limited. The environment these cells are cultured 
in is artificial and not truly reflective of physiological conditions, with usually only a 
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single cell type present meaning cell architecture is lost. Intercellular signalling also tends 
to be impaired due to cell densities typically being lower than 1 % of a tissue environment 
(Hartung and Daston, 2009). A possible way to overcome these problems is the use of 
organ culture, which involves removing organ tissue from the human body and growing 
it in vitro (Carrel, 1937). Organ cultures can be maintained for extended periods of time, 
as long as the correct media, substrate and environment are provided (Resau et al., 1991). 
Another benefit of using an organ culture approach includes retention of tissue 
architecture and representation of pathological features. As tissue is used it also means 
that multiple cell types are present, resulting in cell-cell interactions and preservation of 
cell morphology and function (Ozaki and Karaki, 2002). Organ cultures are particularly 
suited for use in carcinogenic studies where in vivo study is not ethically possible, and 
involve exposing human tissue to a relevant dose of carcinogen and determining 
subsequent morphologic and molecular changes. A protocol for maintaining 3-
dimensional organotypic cultures of ureter has previously been developed (Scriven et al., 
1997; Varley and Southgate, 2011). Ureter organ culture allows the urothelium to be 
studied under conditions which are more reflective of in vivo conditions, and also enables 
communication between urothelial cells and the underlying stroma. The use of organ 
culture in the study of urothelium therefore provides a novel insight into the consequences 
of human exposure to carcinogens that in vitro work alone could not provide. However, 
the disadvantages of using this approach are that cell numbers cannot be expanded, and 
replication of results can be problematic due to inherent heterogeneity.  
1.2 Urothelial Cancer 
1.2.1 Grading and Staging of Tumours 
Around 90-95 % of bladder cancers are urothelial carcinomas, with the remaining 5-10 % 
presenting mostly as squamous cell carcinomas or adenocarcinomas (Montironi et al., 
2016). Urothelial tumours are classified by both staging and grading, using different 
classification systems. The staging of a tumour refers to the depth of invasion, and 
urothelial cancer is most often staged using the Tumour-Node-Metastasis (TNM) system 
(Sobin et al., 2009). Grading of tumours is used to evaluate cytologic and/or growth 
pattern characteristics, and is classified using the World Health 
Organisation/International Society of Urological Pathology criteria (Eble et al., 2004). 
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Graphical representation of the staging and grading systems is depicted below (Knowles 
and Hurst, 2015). 
 
 
Figure 2: Urothelial cancer staging and grading. Staging of bladder tumours is performed 
using the Tumour-Node-Metastasis (TNM) system depending on the depth of invasion. Each 
T-stage is shown above and tumour-depth indicated. Grading of bladder tumours is performed 
according to the World Health Organisation (WHO)/International Society of Urological 
Pathology (ISUP) 2004 criteria, and based on cytologic and/or growth pattern characteristics. 
PUNLMP = Papillary Urothelial Neoplasm of Low Malignant Potential. Figure adapted from 
Knowles & Hurst (2015). 
 
1.2.2 Classification of Urothelial Cancer 
1.2.2.1 The Two-Pathway Model 
Urothelial carcinomas are currently segregated into two groups based on their level of 
invasiveness and unique molecular profile, as summarised in Figure 3A. Tumours are 
classified as either non-muscle invasive (NMI; includes Tis, Ta and T1) or muscle-
invasive disease (MI; includes T2, T3 and T4). These groups are associated with specific 
genetic signatures representing the different molecular pathways of urothelial cancer, and 
demonstrate distinct histopathological phenotypes and clinical behaviour (Cordon-Cardo, 
2008). The majority of bladder cancer diagnoses are NMI (~75 %) and 5-year survival is 
~90 %; however, these tumours frequently recur (70 %) and around 10-15 % progress to 
an invasive form (Prout et al., 1992). High frequency of recurrence is one of the main 
reasons why bladder cancer has the highest lifetime treatment costs of all cancers (Sievert 
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et al., 2009). MI bladder cancer presents less often (~20 %) but has a poor prognosis, with 
5-year survival <50 % (Cheng et al., 1999). Furthermore, ~50 % patients will go on to 
develop metastasis (Knowles and Hurst, 2015).  
 One of the most frequently mutated genes associated with the development of NMI 
bladder cancer is fibroblast growth factor receptor-3 (FGFR3), with up to 80 % of Ta 
tumours demonstrating activating point mutations in this gene (Billerey et al., 2001). The 
PI3-kinase (PI3KCA) gene has also been reported mutated in up to 10 % of NMI tumours, 
and a subset of tumours can harbour mutations in both FGFR3 and PI3KCA (López-
Knowles et al., 2006). The other gene mutation commonly associated with NMI bladder 
cancer is that of human RAS, presenting in ~18 % NMI disease (Prior et al., 2012; 
Knowles and Hurst, 2015). By contrast to PI3KCA, RAS mutation appears mutually 
exclusive with FGFR3 alterations; mutations in one or the other gene are present in >82 
% of NMI bladder cancers (Jebar et al., 2005). In addition to these gain-of-function 
mutations associated with NMI disease, deletions in chromosome 9 are also common 
(Gibas et al., 1984; Smeets et al., 1987) resulting in the loss of genes such as the 
postulated tumour suppressor Tuberous Sclerosis-1 (TSC1; Hornigold et al., 1999). 
Chromosome 9 deletions have also been reported in histologically normal urothelial 
samples, suggesting that these alterations may be an early event in the development of 
carcinogenesis (Stoehr et al., 2005). Interestingly, in the small subset of MI tumours 
presenting with FGFR3 mutations, a high deletion frequency of the chromosome 9 gene 
cyclin-dependent kinase inhibitor (CDKN) 2A has also been observed (Rebouissou et al., 
2012). CDKN2A codes for the tumour suppressor p16, and thus this observation may 
identify a possible pathway of progression for NMI tumours to MI disease.  
 In contrast to NMI bladder cancer, the mutations most commonly seen in MI disease are 
loss-of-function. Moreover, these defective mutations usually occur in tumour suppressor 
genes, and almost every MI tumour presents with mutations in G1 cell cycle checkpoint 
genes. The tumour suppressor genes most frequently associated with the development of 
MI bladder cancer are Tumour Protein-53 (TP53), Retinoblastoma (Rb) and Phosphatase 
and Tensin Homologue (PTEN; reviewed by Castillo-Martin et al., 2010). The mutation 
of such genes allows an accumulation of genetic abnormalities, due to the development 
of genetic instability and anti-apoptotic effects preventing normal cellular function. TP53 
in particular is responsible for controlling apoptosis-regulatory genes, along with DNA 
damage recognition and response. Unusually, loss of TP53 appears to occur as an early 
event in urothelial cancer (Harney et al., 1995), whereas in other cancer types it is usually 
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associated with late carcinogenesis (Fearon and Vogelstein, 1990; Rivlin et al., 2011). 
Indeed, in urothelial cancer it has been reported that TP53 mutations can be correlated 
with tumour stage and grade, as well as with patient outcome (Sarkis et al., 1993).  The 
Rb protein acts as a cell cycle regulator, and mutations in this gene can result in 
undetectable protein levels which have been correlated with poor patient outcome and 
aggressive clinical disease behaviour (Cordon-Cardo et al., 1992; Cordon-Cardo et al., 
1997). Mutation of the tumour suppressor PTEN has also been identified as an 
independent prognostic factor for overall patient survival (Puzio-Kuter et al., 2009). 
Moreover, in advanced MI bladder cancer, a synergistic tumour suppressor relationship 
between PTEN and TP53 has been found in relation to inactivation of the senescence 
pathway (Cully et al., 2006; Puzio-Kuter et al., 2009).   
 To summarise, the evidence suggests that oncogenic gene activation drives cellular 
growth resulting in the proliferative-type lesions associated with NMI disease. In contrast, 
the malignant tumours associated with MI disease arise due to the loss of tumour 
suppressor genes. However, there appears to be some cross-over between the pathways, 
with a small number of cases with oncogenic activation also losing tumour suppressor 
function and progressing to a more malignant, invasive disease. 
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Figure 3: Summary of current and proposed models for the classification of urothelial cancer. 
(A) The currently used two-pathway classification model. The model is based on level of 
invasiveness and genetic profile. ~75 % tumours present as non-muscle invasive (NMI) disease 
(grades Tis, Ta and T1), whereas ~25 % tumours present as muscle-invasive (MI) disease (grades 
T2, T3 and T4). The most commonly mutated genes associated with NMI disease are FGFR3, 
PI3KCA and RAS; MI disease is associated with mutations in the p53, Rb and PTEN genes. ~10-
15 % NMI disease will progress to an invasive form, and it is hypothesised that this may be 
associated with loss of p16 expression. Figure adapted from Castillo-Martin et al. (2010) and 
Knowles and Hurst (2015). (B) Proposed novel methods of classifying urothelial cancer based 
on molecular subtypes. Recent genetic studies addressing the heterogeneity in clinical tumour 
behaviour have reported distinct molecular subtypes of urothelial cancer, although a consensus 
has not yet been reached. CCND1=cyclin D1; CCNE=cyclin E1; ERBB2=receptor 
tyrosine- protein kinase erbB2; ECM=extracellular matrix; ELF3=ETS-related transcription 
factor 3; CDKN1A=cyclin dependent kinase 1A; HER2/3=human epidermal growth factor 
receptor 2/3; CD49=cluster of differentiation 49; FOXA1=forkhead box protein A1; 
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GATA3=GATA binding protein 3; E2F3=E2F transcription factor 3; CGARN=Cancer Genome 
Atlas Research Network. 
 
1.2.2.2 Novel Methods of Classification  
Although the literature has prescribed to the two-pathway model of bladder 
carcinogenesis for some time, there is a vast degree of heterogeneity in clinical tumour 
behaviour. Genetic studies are now beginning to address this issue and question the 
usefulness of grouping all urothelial tumours into only two groups (Figure 3B). One of 
the first studies to investigate novel classification methods analysed transcript expression 
in a number of tumours from all grades and stages, and identified 5 major subgroups; 
urobasal A, urobasal B, genomically unstable, squamous cell carcinoma-like and 
infiltrated. Each subtype showed distinct clinical outcomes and differential expression of 
a number of gene families (such as cell-cycle and cytokeratins; Sjödahl et al., 2012). Not 
long after, the Cancer Genome Atlas Research Network (2014) completed an in-depth 
study of the genetic background of bladder cancer, which also produced several new 
insights. As a result of this study and two others, three transcriptional subtypes of MI 
bladder cancer have been defined, all of which demonstrate similarities with breast cancer 
subtypes (Choi et al., 2014; Damrauer et al., 2014). The two major subtypes are that of 
‘basal’ and ‘luminal’, which were characterised by features such as p63 activation and 
FGFR3 mutations respectively. A third subset was also identified and termed ‘p53-like’, 
which was observed to be inherently resistant to treatment with chemotherapy (Choi et 
al., 2014). Recently, a clinical study was performed with the aim of validating the use of 
luminal and basal subtypes. The results supported the use of these subtypes due to the 
distinct molecular signatures and clinical behaviour observed. Moreover, they also found 
that the expression of just two markers (GATA3 and keratin 5/6) was sufficient to identify 
the subtype with >90 % accuracy (Dadhania et al., 2016).  Despite these advances, 
discussions on how best to classify tumours are still ongoing. New molecular insights 
have been provided due to improved Omics technology; for example, the potential 
prognostic value of STAG2 mutations (reviewed by van der Heijden and van Rhijn, 
2014), and these novel insights need to be taken into consideration when evaluating 
classification methods. Currently, the 2-pathway model is still used to define bladder 
cancer, although a recent consensus was reached to recognise the existence of a subgroup 
of tumours termed ‘Basal-Squamous-like’ (BASQ; Lerner et al., 2016). Further large 
collaborative studies such as those performed by Biton et al., (2014) and Rebouissou et 
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al., (2014) are needed in order to reach general consensus on the best way to classify 
bladder cancer, whilst still accounting for heterogeneity of tumour behaviour and novel 
genetic alterations (e.g. the discovery of mutated PPAR-γ by Biton et al., 2014).   
1.2.3 Epidemiology and Statistics  
Europe has one of the highest incidence rates of bladder cancer in the world, with an 
estimated 39 986 men diagnosed in Western Europe alone in 2012; most cases of which 
arise from malignancy in the urothelium. Moreover, mortality rates in affected European 
men were by far the highest observed worldwide (Antoni et al., 2016). Urinary bladder 
cancer has the 4th highest incidence rate in males in the United States, and an estimated 
58 950 new cases were predicted for 2016 (Siegel et al., 2016). Incidence rates tend to be 
lower in women, although sex differences appear to vary greatly between countries, with 
some showing an increasing trend in women (thought to be due to an increase in female 
smoking rates; Antoni et al., 2016). Not only does bladder cancer rank as the 5th most 
common cancer in males in Western countries (Ferlay et al., 2010), but it is one of the 
most costly cancers to treat (Sangar et al., 2005). As discussed earlier (section 1.2.2.1) it 
is thought that the high treatment costs are due to the recurrent nature of urothelial cancer, 
especially the NMI form, which often requires lifelong monitoring as well as multiple 
treatments (Botteman et al., 2003;  Sievert et al., 2009). On average, bladder cancer 
treatment costs the U.K. health economy £ 55.39 million per year. Furthermore, 
individual patient treatment costs are estimated at around £ 8349.2 per year compared to 
£ 7294.2 for prostate cancer (another costly malignancy). Despite the discrepancy in 
treatment costs between cancer types, it has been calculated that around 5-fold more 
money in the U.K. is invested in prostate cancer research than urothelial, with prostate 
cancer research receiving yearly >£20 million compared to the <£5 million received by 
bladder cancer research (Sangar et al., 2005).  
1.2.4 Causes of Urothelial Carcinogenesis 
1.2.4.1 Genotoxic Carcinogens 
A genotoxic carcinogen is a chemical that causes carcinogenesis by directly altering the 
genetic material of a cell (Hayashi, 1992). The most well-known genotoxic carcinogen 
causing urothelial cancer is tobacco smoke (Burger et al., 2013). Ever-smokers are 
predicted to have 2.5 times more risk than non-smokers of developing the disease 
(Cumberbatch et al., 2016), while ex-smokers are estimated to have double the risk 
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(Brennan et al., 2000). In fact, tobacco smoke is thought to be responsible for half of all 
bladder cancer diagnoses (Freedman et al., 2011; Agudo et al., 2012; Park et al., 2014), 
and in some populations it is thought to cause up to 40 % of all bladder cancer deaths 
(Park et al., 2014). The specific causative agents found in cigarettes are thought to 
primarily be chemical carcinogens (aromatic amines, polycyclic aromatic hydrocarbons 
and N-nitroso compounds) and reactive oxygen species (Janković and Radosavljević, 
2007). However, non-mutagenic (see section 1.2.4.2, below) heavy metals have also been 
found present in tobacco, the possible health effects of which have not been sufficiently 
emphasised in the past (reviewed by Chiba and Masironi, 1992). 
 Other causes of bladder cancer may include urinary tract infections such as chronic 
cystitis (Vermeulen et al., 2015) and Schistosoma haematobium, the latter of which is 
thought to cause the disease via chronic irritation and/or altered metabolism resulting in 
elevated urinary levels of carcinogenic metabolites (International Agency for Research 
on Cancer, 1994). Although generally not regarded as a heritable cancer, certain genetic 
factors have also been identified as risk factors for disease development. For example, 
specific polymorphisms in the N-acetyltransferase (NAC) 1 and 2 genes can impair 
detoxification of aromatic amines, leading to elevated production of urinary carcinogenic 
metabolites and consequently an increased risk of developing bladder cancer (Hein et al., 
2000). Lastly, dietary factors can also influence the probability of bladder carcinogenesis. 
High intake of fats, meats and soy have all been found to increase the risk of bladder 
cancer, whereas fruit and vegetables appear to decrease the risk; however most of these 
studies demonstrating this are based on correlation, and to date no study has investigated 
daily food intake and bladder cancer risk (reviewed by Janković and Radosavljević, 
2007). 
1.2.4.2 Non-Genotoxic Carcinogens 
Non-genotoxic carcinogens (NGC) are substances that can cause the development of 
cancer without directly altering the genetic material of a cell (Hayashi, 1992). 
Currently, the most well-known group of toxicants that exert carcinogenic effects via 
secondary mechanisms is that of the heavy metals, which are introduced later in this 
chapter (section 1.3). 
1.2.5 Cellular Origin of Urothelial Carcinoma  
Cancer ‘stem’ cells, or tumour-initiating cells, are cells with the ability to self-renew, 
initiate tumours, and give rise to a more differentiated progeny (Suraneni and Badeaux, 
Chapter 1: Introduction 
36 
2013). The existence of bladder cancer ‘stem’ cells has not been confirmed, but there 
are studies that indicate their existence. In a murine model of urothelial carcinogenesis 
CK14-expressing urothelial basal cells were fluorescently labelled and increased in 
number before the development of neoplasms, 50 % of which then continued to 
demonstrate fluorescence (Papafotiou et al., 2016). This led the authors to believe that 
these CK14-expressing cells were cells of tumour origin, rather than an acquired 
property of carcinogenesis. Another lineage-tracing study using murine models found 
that basal urothelial cells gave rise to MI tumours, whereas superficial/intermediate 
cells gave rise to papillary, NMI tumours (Van Batavia et al., 2014). In humans there 
has also been evidence indicating the existence of different urothelial cancer stem cell 
types, that give rise to different subsets of tumour. Marker combinations that 
corresponded to different urothelial differentiation states could stratify bladder 
carcinomas into clinically relevant subgroups, identifying a tumour subset with basal 
tumour-initiating cells which was found to have the worst patient outcome (Volkmer et 
al., 2012). Findings such as these support the hypothesis that there may be distinct 
progenitor cells for the cell types of the urothelium, which could act as cells of origin 
for bladder cancer resulting in the development of different tumour subtypes. However 
the existence of either urothelial progenitor or stem cells has not been confirmed, with 
contrasting studies suggesting that urothelial cell phenotype is plastic not hierarchical 
(Wezel et al., 2014), and thus the exact cellular origin of urothelial carcinoma remains 
unknown.  
1.2.6 Clinical Management of Urothelial Cancer 
1.2.6.1 Diagnosis 
Haematuria is the most common presenting symptom of urothelial cancer, and diagnoses 
are confirmed using a combination of cystoscopy, biopsy and/or urine cytology (Metts et 
al., 2000). Urine cytology is non-invasive and specific for urothelial cancer, but has 
moderately low sensitivity and cannot be used in isolation (Bassi et al., 2005). In order to 
reduce the frequency of cystoscopy, which is highly-invasive and can negatively impact 
patient life quality (Stav et al., 2004), various other urinary markers have been 
investigated (Yutkin et al., 2010). However due to poor sensitivity and/or expense none 
have yet been introduced into the standard routine of care, and thus cystoscopy and 
cytology currently remain the most important tools for diagnosis (Cheung et al., 2013). 
More recently, the use of Photodynamic Diagnosis (PDD)/Blue-light cystoscopy has been 
Chapter 1: Introduction 
37 
adopted for the detection of inconspicuous urothelial cancers. This approach involves the 
instillation of 5-aminolevulinic acid or hexaminolevulinate (blue dye) into the bladder, 
where it is only absorbed by dysplastic tissue and emits a red colour under a blue reference 
light (Kriegmair et al., 1994; Burger et al., 2009). PDD/blue-light cystoscopy has been 
recommended for initial diagnosis, especially in patients with positive urine cytology but 
negative cystoscopy, and for post-treatment monitoring of patients with CIS or multifocal 
tumours (Witjes et al., 2010). However, despite the method appearing able to detect more 
urothelial tumours than normal cystoscopy (Mowatt et al., 2011), there is as yet no 
evidence confirming that PDD can prevent progression or improve survival of urothelial 
cancer patients. 
1.2.6.2 Treatment 
The first-line treatment for NMI bladder cancer is usually transurethral resection of the 
bladder tumour (TURBT), where the malignant tissue is physically removed. Surgery is 
often followed by an adjuvant course of chemo- or immunotherapy in order to delay 
disease recurrence. Therapeutic agents such as Mitomycin C or Bacillus Calmette-Guerin 
are instilled directly into the bladder either alone or in various combinations (Babjuk et 
al., 2013). For MI bladder cancer, a radical cystectomy (complete removal of the bladder 
and nearby tissue) is the current gold-standard treatment, although radiotherapy is also 
frequently used (Cheung et al., 2013). Ideally, patients will also receive platinum-based 
neo-adjuvant chemotherapy (for example using cisplatin) either before or after 
cystectomy (Vale, 2003).  
1.2.6.3 Treatment Resistance 
Despite urothelial tumours generally being chemo-sensitive (response to front-line 
chemotherapeutic treatment is 50-70 %), patients who suffer a recurrence after initial 
treatment have a very poor prognosis (Yafi et al., 2011). Up to 70 % of NMI tumours will 
reoccur, which may not affect life expectancy, but necessitates life-long monitoring and 
surveillance of the patient which is both costly and detrimental to life-quality (Cookson 
et al., 1997). MI tumours can also still reoccur post-surgery and up to 50 % of patients 
will develop metastasis (Raghavan et al., 1990). Combination therapy with cisplatin is 
the standard treatment for metastatic disease, however tumours are characteristically 
chemo-resistant and progression-free survival varies from 7 – 9 months (Drayton and 
Catto, 2012). Additionally, it has been reported that no matter which combination of 
chemotherapeutics is used, median survival is at best 14 months for patients presenting 
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with MI disease (von der Maase et al., 2005). A deeper understanding of treatment-
resistance is needed in order to develop new treatments that can circumnavigate resistance 
mechanisms, and thereby prolong the survival of patients diagnosed with MI disease.  
1.3 Heavy Metal Exposure 
1.3.1 Examples and Sources of Heavy Metals 
Heavy metals are naturally-occurring metallic elements that have a relatively high atomic 
weight and density compared to water (Fergusson, 1990). Examples include nickel, 
arsenic, lead, cadmium and chromium. Heavy metals are also considered trace elements 
due to existing in trace concentrations in various environmental substances (Kabata-
Pendia, 2001). Their bioavailability in the environment can be influenced by a number of 
factors such as temperature and sequestration (Hamelink et al., 1994), and biological 
factors such as physiological adaptation can also play a role (Verkleji, 1993). Although 
heavy metals are naturally-occurring and usually reside within the earth’s crust, in recent 
years increasing anthropological activities have resulted in environmental contamination 
and human exposure, either via habitation or occupation. Such anthropological activities 
include mining, smelting, coal-burning, and petroleum combustion among others 
(reviewed by Tchounwou et al., 2012). Certain heavy metals such as iron and zinc are 
also essential nutrients and are required for a number of biological functions, with a lack 
of these metals resulting in deficiency and disease (World Health Organisation, 1996).  
1.3.2 Exposure and Correlation with Carcinogenesis 
Five of the heavy metals (chromium, cadmium, mercury, arsenic and lead) show high 
levels of toxicity and remain a public concern. Moreover, they are classified as either 
‘known’ or ‘probable’ carcinogens by the International Agency for Research on Cancer 
(International Agency for Research on Cancer, 1993) and are thought to exert their 
carcinogenic effects in a non-genotoxic manner (see section 1.2.4.2; Tchounwou et al., 
2012). The ability of metal compounds to cause cancer in exposed workers has been 
documented for some time, with the first studies dating back to the 19th century (Salnikow 
and Zhitkovich, 2008). As mentioned above (section 1.3.1), human exposure to such 
carcinogens has increased over recent years due to anthropological activity and increased 
usage of heavy metals in industrial processes. It is currently estimated that up to 5.3 % of 
cancer deaths in Britain is due to occupational exposure to carcinogens and specifically, 
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occupational exposure to heavy metals has been heavily implicated in the development 
of lung, sinonasal, stomach and bladder cancers (Rushton et al., 2012).  
As previously mentioned (section 1.1.3) the urothelium provides a barrier against toxins 
from the urine re-entering the body. However, as urine is concentrated and stored in the 
bladder before excretion, this can result in chronic long-term exposure of the urothelium 
to toxins such as heavy metals. Therefore, the urothelium in particular can be affected by 
exposure to the same. The vast number of studies documenting a link between urothelial 
cancer and exposure to heavy metals reflects this, with one study identifying occupational 
exposure as the second main carcinogenic risk for urothelial cancer after smoking 
(Ouzzane et al., 2014). Another study demonstrated excess mortality for bladder cancer 
in populations living in close vicinity to coal-burning industries, with a relative risk (RR) 
ratio of 1.18 at a 95 % confidence interval (CI; García-Pérez et al., 2009). This 
observation was supported by a later study from the same authors which also found 
increased bladder cancer mortality (RR = 1.11, 95 % CI) in populations living in the 
vicinity of installations for the production of cement, lime, plaster and magnesium oxide 
(García-Pérez et al., 2015). Carcinogenic risk was especially high when living in the 
vicinity of cement installations which are known for their release of hazardous air 
pollutant emissions, which often contain heavy metals. Occupationally, metal-workers 
have specifically been identified as having a statistically significant higher risk of 
developing urothelial cancer even after adjustment for smoking; a risk that increased with 
cumulative exposure to metal-working fluids (Colt et al., 2014). Other occupations that 
have been identified as high-risk for the development of urothelial cancer include 
bus/truck driving, road and asphalt making, working in refinery and petrochemicals, 
plastic/metal manufacturing, welding and pipeline building; all of which are likely to 
involve heavy metal exposure (Aminian et al., 2014). 
1.3.3 General Mechanisms of Heavy Metal-Carcinogenesis 
Despite being classified as carcinogenic, exactly how the heavy metals exert their effects 
remains elusive. DNA adducts are usually a key initiating event in organically-induced 
carcinogenesis, however heavy metals are only weakly mutagenic and cannot bind to 
DNA (Arita et al., 2012a). It has been suggested that increased production of reactive 
oxygen species (ROS) could be the primary mechanism of metal-induced carcinogenesis, 
however this contrasts with evidence that the majority of metals have little or no 
carcinogenic ability (Salnikow and Zhitkovich, 2008).  
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 In recent years there has been increasing evidence that heavy metals may exert their 
carcinogenic effects by altering the epigenetic state of a cell, influencing DNA 
methylation and/or posttranslational histone modifications (Salnikow and Zhitkovich, 
2008). Further, changes in micro RNA expression have now also been identified after 
exposure to heavy metals (Michailidi et al., 2015). Dysregulation of such epigenetic 
mechanisms has now been found in a multitude of malignancies, particularly in prostate, 
colorectal, colon and breast cancers, and is thought to play a key role in carcinogenesis 
(Kanwal and Gupta, 2012).  
 Chronic arsenic exposure has been shown to alter the expression of DNA 
methyltransferase (DNMT) and methyl binding proteins (MBD) in prostate epithelial 
cells, with increased expression of MBD1 and decreased expression of DNMT3a 
observed. Exposure was also found to cause changes in histone modification levels and 
expression of histone modifying genes (Treas et al., 2012). However, another study in 
mice found that arsenic exposure did not affect DNA methylation, but did alter 
demethylation of histone 3 at lysine 9 (H3K9me2) causing decreased expression of the 
tumour suppressor p16 (Suzuki and Nohara, 2012). Nickel has also been observed to alter 
histone modification levels, with increased expression of H3K4me3 and decreased 
expression of H3K9me2 found in peripheral blood mononuclear cells of workers 
identified as occupationally exposed to the metal (Arita et al., 2012b). A potential 
mechanism for the nickel-induced alteration of histone modifications was demonstrated 
by Chen et al. (2010), who found that nickel ions can replace iron in the structure of the 
histone demethylase Jumonji Domain-Containing protein 1A (JMJD1A) resulting in 
inhibition of its activity. However, the specific mechanisms by which nickel and other 
heavy metals may alter the epigenetic code are still unclear, and whether these changes 
are sufficient to cause carcinogenesis remains to be seen.  
 Heavy metals can affect a number of cellular pathways and thus altered epigenetics may 
not be the only contributor to the development of exposure-related carcinogenesis. Nickel 
exposure has been observed to activate a specific gene signature in human osteosarcoma 
and mice embryo fibroblast cells which is similar to that of hypoxia, resulting in 
stabilisation of the hypoxia-inducible factor (HIF)-α proteins and induction of HIF-1-
dependent transcription (Salnikow et al., 1999; Salnikow et al., 2003b; Salnikow et al., 
2003a;  Maxwell and Salnikow, 2004). Activation of the hypoxia-signalling pathway may 
lead to nickel-induced carcinogenesis through a number of mechanisms, such as 
upregulation of growth factors and altered cell growth/metabolism. Meanwhile, lead has 
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been purported to induce carcinogenesis via increased mitogenesis. A 40-fold increase in 
mitogenic index was observed in the kidney of rats who were given a single injection of 
lead acetate (Choie and Richter, 1972), supported by a further study in rats where a 45-
fold increase in hyperproliferation was found in lead-exposed renal cortices (Calabrese 
and Baldwin, 1992). More recently, it has also been suggested that lead can inhibit DNA 
damage repair, possibly by interfering with important machinery such as DNA and RNA 
polymerases (reviewed by Silbergeld, 2003). Despite the elucidation of a number of 
potential mechanisms of heavy-metal induced carcinogenesis the precise molecular 
mechanisms remain unclear, and it is likely that each heavy metal exerts its effects via a 
combination of molecular alterations that may be unique to the metal in question. Further 
large-scale genomic studies are needed to increase understanding of the mechanisms 
involved and determine the relative contributions of each, with the ultimate aim of 
developing targeted therapies that may be effective in treating this type of cancer.  
1.4 Cadmium Exposure  
1.4.1 Sources of Exposure 
Cadmium is a toxic transition metal, and as mentioned in section 1.3.2, has been classified 
as a known carcinogen by the IARC (International Agency for Research on Cancer, 
1993). Previously, cadmium exposure was very rare; however, anthropological activity 
has seen its release into the environment resulting in wide spread contamination of the 
biosphere (Agency for Toxic Substances and Disease Registry, 1999). Such 
anthropological activities include battery production, electroplating, smelting, soldering 
and burning of fossil fuels, among others (International Agency for Research on Cancer, 
1993). Once it has entered the environment, cadmium can be transported and spread in a 
number of ways. Soluble forms can be transported easily by water and accumulate in 
aquatic organisms (Keil et al., 2011), with high levels of cadmium having been recorded 
in seafood (Feki-Tounsi and Hamza-Chaffai, 2014). Cadmium can also be transported for 
long distances in the atmosphere as either a particle or vapour, before deposition onto 
either soil or water. Lastly, cadmium can also bind strongly to organic matter and become 
immobilised in soil, where it is then taken up by plants and crops (Keil et al., 2011). This 
may explain why smoking is a prominent source of cadmium in the general population 
(Adams et al., 2011). Tobacco leaves that grow in contaminated environments can end 
up accumulating cadmium from the surrounding soil, and blood cadmium levels of 
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smokers have been reported as approximately double that of non-smokers (Agency for 
Toxic Substances and Disease Registry, 1999). 
1.4.2 Types of Exposure 
The main routes of exposure to cadmium are through ingestion of contaminated food or 
water, and through inhalation of particles. Dermal contact is of minimal concern, as only 
0.05 % of cadmium is able to penetrate the skin’s protective barrier (Agency for Toxic 
Substances and Disease Registry, 1999). However, dietary intake of contaminated food 
can range from 10 µg/day up to hundreds of micrograms, depending upon environmental 
contamination conditions (Nordberg, 2003). Ingestion of contaminated water barely 
contributes to dietary intake, as most cadmium concentrations are 5-fold less than the 
maximum limit of 5 µg/L (World Health Organisation, 2010; European Commission 
Council, 1998). Inhalation is by far the most concerning route of entry, as it is estimated 
that 100 % of cadmium that reaches the alveoli is absorbed into the blood (Satarug and 
Moore, 2004). This is a major problem for cigarette smokers, as well as occupations in 
contaminated workplaces, where the major route of exposure is inhalation and between 
5-35 % of inhaled cadmium is into adsorbed into the body (Feki-Tounsi and Hamza-
Chaffai, 2014). Recent studies have suggested that exposure to contaminated dust 
specifically is the main route of entry for cadmium into the body. Moreover, significantly 
higher levels of cadmium have been found in dust from industrial and urban population 
areas compared to rural (Mohmand et al., 2015), further suggesting that certain industrial 
occupations may result in exposure to cadmium. 
  One of the major problems with cadmium exposure is that the human body has limited 
capability to respond to such a threat. Once ions have entered the body they tend to 
accumulate in an almost irreversible manner (Feki-Tounsi and Hamza-Chaffai, 2014). 
The body is unable to metabolise cadmium to a less toxic species (Waalkes, 2003), and 
although the main elimination route is via the urine, the rate of excretion is very low 
(Agency for Toxic Substances and Disease Registry, 1999). In fact, it is thought that free 
cadmium eliminated via the urine may represent less than 0.01 % of the total body burden 
at that time (Goering et al., 1994). Moreover, cadmium has a long biological half-life of 
approximately 13.8 years (Suwazono et al., 2009) adding to its cumulative nature. It is 
generally thought that the long-term presence of cadmium in the body is attributable to 
metal-binding proteins which act to sequester and thereby detoxify the ions, which is 
explored in-depth in section 1.5.4.  
Chapter 1: Introduction 
43 
1.4.3 Implication in Urothelial Carcinogenesis 
As mentioned in section 1.3.2, exposure to heavy metals has been linked to the 
development of urothelial cancer in a number of studies (García-Pérez et al., 2009; 
Rushton et al., 2012; Aminian et al., 2014; Colt et al., 2014; Ouzzane et al., 2014; García-
Pérez et al., 2015). Cadmium specifically has also been linked to urothelial carcinogenesis 
in a number of cases. One study observed that the median cadmium concentration in urine 
from urothelial cancer patients was 1.8 µg/L, compared to 0.8 µg/L in control cases (Wolf 
et al., 2009). Another study looked at blood cadmium concentrations from a cohort of 
bladder cancer patients compared to control. After adjustment for occupation and 
smoking, they found an increased risk of bladder cancer development for those with 
increased exposure to cadmium (Kellen et al., 2007). A similar result was obtained by 
Feki-Tounsi et al. (2013), who also measured blood cadmium concentration and found 
that concentrations from urothelial cancer patients were twice that of control cases. This 
link between elevated cadmium in bodily fluids and increased risk of urothelial 
carcinogenesis has now been repeatedly observed, more recently by Chang et al. (2016) 
who showed that patients with urothelial carcinoma had higher concentrations of urinary 
cadmium compared to control. Measurement of cadmium in bodily fluids has proved 
popular for studying the correlation between cadmium exposure and risk of urothelial 
carcinogenesis. However, one study performed metal quantification on urothelial 
tumours and adjacent tissues instead (Feki-Tounsi et al., 2014). Even with a change in 
source material, increased cadmium concentrations were still found in tissue from 
urothelial cancer patients compared to control. Interestingly, the elevated levels of 
cadmium were not observed in the tumour itself; rather, in the ‘normal’ tissue adjacent to 
the tumour. The authors suggest this may imply that such carcinogenic metals are able to 
affect surrounding cellular mechanisms and prime an oncogenic pathway (Feki-Tounsi et 
al., 2014), perhaps as part of a field effect (Jones et al., 2005).  
 The link between cadmium exposure and carcinogenesis has also been studied in vitro 
using various cell lines. The normal human prostate epithelial cell line RWPE-1 was 
chronically exposed to 10 µM cadmium chloride (CdCl2) for 8 weeks. After exposure 
cells exhibited a loss of contact inhibition, and upon inoculation into mice formed highly 
invasive adenocarcinomas which were occasionally metastatic (Achanzar et al., 2001). 
However, RWPE-1 cells have not only undergone immortalisation, but are also already 
able to form colonies in vitro (Rhim et al., 1994), and thus it could be argued that they 
already have neoplastic properties and thus may not be suitable for investigating 
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malignant transformation. Another study used the TLR1215 rat liver cell line and found 
that continuous exposure to 2.5 µM CdCl2 for 10 weeks was sufficient to induce a 
fibroblastic morphology, as well as a cell proliferation index twice that of controls 
(Takiguchi et al., 2003). The cells also displayed enhanced invasiveness and significantly 
elevated growth in serum-depleted medium, suggesting that cell growth had become 
independent of growth factors (a hallmark of tumorigenic/malignant cells). The human 
bronchial epithelial cell line 16HBE has additionally been transformed by chronic 
exposure to cadmium.These cells exhibited overlapping growth and significantly 
increased colony-formation, which was observed to be dose-dependent. Upon inoculation 
into nude mice tumours began to form after 2 weeks, and pathological examination 
revealed the tumours to be poorly differentiated (associated with poor prognosis, as 
explored in section 1.2.2; Lei et al., 2008).  
 Few studies have so far investigated the carcinogenic effect of cadmium on human 
urothelial cells, and these have tended to use immortalised cell lines. Sens et al. (2004) 
used the UROtsa cell line (previously established by immortalisation of normal human 
urothelial cells using an SV40 large T-antigen gene construct; Petzoldt et al., 1995), 
exposing the cells to 1 M CdCl2 for a prolonged time period and then selecting cells that 
were capable of forming colonies in soft agar. These cells were also able to form tumours 
when transplanted into nude mice, and the tumours were observed to have epithelial-like 
features that are consistent with transitional cell carcinoma of the bladder. However, it 
should be noted that the concentration used in this study is particularly high compared to 
other studies and to reported in vivo exposure (Aimola et al., 2012). Also, although 
immortalised cell lines are useful for long-term treatment, the major flaw of these cells is 
that they are no longer genetically ‘normal’ and a number of signalling pathways are 
already altered (as mentioned in section 1.1.4). Therefore, in order to understand how 
cadmium exposure may cause early molecular changes in the cell, primary cells should 
ideally be utilised (Feki-Tounsi and Hamza-Chaffai, 2014).  
1.4.4 Mechanisms of Cadmium-Induced Carcinogenesis 
As stated earlier (section 1.3.2) cadmium is a non-genotoxic carcinogen, with a low 
affinity for DNA-binding and only weak mutagenic properties (Pilger and Rüdiger, 
2006). Thus, how cadmium exerts its carcinogenic effects remains poorly understood. A 
multitude of studies have been conducted in order to investigate this, implicating a vast 
array of potential mechanisms, some of which are explored below. 
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1.4.4.1 Epigenetics 
One of the ways that cadmium exposure is thought to induce carcinogenesis is by altering 
the epigenetic state of cells (Salnikow and Zhitkovich, 2008; as mentioned in section 
1.3.3). As explored earlier (section 1.4.3) experiments using the rat liver cell line 
TLR1215 revealed that acute exposure to cadmium resulted in significantly decreased 
DNA methyltransferase (DNMT) activity and reduced global DNA methylation. 
Conversely, the study observed that chronic exposure resulted in significantly increased 
DNA methylation and DNMT activity, as well as cellular transformation (Takiguchi et 
al., 2003). These findings indicate that length of exposure may have distinct effects on 
the cell, and emphasises the importance of mimicking in vivo chronic exposure as closely 
as possible when using in vitro methods. Benbrahim-Tallaa et al. (2007) also found 
significant changes to the DNA methylome in cadmium-transformed cells using the 
normal prostate epithelial cell line RWPE-1 (see section 1.4.3). Once transformed by 
chronic exposure these cells exhibited increased DNMT activity, which was associated 
with overexpression of DNMT3b. The authors also found reduced expression of the 
tumour suppressor genes RASSF1A and p16 in transformed cells, and discovered that the 
promoters of these genes were hypermethylated. Severson et al. (2012) also found 
hundreds of abnormal DNA methylation events in cadmium-transformed cells, some of 
which occurred in an agglomerative fashion, further suggesting that DNA methylation is 
an important target of cadmium-induced cellular changes.  
 Post-translational histone modifications are also thought to be affected by cadmium 
exposure, with a recent study in the bronchial epithelial cell line BEAS-2B showing that 
exposure resulted in elevated global levels of H3K4me3 and H3K9me2 (Xiao et al., 
2015). Cadmium exposure has also been reported to cause reduced H3 acetylation and 
decreased H3K27me1 protein expression in human breast cancer cells (Choi et al., 2008) 
and mouse embryonic stem cells (Gadhia et al., 2012) respectively. One of the few studies 
looking at cadmium-induced epigenetic changes in urothelial cells found that cadmium-
induced malignant transformation of the UROtsa cell line also resulted in increased 
H3K4me3, as well as H3K9me3 and H3K27me3 levels. Interestingly, investigation of a 
specific gene promoter showed that transformation had resulted in the establishment of a 
bivalent chromatin domain, preparing the gene for rapid transcriptional activation (Somji 
et al., 2011b). 
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1.4.4.2 Zinc Substitution 
Another potential mechanism of cadmium-induced carcinogenesis is thought to be 
through cadmium substitution for zinc. These two metallic elements have highly similar 
properties, meaning that cadmium can substitute for zinc relatively easily in biological 
systems (Chaney, 2010). However, substitution can destabilise the functional sites of 
zinc-containing proteins, changing the character and/or rendering them non-functional 
(Tang et al., 2014). This is especially a problem for zinc-finger proteins as their activities 
are dependent upon zinc-binding, and cadmium substitution in zinc-finger transcription 
factors can result in lowered affinity for DNA-binding (Malgieri et al., 2011). Although 
the effect of cadmium substitution in zinc proteins has been extensively studied in plants 
(Tang et al., 2014) the effect of substitution, and possible carcinogenic consequences, has 
been less extensively studied in humans. However, substitution has been investigated in 
the tumour suppressor protein p53 in human breast cancer cells (MCF-7). The authors 
found that exposure to cadmium disrupted native p53 conformation, inhibited its ability 
to bind DNA and decreased transcriptional activity of a downstream reporter gene. They 
also observed that exposure to cadmium impaired p53 induction in response to DNA 
damage-inducing agents (Méplan et al., 1999). These results suggest that cadmium may 
be able to replace zinc in p53 and disrupt its function. The authors later went on to perform 
a similar experiment but added extracellular zinc after cadmium-induced denaturation of 
p53. They found that the addition of zinc at physiological concentrations resulted in 
renaturation and reactivation of p53, suggesting that cadmium exposure caused p53 zinc 
depletion and that addition of extracellular zinc rescued p53 activity (Méplan et al., 2000).  
 A secondary problem of cadmium substituting for zinc is that there may be a resultant 
excess of labile zinc in the cell. Not only can excess zinc in the cell be toxic, but changes 
in intracellular zinc levels are also associated with tumour growth and progression. This 
may be because zinc is a cofactor of many proteins involved in carcinogenesis, 
influencing processes such as cell proliferation and metastasis (Jeong and Eide, 2013). 
To investigate the effect of cadmium on cellular zinc homeostasis the expression of Zinc 
Transporter-1 (ZnT-1) has previously been analysed, as it is a key regulator of free zinc 
and responsible for zinc efflux from the cell (McMahon and Cousins, 1998). The human 
hepatic cell line HepG2 was exposed to low doses of cadmium (0.1 and 10 µM) which 
resulted in elevated expression of the ZnT-1 protein, as well as increased localisation at 
the cell membrane (Urani et al., 2010). This indicated increased cellular zinc levels and 
therefore a need to increase efflux, supporting the hypothesis that cadmium exposure may 
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alter zinc homeostasis. After these observations, the authors of the study went on to 
directly quantify intracellular zinc levels post-exposure to cadmium. The zinc-specific 
probe Zinquin was utilised and it was found that intracellular labile zinc concentrations 
increased by 93 % when the cells were exposed to cadmium, indicative of a large 
displacement of zinc from the proteome (Urani et al., 2015). These results suggest that 
cadmium can displace zinc from proteins in the cell resulting in increased intracellular 
labile zinc, which the cell may attempt to counteract by increasing expression of zinc 
effluxors such as ZnT-1. 
1.4.4.3 Miscellaneous 
A number of other potential mechanisms of cadmium-induced carcinogenesis are 
summarised in the table below, along with respective references and the primary findings 
(Table 1). With regards to cadmium carcinogenicity in urothelial cells, studies have 
mainly focused on altered gene expression in immortalised cell lines and have identified 
3 gene families of interest: Secreted Protein, Acidic, and Rich in Cysteine (SPARC); 
Keratin (KRT); and Metallothionein (MT; Feki-Tounsi and Hamza-Chaffai, 2014). These 
families are summarised in Table 2. Currently, the relationship between KRT and MT 
expression and urothelial carcinoma is correlational, with their expression primarily used 
as prognostic factors (Karantza, 2011, and Yamasaki et al., 2006, respectively). In 
contrast, SPARC expression is thought to play a direct role in the development of 
urothelial carcinogenesis, with a loss of expression resulting in increased carcinogen-
induced inflammation, accumulation of ROS, increased cellular proliferation and 
increased activation of NF-ĸB and AP-1 (Said et al., 2013) (Said, 2016)   
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Table 1: Summary of other main mechanisms implicated in cadmium-induced carcinogenesis. 
Each mechanism is accompanied by several findings in the area and the respective references. 
Mechanism Main Findings References 
Aberrant Gene 
Expression 
↑ c-fos, c-jun, c-myc; ↓ p16, 
RASSF1A; ↑ ACTB, HSP90AA1, 
HSPA5, HSPA8; ↑ Snail1, MET, 
TGF-βR, Rac, cdc42 
(Garrett et al., 2002; 
Benbrahim-Tallaa et al., 
2007; Kwon et al., 2013; 
Urani et al., 2015) 
Inhibition of DNA 
Repair 
↓ repair of visible light-induced 
DNA lesions; ↓ repair of oxidative 
DNA damage, ↓ DNA glycosylase 
and endonuclease; ↓ nucleotide 
excision repair; ↓ expression DNA 
repair genes 
(Dally and Hartwig, 1997, 
Potts et al., 2001; 
Mukherjee et al., 2004; 
Zhou et al., 2012) 
Inhibition of 
Apoptosis 
↓ caspase activity and DNA 
fragmentation; ↓ benzopyrene-
induced apoptosis and AP-1 
activation, ↑ ERK 
(Gunawardana et al., 2006; 
Mukherjee et al., 2008) 
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Table 2: Summary of the main gene families altered in cadmium-induced urothelial 
carcinogenesis. The main observations are summarised along with the respective studies.  
Gene Family Main Findings References 
SPARC ↓ in CdCl2-transformed UROtsa cells 
and subsequent tumours 
(Larson et al., 2010), 
(Slusser-Nore et al., 2016) 
KRT ↑ KRT6a in CdCl2-transformed 
UROtsa cells exposed to insulin and 
epidermal growth factor; ↑ KRT6, 16, 
17 in CdCl2-transformed UROtsa 
cells and areas of squamous 
differentiation in subsequent tumours 
(Somji et al., 2008; Somji 
et al., 2011a) 
MT ↑ MT-1/2 protein due to ↑ MT-1X 
gene in urothelial cancer; ↑ MT-3 in 
urothelial cancer cells;   
(Somji et al., 2001; Sens et 
al., 2000) 
 
1.5 The Metallothionein Proteins 
The metallothioneins (MTs) are a family of low-molecular weight (~6 kDa), cysteine-
rich proteins that are capable of binding to a range of metals, including cadmium (Kägi 
and Schäffer, 1988). They were first discovered in 1957 as a cadmium-binding protein in 
equine kidney (Margoshes and Vallee, 1957) and went on to receive much attention due 
to their unique metal-binding ability and elusive function(s). As mentioned in Table 2, 
they have also been implicated in cadmium-induced urothelial carcinogenesis, which will 
be explored in-depth in section 1.5.6. 
1.5.1 3-Dimensional (3-D) Structure and Conformation 
As mentioned above, MTs are capable of binding to a range of metals, and this binding 
is essential for their 3-dimensional conformation and structure (Figure 4; originally 
depicted by Babula et al., 2012). Once bound to metal ions, the MT protein forms a 
molecule with two separate globular domains; a C-terminal α-domain, and an N-terminal 
β-domain, linked by a short but highly flexible bridging region (Coyle et al., 2002; 
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Penkowa et al., 2006; Nielsen et al., 2007; Pedersen, Larsen, Stoltenberg, & Penkowa, 
2009). Each MT protein is 61-68 amino acids in length, one-third of which is cysteine 
residues that form metal thiolate clusters in a series of motifs as follows; Cys-X-Cys, Cys-
X-Cys-Cys, Cys-X-X-Cys (where X is any amino acid other than cysteine; Kägi and 
Kojima, 1987). Up to 4 divalent (or 6 monovalent) metal ions can be bound by the 11 
cysteine residues of the α-domain, whereas only 3 bivalent (6 monovalent) ions can be 
bound by the β-domain, due to the domain containing only 9 cysteine residues (Nielsen 
et al., 2007; Coyle et al., 2002). The metal-binding property of MT confers molecular 
stability to the protein, with the metal linkages stabilising the secondary structure, and 
the rate of degradation dependent upon the metal ions within the complex. If the metal is 
lost the protein structure is rendered disordered, becoming susceptible to proteolysis and 
consequently being rapidly degraded (Klaassen et al., 1994). 
 
 
Figure 4: Schematic diagram showing MT protein structure. The image depicts the 3-
dimensional structure of a MT protein bound to metal ions (blue). The different globular domains 
(α and β) are labelled, separated by a flexible hinge region. 
 
1.5.2 MT Gene Superfamily 
The human MT gene superfamily (Figure 5) consists of 11 functional isoforms that are 
divided into four different subfamilies (MT-1 to MT-4), and five pseudogenes that are 
thought to originate from duplication and loss-of-function mutations of the parent MT-1 
gene (Binz and Kägi, 1997; Sigel et al., 2009; Kimura and Kambe, 2016).  Eight of the 
functional MT gene isoforms are in the MT-1 subfamily; MT-1A, 1B, 1E, 1F, 1G, 1H, 
1M and 1X. However, the other MT subfamilies consist of only one gene each; MT-2 
(MT-2A), MT-3 and MT-4 (Serén et al., 2014). MT-1 and MT-2 are the most studied 
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subfamilies to date and are thought to be expressed in a variety of tissues throughout the 
body (Babula et al., 2012). MT-2 in particular is thought to be the most widely expressed 
isoform, accounting for up to 50 % total MT expression in humans (Sigel et al., 2009; 
Raudenska et al., 2013). MT-1 isoforms are thought to be inducible by a variety of factors 
(Miles et al., 2000; Thirumoorthy et al., 2007; Capdevila et al., 2012). However, MT-3 
and MT-4 are non-inducible and demonstrate tissue-specific expression; MT-3 is 
confined to neuronal tissue, and MT-4 to squamous epithelia (Palmiter et al., 1992; 
Quaife et al., 1994). 
 
 
Figure 5: Diagram of the MT gene superfamily. The superfamily consists of 11 functional 
isoforms divided into 4 subfamilies; MT-1, MT-2, MT-3 and MT-4. MT-1 consists of 8 isoforms 
whereas the other subfamilies only consist of one. Each subfamily has distinct expression 
patterns, and MT-1 and MT-2 are the best studied. Isoforms: genes coding for highly homologous 
yet distinct proteins. 
 
1.5.2.1 MT Gene Duplication Events 
The MT genes are clustered together at a single locus on chromosome 16 (16q13), which 
is known for its intra-chromosomal duplication events (Karin et al., 1984; West et al., 
1990; Martin et al., 2004). This, and the fact that multiple MT gene isoforms exist in 
humans, led to studies investigating the evolutionary history of the MT family. A number 
of phylogenetic studies have been performed in recent years with a view to understanding 
how multiple isoforms have been produced, and moreover, maintained. Moleirinho et al. 
(2011) used a combination of phylogenetic, transcriptional and polymorphic analyses in 
order to explore the diversification of the MT family. They found that the 4 subfamilies 
arose from a single duplication event prior to the radiation of mammals. However, a 
second duplication event then occurred in the primate lineage, whereby the MT-1 gene 
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expanded and formed the 8 active isoforms currently identified in humans.  Another study 
performed phylogenetic, synteny, reconciliation, selection pressure and functional 
analyses on all active MT isoforms. The reconciliation analyses supported previous 
studies, revealing a high turnover of gene duplication and loss events. The study also 
found that there were significant variances in selection pressure during MT gene 
evolution, and that evolution was primarily in the form of ‘purifying selection’; whereby 
genes are duplicated and maintain related but distinct functions. Interestingly, the results 
also indicate there was increased selection pressure in the MT-1 and MT-2 subfamilies, 
which is concordant with the number of isoforms present in the MT-1 subfamily. Lastly, 
the results showed that there is a higher number of conserved amino acids in the α-domain 
of the MT structure, suggesting that this domain is quite structurally constrained. 
However, high variability was observed in the amino acid sequence of the β-domain, 
which is thought to be the domain most involved in functional divergence of the MTs 
(Serén et al., 2014). These results support the hypothesis that the MT isoforms may have 
overlapping but distinct functions, as explored later (section 1.5.5.4).  
1.5.3 MT Gene Transcriptional Regulation 
Investigation of the upstream region of mouse MT-1 revealed a number of imperfect 
repeats which were named ‘metal response elements’ (MREs), and such regulatory 
elements were also identified in other MT genes (Stuart et al., 1985). DNA binding assays 
were performed using MREs as probes, resulting in the discovery of a zinc-dependent 
MRE-binding protein now known as MRE-binding transcription factor-1 (MTF-1). 
MTF-1 was identified as the primary inducer of MT genes and thus co-ordinating the 
heavy metal response (Palmiter, 1994). MTF-1 is constitutively expressed, having been 
observed present at both the mRNA and protein levels in various cell lines, and its 
expression is not influenced by heavy metal exposure (Radtke et al., 1993; Otsuka et al., 
2000). However, MTF-1 can be activated by cellular zinc levels increasing, although it 
requires a higher concentration than other zinc-finger proteins to become saturated 
(Radtke et al., 1995). Once activated, MTF-1 then binds to the MREs in the MT promoter 
and induces transcription (Radtke et al., 1993). However, with regards to cadmium 
exposure, it is currently unclear whether zinc or cadmium by themselves can activate 
MTF-1. As mentioned earlier (section 1.4.4.2) the two metal ions are structurally similar, 
and thus cadmium could substitute for zinc in the MTF-1 structure (Chaney, 2010). 
However, it is also possible that cadmium exposure results in increased intracellular zinc 
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due to zinc substitution (see section 1.4.4.2), meaning labile zinc is then able to bind and 
activate MTF-1.  
 Despite much being known about MTF-1, questions still remain about its metal 
specificity, as it is currently unclear whether all metals require MTF-1 to induce MT 
transcription (Miles et al., 2000). Initial studies suggested that MTF-1 was essential for 
cadmium-induced MT gene transcription, with MTF-1-null cells failing to induce MT 
expression upon both zinc and cadmium treatment (Heuchel et al., 1994). However, 
contrasting studies have suggested that cadmium induction of MT is independent of 
MTF-1. IMR-32 neuroblastoma cells lack functional MTF-1 and yet cadmium was still 
able to induce MT-1 transcription through an MRE-dependent mechanism. In contrast all 
other heavy metals tested, including zinc and arsenic, failed to induce transcription (Chu 
et al., 1999). This suggests that cadmium can induce MT expression via its own unique 
pathway, which is independent of MTF-1 yet still requires MREs, supporting the 
hypothesis that other MRE-binding TFs exist. One such factor has already been 
identified, termed MRE-binding protein (MREBP), which was discovered to bind MREs 
upstream of the MT-2A gene (Koizumi et al., 1992). However, the role of MREBP 
remains unclear. Further studies are needed in order to clarify whether MTF-1 is essential 
for cadmium-induced MT expression, and if not, what other TFs (such as MREBP) and 
mechanisms may be involved in this potentially novel induction. 
1.5.4 Proposed Functions of MT 
Over the years MT has been suggested to play a role in a number of functions, and thus 
appears to be a multi-purpose protein. The most well-defined roles are summarised in 
Table 3, and functions especially pertinent to this research are explored in detail. 
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Table 3: Summary of the different proposed functions of metallothionein. Each function is 
accompanied by respective references. 
Function References 
Reactive oxygen species 
scavenger 
(Ruttkay-Nedecky et al., 2013; Penkowa et 
al., 2006; Lazo et al., 1995) 
Regulation of cell cycle 
progression, differentiation 
and proliferation  
(Cai et al., 2014; Schulkens et al., 2014; Yap 
et al., 2009; Liu et al., 2009; Ioachim et al., 
2001; Jin et al., 2002; Cherian and 
Apostolova, 2000) 
Angiogenesis (Wierzowiecka et al., 2016; Schulkens et al., 
2014; Lee et al., 2004; Penkowa et al., 2000) 
Immune Responses (Ugajin et al., 2015; Mita et al., 2008; 
Penkowa et al., 2006; Kimura et al., 2001) 
Zinc 
Homeostasis/Regulation of 
Zinc-Containing Proteins 
See section 1.5.4.1 
Metal 
Detoxification/Sequestration 
See section 1.5.4.2 
 
1.5.4.1 Zinc Homeostasis/Regulation of Zinc-Containing Proteins 
MT is the most prominent binder of zinc in the body, and 5-20 % total cellular zinc is 
bound to MT in the cytoplasm (Kägi and Kojima, 1987; Sigel et al., 2009). It is therefore 
logical that MT may play a role in zinc homeostasis, and which is supported by the 
observation of a close relationship between tissue MT expression and zinc content 
(Bremner, 1987). Numerous studies have attempted to determine the importance of MTs 
in controlling intracellular zinc. For example, Dalton et al. (1996) found that transgenic 
mice overexpressing MT-1 were more resistant to zinc deficiency, and they postulated 
that this may be due to an increased pool of zinc bound to MT. Another study used 
pregnant transgenic mice constitutively expressing MT-1 and fed them a zinc-deprived 
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diet. They found that in these mice, only 5.8 % embryos had morphological defects, 
compared to 21.3 % in control mice (Lee et al., 2003). Both these studies suggest that MT 
may be an important source of intracellular zinc. However, another study found that 
although MT-null, zinc-deprived mice had abnormal kidney development and 
maturation, MT-null-only mice appeared to live normally (Kelly et al., 1996). This 
questions the role of MT as an essential source of zinc under normal physiological 
conditions, and instead infers that MT may act as a reservoir for zinc that is only used 
under zinc-deprived conditions (Miles et al., 2000). 
 MTs are thought to work in cooperation with zinc transporters (ZnTs) in order to 
maintain cellular zinc homeostasis, and are implicated in both the maintenance 
mechanisms of zinc ‘buffering’ and zinc ‘mumbling’ (Kimura and Kambe, 2016). 
Buffering allows the zinc cytosol concentration to remain within the picomolar range 
under normal conditions, whereas muffling occurs under non-steady state conditions 
where transient changes in zinc cytosolic concentrations are carefully modulated (Colvin 
et al., 2010; Krezel and Maret, 2006). It has been shown that when cellular zinc levels 
become too high, transcription of MT is induced along with concordant induction of 
several ZnTs, possibly by a common transcription factor such MTF-1 (Günther et al., 
2012). Their cooperative expression then aids the reduction of zinc levels until a normal 
level is once again reached, probably via ZnT efflux and MT binding of zinc (Tomoki 
Kimura, Itoh, & Andrews, 2009; Otsuka, 2001; Langmade et al., 2000; Guo et al., 2010). 
This suggests that MT and ZnT may act synergistically to counteract abnormal cellular 
zinc levels and maintain homeostasis (Kimura and Kambe, 2016). 
 As part of its role in zinc homeostasis it is thought that MT can also act as a zinc buffer, 
donating zinc to target proteins in times of need (Krezel and Maret, 2008; Costello et al., 
2011). Transfer of zinc occurs via ligand exchange in zinc mediated protein-protein 
interactions, known as the ‘associate mechanism’ (Costello et al., 2011; Maret and Li, 
2009; Maret, 2011). The donation of zinc to apo-enzymes results in their reactivation; for 
example, zinc-saturated MT (Zn-MT) is thought to be the primary zinc-donator for the 
zinc-requiring enzyme apo-carbonic anhydrase (Pinter and Stillman, 2015). Zinc-finger-
containing transcription factors are also thought to be a target of Zn-MT, with the 
complex translocating into the nucleus under times of cellular stress and promoting 
activation of zinc-finger transcription factors by zinc donation (Sigel et al., 2009). By 
contrast, it has also been reported that apo-MT can extract zinc from certain transcription 
factors and inhibit their activity. For example, apo-MT has been observed to extract zinc 
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from the transcription factors Sp1 and TFIIIA rendering them unable to bind to DNA 
(Zeng et al., 1991a; Zeng et al., 1991b). Thus, it appears that MT can act as a chaperone 
for zinc proteins/enzymes, acting to modulate their actions via both the donation and 
removal of zinc ions. 
1.5.4.2 Metal Detoxification/Sequestration 
As stated earlier, MT was originally identified as a cadmium-binding protein (Margoshes 
and Vallee, 1957). Due to further extensive in vitro and in vivo studies it is now widely 
recognised to play an essential role in metal detoxification, due to its high affinity for 
binding and sequestering metal ions. Sequestration means that the toxic ions are no longer 
free to bind other proteins and/or alter physiological processes within the cell (Miles et 
al., 2000; Capdevila et al., 2012; Babula et al., 2012). Studies supporting this role have 
shown that exposure to various metals results in significant increases of MT levels in a 
number of tissues, and that the protein appears to accumulate in cell lines that have 
undergone metal exposure (Cherian and Goyer, 1978; Kägi et al., 1979; Kobayashi and 
Kimura, 1980). It has also been shown that increased MT expression (due to ‘priming’ 
via repeated low-dose metal exposure) can increase a cell’s tolerance to toxic doses, 
presumably due to MT’s ability to sequester the metal ions (Goering and Klaassen, 1984).  
Indeed, cell lines that have developed resistance to cadmium exposure demonstrate very 
high MT expression, and this resistance crosses over to other heavy metal exposure (e.g. 
copper; Durnam and Palmiter, 1984).   
 Once sequestered it is unclear how and where the metal-MT complex is stored, and for 
what duration. As mentioned in section 1.5.1, metal-bound MT protein is much more 
resistant to degradation, and the rate of degradation depends upon the metal ions within 
the structure (Klaassen et al., 1994). For example, Cd-MT has been observed much more 
resistant to proteolysis than Zn-MT, and therefore has a longer half-life (Coyle et al., 
2002; Sigel et al., 2009). This is because MT preferentially binds cadmium over zinc 
(Kägi and Kojima, 1987), and the difference in binding affinity/degradation rate supports 
MT’s function as a detoxifier of toxic metals yet regulator of essential ones. Indeed, a 
recent study has suggested that cadmium and zinc bind to MT via separate pathways. The 
authors observed that zinc appears to form beaded structures in a non-cooperative manner 
when binding to MT, whereas cadmium forms a four-metal domain cluster via a 
cooperative mechanism. The authors suggest these metal-specific pathways are reflective 
of MT’s multiple roles as both a zinc donator and metal detoxifier; the MT protein 
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terminally binds zinc so that the metal can be donated to proteins, whereas MT binds 
cadmium in a manner that sequesters and detoxifies it (Irvine et al., 2016).    
 Interestingly, it has been suggested in the literature that metal-MT may be sequestered 
within the cell in structures termed ‘inclusion bodies’ (IBs). For example, lead-poisoning 
has been observed to cause the production of protein-lead complexes which appear within 
the cell as IBs. Lead was highly concentrated within these organelles, which were often 
nuclear, and it was unclear whether they were permanent structures or degraded with the 
cessation of exposure (Choie & Richter, 1972; Goyer et al., 1970). MT has been 
implicated as the protein in these structures, with one study showing that MT-null cells 
could not form IBs upon lead-exposure (Qu et al., 2002). Moreover, renal lead-containing 
IBs from lead-exposed mice were discovered to have MT protein associated with the 
outside portion of these bodies (Waalkes et al., 2004).  
 More recent studies have also seen the production of these IBs after arsenic exposure. 
Originally mislabelled as ‘micronuclei’, they were observed in urothelial cells from 
human populations exposed to arsenic-contaminated drinking water in India (Basu et al., 
2002). One study repeatedly exposed mice to arsenic in order to further characterise these 
‘micronuclei’, and found that the structures were both eosinophilic and negative for 
DNA/chromosomal staining; suggesting that the bodies were not micronuclei. The IBs 
appeared as soon as 6 hours post-exposure, and with high doses could be observed in all 
cell layers as both intranuclear and intracytoplasmic structures (Dodmane et al., 2014). 
IBs have also been identified in exfoliated superficial urothelial cells from patients with 
acute promyelocytic leukaemia undergoing arsenic-based chemotherapy. There were 
multiple bodies per cell of various sizes, which were identifiable using light microscopy. 
Moreover, these IBs could still be observed up to 7 months post-chemotherapy. The 
authors postulated that the metal-containing IBs act as a cellular depot and remained 
intact until the superficial urothelial cells were sloughed off (Wedel et al., 2013). 
Although the exfoliated cells analysed in this study showed signs of autolysis, control 
exfoliated cells did not demonstrate these IBs, suggesting that their presence was due to 
arsenic exposure and not as a result of cellular damage. However, it should be noted that 
the authors did not confirm the urothelial origin of these exfoliated cells, and exfoliated 
renal cells have also been reported in urine (Zhou et al., 2011). Despite this, if further 
studies can confirm the presence of MT protein in urothelial inclusion bodies, this would 
further support the sequestration role of MT as a detoxifying mechanism. 
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1.5.5 Metallothionein Isoforms 
The individual characteristics of the different MT isoforms have not been extensively 
studied due to high isoform homology and the assumption of shared function. However, 
there has been accumulating evidence in recent years that the isoforms are distinct in a 
number of ways, and in the following sections these differences are explored.  
1.5.5.1 Structural Differences 
As explored earlier (section 1.5.2), the MT gene family is diverse and contains a number 
of homologous isoforms. The MT-1 and MT-2 subfamilies are the most similar, differing 
by only a single negative charge (Kägi et al., 1979). However, the differences between 
these subfamilies and the MT-3 and MT-4 subfamilies are more distinct, reflective of 
their duplicative origin. For example, MT-3 has an additional 8 amino acid sequence that 
marks it as unique (Palmiter et al., 1992). At the  individual isoform level, the structural 
differences become finer. The MT-1 subfamily genes in particular are extremely 
homologous and also have similar charges; however, the isoforms appear to have small 
structural differences and can differ in their post-translation modifications (Miles et al., 
2000). Moreover, the isoforms also differ at their N-terminal tryptic peptide, which can 
be used to differentiate between all 11 functional isoforms (Mehus et al., 2014).   
1.5.5.2 MT Isoform Expression and Degradation 
Basal expression of the MT isoforms appears to vary depending on the tissue of origin 
(Capdevila et al., 2012). For example, MT-2A has been observed constitutively expressed 
in HepG2 cells under basal conditions, whereas the MT-1F and 1G isoforms are not 
expressed at all (Jahroudi et al., 1990). In contrast, the MT-1F and 1G isoforms are 
constitutively expressed in human umbilical vein epithelial cells (HUVEC) under basal 
conditions, with expression levels higher than those of MT-2A (Conway et al., 2010). It 
has also been observed that protein translation efficiency can vary depending on the 
isoform. Mehus et al. (2014) found that MT mRNA expression did not always correlate 
one-to-one with protein expression, and that varied depending on the specific isoform 
transcript. For example, the MT-1E isoform represented 30-50 % all MT transcripts 
expressed, yet only 10-18 % total MT protein. Upon calculation, its protein:mRNA ratio 
was 4-6 fold lower than the other two isoforms studied (MT-1X and MT-2A), further 
highlighting fundamental differences between the isoforms. Lastly, it has been 
hypothesised that there may be separate degradation pathways for the different isoforms, 
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with some proving more resistant to proteolysis and thereby remaining in the cell for 
longer (Miles et al., 2000). 
 These differences in degradation-resistance have been demonstrated in rat liver cells, 
where MT-1 and MT-2 were observed to degrade at different rates. The biological half-
life of Zn-MT-1 was 12.2 hours, whereas the half-life for Zn-MT-2 was 21.9 hours, 
suggesting that MT-2 is more resistant to proteolysis in these cells (Lehman-McKeeman 
et al., 1988; Klaassen and Lehman-McKeeman, 1989). Moreover, characterisation of MT 
degradation products in rat liver has identified different domains from MT-1 and MT-2 
present, suggesting that there may be differences in the stability of the metal-binding 
domains of the two (Saito and Hunziker, 1996). 
1.5.5.3 Specific Induction Patterns 
Although the primary inducer of MT transcription is thought to be metal ions a variety of 
other factors have also been implicated. These include ROS, cytokines, hormones, 
hypoxia and cellular stress (Bremner, 1987; Futakawa et al., 2006; Kikuchi et al., 1993; 
Richards et al., 1984; Tanji et al., 2003; Conway et al., 2010). Of note, it is suggested that 
ROS induce MT expression via antioxidant response elements (AREs) in the promoter, 
and hormones via the glucocorticoid receptor elements (GREs); however, not all MT 
promoters are thought to contain these elements (Dalton et al., 1996; Karin et al., 1984b; 
Miles et al., 2000). The idea that isoforms may contain different elements in their 
promoter is supported by the observation that MT isoforms can be differentially induced 
depending upon the factor they are exposed to. For example, glucocorticoids appear able 
to induce expression of MT-2A, but not MT-1A or 1F (Richards et al., 1984; Varshney 
et al., 1986).  
 Furthermore, the isoforms appear to show metal specificity, with different metals 
inducing distinct isoforms. In HeLa cells it was observed that copper exposure could 
cause induction of all the MT-1 subfamily, except for MT-1A; however, MT-1A could 
be significantly induced by both zinc and cadmium exposure. It was also found that zinc, 
cadmium and copper seemed to preferentially induce MT-1X and MT-2A, causing a 
much higher induction of these isoforms compared to others (Miura and Koizumi, 2007). 
Moreover, experiments in the fruit fly Drosophila melanogaster have indicated that  
metal specific induction of isoforms is co-ordinated by MTF-1. Using genomic mapping 
it was shown that MTF-1 bound different DNA sites depending on the metal stressor, 
leading the authors to conclude that different MT isoforms preferentially protect against 
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different insults (Sims et al., 2012). Another group studying D.melanogaster also 
reported exposure-specific results, and suggested that the spatial arrangement of MTF-1 
binding sites in isoform gene promoters may be responsible for differential induction 
(Selvaraj et al., 2005).   
 The MT isoforms not only differ in their inducers, but it has also been reported that they 
differ in the timing of their induction. For example, cadmium exposure of HepG2 cells 
revealed that MT-1G isoform transcript expression was significantly induced after one 
hour; however, MT-1F was not significantly transcribed until after four hours induction 
(Sadhu and Gedamu, 1988). To account for the isoform-specific variations in expression 
it has been suggested that the MT family may be regulated by a family of TFs that are 
specific to MREs in the promoters, rather than just MTF-1 alone (Searle, 1990; explored 
earlier in section 1.5.3). 
1.5.5.4 Differential Functions 
It is now a commonly held belief that the MT isoforms may serve different functions 
(Miles et al., 2000; Coyle et al., 2002; Sigel et al., 2009; Capdevila et al., 2012; Brazão-
Silva et al., 2015; Kimura and Kambe, 2016). Much of the evidence contributing to this 
belief has been summarised in the above sections (1.5.1 – 1.5.4), which demonstrate the 
vast array of differences between the isoforms. It possible that these differences are 
simply a result of duplication of function, however, there is now strong evolutionary data 
suggesting that these gene duplications have been selected for and maintained. The recent 
study by Serén et al. (2014) showed that the MT family had undergone changes in 
selection pressure, especially in the MT-1 subfamily, resulting in high turnover of gene 
duplication and loss; yet some gene duplications were maintained. The authors also 
observed high variability in the amino acid sequence of the β-domain which is involved 
in functional divergence. These evolutionary studies support the hypothesis that the MT 
isoforms may have overlapping yet distinct functions. 
 However, deciphering the different functions of the isoforms is problematic, as it is 
difficult to study the isoforms in isolation. This is due to their high levels of homology, 
minimal basal synthesis levels and complicated expression patterns (Capdevila et al., 
2012). Isoform expression is particularly hard to study at the protein level due to the high 
similarity, whereas transcript expression is easier due to sufficient divergence at the 5’ 
and 3’ untranslated regions (Mehus et al., 2014). As explored earlier however (section 
1.5.5.2) transcript levels do not always reflect protein levels, and therefore it is important 
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to attempt to differentiate between the isoforms at the protein level. MT protein 
expression has generally been investigated using antibodies, which has proved useful to 
obtain basic knowledge but is limited by the reagents available. Currently, there are no 
validated commercially available antibodies that can distinguish between MT-1 and MT-
2 subfamilies, let alone between the isoforms of MT-1 (Jasani and Schmid, 1997). Mass-
spectrometry techniques have been employed to some success, however these methods 
are timely and expensive (Wang et al., 2007; Mehus et al., 2014). The development and 
validation of isoform-specific MT antibodies is sorely needed, so that initial results 
investigating transcript expression can be supported and potentially novel isoform-
specific functions determined. 
1.5.6 MT Expression in Cadmium-Induced Urothelial Carcinogenesis 
1.5.6.1 Cadmium-Induced MT Expression 
Cadmium has been demonstrated to be the most potent inducer of MT (Kim et al., 2008), 
with numerous studies confirming MT induction by cadmium exposure in vitro (Durnam 
and Palmiter, 1984; Karin et al., 1984b; Varshney et al., 1986; Kikuchi et al., 1993; Potts 
et al., 2001; Forti et al., 2010; Fabbri et al., 2012; Mehus et al., 2014; Irvine et al., 2016). 
Increased MT expression has also been seen in vivo in humans that have been 
occupationally or environmentally exposed to the metal. In male Polish battery-
production workers, a significant 2.5-fold increase in general MT transcript expression 
was found in the blood of workers identified as having been exposed to ambient cadmium 
(Ganguly et al., 1996). More recently, an association between blood cadmium levels and 
MT transcript expression was found in humans living in cadmium-contaminated areas of 
Thailand. The authors produced some distinction between isoforms, looking at MT-1A, 
MT-2A and MT-3 transcripts separately. They found that MT-1A expression was 
significantly associated with blood cadmium levels, whereas MT-2A expression was 
associated with smoking status, and there was no association between MT-3 expression 
and blood cadmium (Boonprasert et al., 2012). These results emphasise the importance 
of distinguishing between the isoforms, as only MT-1A was identified as being induced 
by environmental cadmium exposure in this study. 
 As mentioned earlier, MT isoform expression appears cell- and tissue-specific (section 
1.5.5.2). Therefore, to identify cadmium-induced isoforms relevant to the bladder it is 
essential that normal human urothelial tissue/cells are used. Few studies have been 
conducted looking at MT expression in urothelium, with or without cadmium exposure. 
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However, one study used the immortalised urothelial cell line UROtsa to look at MT 
isoform and transcript expression in cadmium-transformed cells. They found increased 
transcript expression of all three MT isoforms studied; MT-1E, MT-1X and MT-2A. They 
also found increased MT protein expression using the pan-specific E9 antibody, which 
identifies both MT-1 and MT-2 subfamilies (Zhou et al., 2006a). This study clearly seems 
to indicate that cadmium exposure induces MT expression in the urothelium; however, 
only three isoforms were studied at the transcript level and only general MT-1/2 
expression at the protein level. Moreover, the urothelial cells used were an immortalised 
cell line and thus were already genetically altered from normal human urothelium (see 
section 1.1.4). Further studies using primary samples to determine expression of all MT 
isoforms would aid the understanding of how in vivo cadmium exposure can alter MT 
expression in the bladder. 
1.5.6.2 MT Expression in Urothelial Cancer 
Altered MT expression has been observed in a number of different cancers, including 
lung, hepatic, breast, colorectal and urothelial carcinomas (Pedersen et al., 2009). In 
urothelial cancer, high expression of MT-1 and MT-2 has been associated with advanced 
tumour grade and stage, worse overall survival, reduced disease-free survival and 
decreased disease-free progression (Siu et al., 1998; Sens et al., 2000; Ioachim et al., 
2001; Somji et al., 2001; Saga et al., 2002; Yamasaki et al., 2006; Zhou et al., 2006a; 
Wülfing et al., 2007; Hinkel et al., 2008). Specifically, it was found that the 5 year 
survival rate for patients with low MT-1/2 expression was 72 %, whereas for patients 
with high MT-1/2 expression it was only 32 % (Hinkel et al., 2008). It was also observed 
that only 37.5 % superficial tumours demonstrated MT-1/2 expression, whereas 65.2 % 
invasive tumours showed expression (Yamasaki et al., 2006). Originally, MT-3 was also 
thought to be highly expressed in bladder tumours, with negative expression at both the 
transcript and protein level in normal bladder tissue (Sens et al., 2000). However, this has 
only been found by one research group, and the results are in direct contrast to the general 
consensus that MT-3 expression is restricted to neural tissue (Palmiter et al., 1992).  
 Again, the problem with these studies is a lack of discrimination between the MT 
isoforms. Most of the studies conducted looking at MT expression in urothelial cancer 
only analysed protein expression using the pan-specific MT-1/2 E9 antibody, meaning 
the isoform(s) responsible for increased MT protein abundance remain unknown. 
However, one study using the E9 antibody also went on to determine isoform-specific 
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transcript expression in normal and malignant bladder tissue, having detected over-
expression of MT-1/2 protein expression in all high-grade tumour samples. They found 
that MT-2A transcript was expressed in both normal and malignant tissue, but that the 
MT-1E transcript was expressed inconsistently. They also observed that MT-1X 
transcript expression was highly over-expressed in bladder cancer tissue compared to 
normal tissue. However, in contrast to MT-1/2 protein expression, MT-1X transcript 
levels did not vary with tumour grade (Somji et al., 2001). The data emphasises the 
importance of analysing MT isoform expression, so that individual isoforms responsible 
for gross protein changes may be identified and subtle changes in transcript expression 
identified. 
1.5.6.3 MT Expression in Cadmium-Induced Urothelial Carcinogenesis 
Studies directly investigating MT expression in cadmium-induced urothelial 
carcinogenesis are rare, most likely due to difficulty in gaining access to patient samples 
that have been strongly linked to cadmium exposure. To overcome this, one group have 
developed an in vitro cell culture model using cadmium-exposed malignantly-
transformed UROtsa cells, to determine factors such as MT expression. Upon inoculation 
into nude mice these cells were capable of forming tumours, and the authors went on to 
analyse MT protein expression in these heterotransplants. They observed high MT-1/2 
protein expression similar to that observed in high-grade bladder tumours, with the 
highest expression observed in less-differentiated areas of the tumour. Interestingly, the 
authors also found expression of MT-3 transcript and protein which had not been present 
in the transformed cell cultures prior to inoculation, leading to the suggestion that MT-3 
expression may be a consequence of tumour-formation. To identify the MT isoforms 
responsible for high expression of MT-1/2 protein in the heterotransplants, transcript 
expression in the malignantly-transformed UROtsa cell cultures was analysed. 
Significantly increased levels of MT-1E, 1X and 2A transcripts were observed in the 
cadmium-exposed, malignantly-transformed cells, suggesting that these isoforms may be 
responsible for the increased MT-1/2 protein expression. However, the other MT 
isoforms were not analysed, and thus may also play a role in the increased protein 
abundance (Zhou et al., 2006a; Zhou et al., 2006b).  
 To date, there has been only one in vivo study looking at MT expression and cadmium 
concentrations in urothelial carcinoma (mentioned briefly earlier in section 1.4.3). Wolf 
et al. (2009) took urinary samples from control and bladder cancer patients and analysed 
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them for MT-bound cadmium, using a combination of mass-spectrometry approaches. 
The authors found that urinary cadmium was predominantly bound to the MT fraction, 
and that the median concentration of MT-bound cadmium was significantly higher in 
bladder cancer patients; 1.8 µg/L compared to 0.8 µg/L in the control group. This is the 
first study showing such a correlation between MT, cadmium and urothelial cancer. 
However, it is unclear how many of the urothelial carcinoma samples may have been 
linked to cadmium exposure, as no account was made for smoking and/or occupation. 
This could explain why there was a high amount of data variance in the cancer cohort, as 
some patients were probably never exposed to cadmium and thus may have had much 
lower cadmium concentrations. In order to further investigate the correlation between MT 
expression and cadmium-induced urothelial cancer a more in-depth study is needed, with 
sufficient patient details to stratify cases into exposed and control patient cohorts.  
1.5.7 MT Expression in Cadmium-Induced Urothelial Carcinogenesis – Cause or 
Consequence?  
1.5.7.1 Cause – Potential Mechanisms of Carcinogenesis 
A number of the proposed normal functions of MT could potentially contribute to 
carcinogenesis, such as its role in proliferation, angiogenesis and ROS scavenging 
(section 1.5.4). It is for this reason that MT expression is often seen as a ‘double-edged 
sword’; on the one hand, it functions to protect the cell, but by the same mechanisms can 
also facilitate malignant events (Hart et al., 2001; Sigel et al., 2009; Pedersen et al., 2009; 
Capdevila et al., 2012). For example, it has been shown that MT can contribute to cell 
survival by increasing resistance to ROS-induced apoptosis, which becomes a problem 
when the cell in question has acquired neoplastic properties (Eneman et al., 2000). 
Resistance to apoptosis, along with increased cellular proliferation (also mediated by MT; 
Ioachim et al., 2001) can result in the survival and expansion of deleterious cells which 
would otherwise be removed from the body. It has additionally been shown that cadmium 
exposure can result in inhibition of DNA repair (Potts et al., 2001), which coupled with 
increased cellular protection via cadmium-induced MT expression, increases the 
probability of cells with dangerous mutations proliferating and passing on these defects 
to their progeny (Hart et al., 2001). The ability to counteract ROS could also play a role 
in chemotherapy resistance, and high levels of MT expression have been correlated with 
treatment resistance in bladder cancer (Satoh et al., 1993; Wülfing et al., 2007). 
Specifically, after radical surgery and adjuvant chemotherapy, 100 % patients with high 
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tumour MT expression progressed within 9 months. By contrast, even after 5 years only 
65 % patients with low MT expression had progressed (Yamasaki et al., 2006). MT has 
not only been suggested to indirectly inhibit chemotherapy due to ROS scavenging and 
upregulation of pro-survival mechanisms, but also via direct sequestration of platinum-
based chemotherapeutic agents such as cisplatin (Hagrman et al., 2003).  
 The ability of MT to sequester carcinogenic metals is also a potential contributor to the 
development of carcinogenesis. Although sequestration is an efficient detoxification 
method in the short-term, it also means that the metal ions remain in the body for 
prolonged periods of time. MT-cadmium complexes may have a slow rate of degradation 
(section 1.5.4.2) but at some point the protein is lost, meaning that the cadmium ions are 
freed, before again being bound by MT protein. MT therefore appears to play a key role 
in the systemic cycling of cadmium, which may result in repeated release of carcinogenic 
ions over time (Sandbichler and Höckner, 2016). This imperfect system of cadmium 
chelation supports the hypothesis that cadmium detoxification is a property of MT rather 
than its evolutionary function, and that its ability to bind cadmium is actually just a result 
of its ability to regulate zinc (Vašák and Meloni, 2011; Capdevila et al., 2012). Despite 
these data, a putative role for MT expression in urothelial carcinogenesis has not been 
confirmed. The consequences of cadmium-induced MT expression remain to be 
elucidated, with questions surrounding a potential switch from cytoprotective 
mechanisms to pro-carcinogenic, and whether once a tumour is established MT 
expression only contributes to carcinogenesis rather than initiating it. 
1.5.7.2 Consequence – MT as a Potential Biomarker of Cadmium Exposure 
As discussed earlier (section 1.5.6.1), cadmium appears to be a potent inducer of MT 
expression. It has therefore been suggested that MT may be a useful biomarker of 
cadmium exposure. MT expression is already used in a number of organisms as a means 
of monitoring environmental contamination and remediation. Waterborne cadmium-
contamination is often monitored using aquatic organisms such as fish, where MT protein 
can accumulate in organs such as the gills (Smaoui-Damak et al., 2009; Shariati et al., 
2011). Invertebrate organisms are commonly used for monitoring soil-contamination, 
with earthworms especially proving useful indicators. The MT concentration in their 
coelomic fluid has proved a particularly sensitive biomarker and has been recommended 
for use in the monitoring and assessment of polluted soil (Calisi et al., 2014).  
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 MT has also been suggested as biomarker of human exposure to occupational and 
environmental cadmium.  MT expression in peripheral blood lymphocytes (PBLs) has 
been suggested as a sensitive marker of exposure, where one study showed a significant 
increase in PBL MT-1/2 transcript in workers occupationally exposed to ambient 
cadmium (Ganguly et al., 1996). The use of MT as a biomarker has been further supported 
by in vitro studies demonstrating that culturing PBLs with cadmium resulted in dose-
dependent increases in MT-1/2 transcript (Yamada and Koizumi, 2001). A recent study 
attempted some differentiation between the PBL MT isoforms in workers exposed to 
cadmium. Using MT-1A, 1E, 1F and 1X transcript analysis they found that MT-1E, 1F 
and 1X transcript expression increased with blood cadmium levels, whereas MT-1A 
transcript expression increased with urinary cadmium levels (Chang et al., 2009). 
Correlation between PBL MT expression and cadmium-exposed individuals was 
supported by a further study looking at populations residing in cadmium-contaminated 
areas in Thailand. The authors found that PBL MT-1A and MT-2A transcript expression 
was significantly elevated in exposed individuals and correlated with blood and urinary 
cadmium levels (Boonprasert et al., 2012). Due to the findings of studies such as these it 
has been suggested that PBL MT-1/2 isoforms may be a useful biomarker of cadmium 
exposure and internal dose, and may therefore have a role in monitoring occupational 
exposure (Chang et al., 2009).  
 However, a potential flaw of using PBLs to monitor human cadmium exposure is that it 
involves obtaining blood samples, when other bodily fluids such as urine are more easily 
obtained and readily available. It has also been suggested that blood cadmium levels are 
only reflective of recent exposure, whereas urinary cadmium reflects cumulative 
exposure over time and overall body burden (Agency for Toxic Substances and Disease 
Registry, 2008). This supports the hypothesis that cadmium may accumulate in the 
bladder, and thus urinary MT expression may prove a more useful biomarker of long-
term exposure than PBL MT. This hypothesis has been investigated by a number of 
different research groups looking at occupationally exposed workers, with concurring 
results. Urinary metallothionein levels have been found to be elevated in cadmium-
exposed worker groups and correlated with cadmium concentrations in the liver, kidney, 
blood and urine (Tohyama et al., 1981; Shaikh and Tohyama, 1984; Shaikh et al., 1990; 
Nakajima et al., 2005; Chen et al., 2006). Moreover, elevated MT levels were observed 
in the urine from an environmentally-exposed patient for up to 14 years after cessation of 
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exposure, and correlated with urinary cadmium levels which also remained elevated 
(Tang et al., 1999).  
 The ability to detect elevated MT expression post-exposure supports MT as a potential 
biomarker, as exposure of an individual may no longer be current. However, the longevity 
of MT expression would need further investigation, as it is important to establish how 
recent exposure would have to be for MT expression to remain elevated. Another flaw 
with the biomarker studies previously performed is that there is no discrimination 
between the urinary MT isoforms induced by cadmium exposure. As examined earlier 
(section 1.5.5.3), MT isoform induction appears highly specific, and thus it would be 
important to identify a urinary isoform specific to cadmium exposure. Otherwise, 
elevated general MT expression could be a result of secondary exposure events such as 
increased ROS, which could also be caused by a number of other factors e.g. infection 
(Wang et al., 2004; Mita et al., 2008).  
 A biomarker of exposure to cadmium would be useful for several reasons. Monitoring 
worker exposure to occupationally-based cadmium would be useful in preventing toxicity 
from the same, as well as preventing long-term effects such as osteoporosis and potential 
carcinogenesis (see section 1.4.3; Roels et al., 1999; Jarup et al., 1998). Furthermore, a 
biomarker could be used to identify patients whose urothelial cancer may be linked to 
cadmium exposure. Molecular analysis of these cancers could potentially prove useful 
for further elucidation of the mechanisms of cadmium-induced carcinogenesis, and thus 
how to target treatment. Additionally, as MT expression has been linked to chemotherapy 
resistance (section 1.5.7.1), its expression in tumours could potentially inform clinicians 
that frequent monitoring of these patients for recurrence is required post-treatment.  
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1.6 Thesis Aims and Objectives. 
1.6.1 Aims 
To investigate the MT response of normal human urothelium to cadmium exposure, 
assessing individual MT isoforms as potential biomarkers of exposure. 
1.6.2 Objectives 
➢ To characterise basal and heavy metal-inducible MT isoform expression in normal 
human urothelium. 
➢ To determine whether cadmium can cross an intact urothelial barrier. 
➢ To investigate the specificity and longevity of MT isoform induction. 
➢ To observe whether in vitro MT induction can be translated to ex vivo ureter organ 
culture. 
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Chapter 2: Materials and Methods 
2.1 General 
All laboratory work was carried out at the Jack Birch Unit for Molecular Carcinogenesis, 
Department of Biology, University of York. Support and use of equipment was also 
provided by the Department of Environment, University of York. Human tissue biopsies 
were taken at multiple sites (see section 2.6.1). 
2.2 Suppliers 
Commercial manufacturers and suppliers of laboratory equipment and reagents are 
named in the text at first mention. A full list detailing names and addresses can be found 
in the Appendix. 
2.3 Glassware and Plastic-ware 
All glassware (including glass pipettes; Scientific Laboratory Supplies) and plastic-ware 
(including microfuge tubes; Sarstedt, and pipette tips; Starlab) were sterilised by 
autoclaving at 121ºC for 20 min followed by air drying in an oven at 60ºC. Glass pipettes 
were placed in a metal container (Jencons) for the sterilisation process. All sterile single-
use plastic-ware were manufactured by Sterilin and provided by SLS, with the exception 
of serological pipettes which were supplied by Sarstedt. 
2.4 Stock Solutions 
Formulae for all stock solutions used can be found in the Appendices (section 9.1). All 
chemicals used were of either analytical reagent grade or tissue culture grade. All 
solutions were prepared using ultra-pure water (H2O) from a Purelab Ultra Genetic ultra-
violet water purification system (ELGA). Sterilisation of water and solutions was carried 
out by autoclaving at 121ºC for 20 min or use of a 0.2 µm nitrocellulose syringe filter 
(Millipore). 
2.5 Handling and Use of Cadmium Chloride 
Cadmium chloride is known to be a human carcinogen as recognised by the International 
Agency for Research on Cancer (IARC). It is toxic if inhaled or swallowed and an irritant 
to skin, as well as posing a significant threat to aqueous organisms. Prior to purchase a 
risk assessment was carried out by the Biology Department Safety Officer, and a Standard 
Operating Procedure was prepared (see Appendices; section 8.7) in order to minimise 
exposure and risk to the aquatic environment. 
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2.5.1 Storage and Handling  
Stock powder of cadmium chloride (CdCl2; Sigma) was kept in a tightly closed container 
containing silica gel beads as desiccant. The container was kept in a locked and labelled 
‘Dangerous Chemicals’ cabinet. Once powder had been dissolved in water to produce a 
working stock solution, aliquots were kept in a clearly labelled box in a locked -20 °C 
freezer. 
When handling CdCl2 a lab safety coat and nitrile gloves were worn at all times. CdCl2 
was only used in externally-vented hoods with safety cabinet shields which provided 
adequate protection for the eyes and minimised risk of inhalation. 
2.5.2 Making up Stock Solutions 
All weighing of powder stock was carried out in an externally vented fume hood (model 
number E32841; Fumetec Ltd). A tray containing damp blue roll was used to catch any 
spillage and strength of air flow was tested on a non-toxic substance to ensure powder 
was not blown into the air. A disposable spatula was used to place an undefined amount 
of CdCl2 powder into a pre-weighed bijou tube (Greiner Bio-one) which was then sealed. 
The bijou was then placed in an Explorer® Pro (Ohaus) enclosed digital scale. H2O was 
added to make up a working stock solution, which was then passed through an Acrodisc 
0.02 µM syringe filter (VWR) and stored appropriately. 
2.5.3 Disposal 
Any equipment that came into contact with CdCl2 was placed in a small autoclave bag, 
which contained enough blue roll to capture any excess liquid. Bags were then sealed and 
placed into double-bagged clinical waste bags for disposal by incineration. 
Liquid waste (including aspirated tissue culture medium) was stored in a clearly-labelled 
waste bottle containing 10 % (w/v) Virkon™. The bottle was kept in a locked ‘Dangerous 
Chemicals’ cabinet when not in use. When 90 % full, bottles were further labelled with 
the required paperwork and taken to Biology Stores for disposal by incineration. CdCl2 
was not allowed to enter the water system at any point. 
2.5.4 Use of other Carcinogenic Metalloids 
The work also involved the use of the carcinogenic metalloids arsenite and nickel 
chloride. For health and safety measures these substances were handled in the same 
manner as CdCl2. 
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2.6 Tissue Specimens 
2.6.1 Source of Human Tissue Specimens 
2.6.2.1 ‘Normal’ Human Urothelial Tissue 
Surgical specimens of human urothelium were collected with NHS Research and Ethics 
Committee (REC) approval and informed consent as required.  Samples of ureter and 
renal pelvis were obtained from patients undergoing urological surgery with no known 
history of urothelial malignancy from St. James’s University Hospital, Leeds and 
Pinderfields Hospital, Wakefield (REC references 99/095, 02/208, respectively).   
All samples were anonymous and provided with basic details of the surgical procedure, 
patient age, gender and urological diagnosis (if appropriate). Upon arrival, normal human 
urothelial specimens were allocated an arbitrary Y-number for laboratory records (all Y-
numbers used during this work are detailed in Table 14). Surgical samples were collected 
aseptically in sterile Transport Medium (see Appendices) in a 30 mL Universal container. 
Samples were stored at 4 ºC until use (generally <5 days). For each sample obtained, a 
small representative sample was taken for routine histology using Haematoxylin and 
Eosin (H&E; see section 2.8.3) staining to confirm a normal urothelium, with absence of 
metaplasia, dysplasia or neoplasia. 
2.7 Cell and Organ Culture 
2.7.1 Cell and Organ Culture Equipment 
All procedures for cell and organ culture were carried out under strict aseptic conditions 
using class II laminar air flow safety hoods with HEPA filters (Medical Air Technology). 
A vacuum pump connected to a Buchner flask was used for aspiration of waste medium 
and subsequently decontaminated in 10 % (w/v) Virkon™ solution. Hood surfaces were 
wiped before, during and after use with 70 % (v/v) EtOH.  
 All cell cultures were maintained in HERAcell™ 240 incubators (Thermo Scientific) at 
37 ºC in a humidified atmosphere, with 5 % or 10 % CO2 in the air depending on medium 
used. All organ cultures were maintained in a Forma Steri-cult CO2 humidified incubator 
with HEPA filter (Thermo Scientific) at 37ºC in 10% CO2 in air. In accordance with the 
Human Tissue Act (HTA) license the incubator was only used for the growth of human 
tissue and was kept locked at all times. 
 Cell cultures were observed and phase-contrast images captured using an EVOS® XL 
Core cell imaging system (Life Technologies). All images were captured using x10 
objective.  Centrifugation of cells was carried out using a Sigma 2-4 centrifuge (Philip 
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Harris). All centrifugation steps were performed at 250 g for 4 min unless otherwise 
stated. 
 Cell enumeration was performed using a Neubauer haemocytometer (VWR). Once cells 
were suspended in medium, 2 x 10 µL cell suspension were placed under each side of the 
coverslip. Cell counts were performed for the four individual 1 mm squares, from both 
sides of the haemocytometer. Counts were then averaged to give a mean cell count and 
multiplied by 104 to obtain mean cell number per mL. Cell suspension was then diluted 
accordingly to give the desired cell seeding density. 
2.7.2 Cell and Organ Culture Media 
NHU cells were maintained in low-calcium [0.09 mM] Keratinocyte Serum-Free Media 
(KSFM; Gibco). Prior to use, KSFM was ‘completed’ (known as KSFMc) by the addition 
of bovine pituitary extract (BPE; 50 µg/ml; Gibco) and recombinant epidermal growth 
factor (rEGF; 5 ng/ml; Gibco) as recommended by the manufacturer. Cholera toxin (30 
ng/ml) was also added in order to augment plating efficiency and suppress the growth of 
fibroblasts (Southgate et al., 1994). 
Bladder cancer cell lines (EJ, RT112 and RT4; ATCC) and organ cultures were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco) and Roswell Park 
Memoriam Institute 1640 medium (RPMI; Gibco) in a 1:1 ratio. The DMEM:RPMI 
medium was further supplemented with 5% (v/v) fetal bovine serum (FBS; Seralabs) and 
1% (v/v) L-Glutamine (Sigma) was added before use due to its lability. Bladder cancer 
cell lines were also tested for Mycoplasma spp. infection (see section 2.7.7) and 
genotyped to ensure authenticity of the cell line.  
 Depending on cell type, cultures were incubated at different CO2 concentrations in order 
to maintain optimum medium pH levels. Established bladder cancer cell lines were 
maintained in 10% CO2 in air, whereas normal human urothelial (NHU) cells were 
maintained in 5 % CO2. 
2.7.3 Isolation of NHU Cells 
Isolation and culturing of NHU cells was performed as previously described (Southgate 
et al., 1994). 
 Surgical samples of normal urothelium were placed in Petri-dishes containing Transport 
medium and aseptically dissected in order to remove excess tissue. Following this, 
samples were sectioned into approximately 1 cm2 pieces and placed into a Universal tube 
containing Stripper medium (see Appendix). Samples in the Stripper medium were 
incubated at either 37 ºC for 4 h or at 4 ºC overnight in order to promote urothelial 
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separation from the underlying stroma. The tissue was then transferred into a Petri-dish 
and the urothelial sheet was physically separated using a pair of sterile forceps. Sheets 
were centrifuged for collection and then further disaggregated by re-suspension in 2 ml 
(400 U) collagenase type IV (see Appendix) at 37 ºC for 20 min, which disaggregates 
cells with minimum damage and primes them for primary culture. After another 
centrifugation step the cell pellet was re-suspended in KSFMc and seeded into Cell+™ 
tissue culture flasks (Sarstedt) at a minimum seeding density of 4 x 104 cells/cm2. This 
was the minimum seeding density used for all primary NHU cell culture experiments. 
KSFMc was removed and replenished twice a week in order to maintain primary cultures. 
2.7.4 Subculture of NHU Cells 
Once in culture, NHU cells adopt a non-differentiated proliferative phenotype and 
propagate as a monolayer (Southgate et al., 1994). Upon reaching approximately 95 % 
confluence, cultures were passaged in order to maintain proliferation and prevent contact-
inhibited growth. All cultures were used for experiments between passage 2 and 6 to 
reduce any extraneous effects of long-term culture, which can induce culture senescence. 
When routinely passaged, cells were generally split in a 1:3 ratio. However, for 
experiments involving cadmium exposure cells were seeded at a density of 6 x 104 
cells/cm2, the minimum density required for ‘normal’ proliferation (see Figure 21).  
For routine passage, the culture medium was aspirated and replaced with 0.1 % (w/v) 
ethylenediaminetetra-acetic acid (EDTA) in phosphate-buffered saline (PBS; see 
Appendix). Cultures were then incubated at 37 ºC for approximately 5 min, until the cells 
began to ‘round up’ and dissociate from each other. EDTA was aspirated and depending 
on culture-ware size 0.5-1 mL Trypsin-Versene® (TV; see Appendix) was added, before 
incubation at 37 ºC for a further 1-2 min. At this point gentle tapping of the flask 
facilitated the detachment of cells, and trypsin activity was quickly inhibited by the 
addition of KSFMc containing 1.5 mg/mL of soybean trypsin inhibitor (TI; see 
Appendix). This TI step was omitted for cultures whose medium already contained 
serum, such as established cell lines (section 2.7.5). Cells were centrifuged at 250 g for 4 
min to form a pellet, which was then flicked and re-suspended in KSFMc at the required 
seeding density before deposition onto either Cell+™ tissue culture flasks, Primaria™ 6-
well plates (SLS) or ThinCert™ membranes (Greiner) as appropriate for the subsequent 
experiment. After subculture cells were left for 24 h to reattach and stabilise before any 
experimentation was started. 
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2.7.5 Subculture of Urothelial Cancer Cell Lines 
Established bladder cancer cell lines were passaged using the same method as described 
above (2.7.4), with the omission of the TI step. Cells were seeded onto Cell+™ tissue 
culture flasks at different ratios depending on the cell line and sub-cultured when 
confluent (see Table 4). 
 
Table 4: Summary of the urothelial cancer cell lines used for this thesis. The name of each 
urothelial cancer cell line is provided, as well as tissue of origin, grade of cancer and subculture 
ratio.  
Cell Line Tissue of Origin Cancer Grade Subculture Ratio 
EJ Human bladder 
carcinoma 
3 1:80 
RT112 Human bladder 
carcinoma 
2 1:40 
RT4 Human bladder 
papilloma 
1 1:10 
 
2.7.6 Cryopreservation of NHU Cells 
Cells were harvested from tissue culture flasks as described in section 2.7.4. However 
once cells were pelleted, instead of re-suspension in KSFMc they were re-suspended in 
Freezing mix at approximately 1 x 106 cells/mL. Freezing mix consisted of the 
appropriate culture medium, 10 % (v/v) FBS and 10 % (v/v) dimethylsulphoxide 
(DMSO), and 1 mL of mix was used for each 25 cm2 area of cells harvested. 1 mL cell 
suspension was transferred into a pre-labelled 2 mL cryovial (Starstedt), and the cryovial 
was placed into an isopropanol freezing bath (Nalgene) at -80 ºC overnight. This was to 
allow the cells’ temperature to be gradually reduced to -80 ºC at a steady rate of -1 ºC per 
min. The following morning the vial was then transferred to a liquid nitrogen dewar for 
long-term storage. 
 For recovery of cells, vials were immediately placed into a 37 ºC water bath for rapid 
thawing. The Freezing mix was then aspirated and added to 9 mL pre-warmed KSFMc in 
a 30 mL Universal tube. Cells were then pelleted at 250 g for 4 min, re-suspended in 10 
mL KSFMc and seeded onto a 75 cm2 Cell+™ tissue culture flask for further culturing. 
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2.7.7 Cell Culture Screening for Mycoplasma spp. Infection 
All cell cultures (NHU and cell line) were routinely checked for bacterial infection by 
Mycoplasma spp. using the DNA intercalating dye bisbenzimide (Hoescht 33258; 
Molecular Probes). Cell suspensions were seeded onto a Teflon™-coated 12-well multi-
test slide (Hendley-Essex) at a volume of 50 µL per well and a density of approximately 
5 x 104 cells/mL. Cells were allowed to attach by incubating at 37 ºC for 3 h. At this point 
the slides were flooded with 5 mL appropriate medium (enough to cover the slide) and 
returned to the incubator overnight. The following morning medium was aspirated and 
the cells washed twice with PBS, before fixation for 30 secs by immersion in a 1:1 ratio 
of methanol and acetone (Fisher Scientific). Slides were then allowed to air-dry. 
Following this the cells were stained by Hoescht 33258 (1 µg/mL in PBS) by washing 
the slides and incubating on a Primix 7 orbital shaker (Jencons PLS) at ambient 
temperature for 5 min (slides were covered in foil during this incubation to exclude light). 
Cells were rinsed in H2O to remove Hoescht 33258 and mounted with antifade (see 
Appendices) before being left to dry. Cells were then viewed using an Olympus BX60 
microscope (Olympus) using epifluorescent illumination to look for extra-nuclear DNA 
staining. Absence of ectopic staining indicated a negative result for infection. 
2.7.8 Induction of NHU Cell Differentiation 
Stimulation of NHU cells to terminally differentiate was performed using a previously 
developed method (Cross et al., 2005). Proliferating NHU cells were grown until 
approximately 95 % confluent, when KSFMc medium was aspirated and replaced with 
KSFMc supplemented with 5 % (v/v) adult bovine serum (ABS; Seralab). Cells were 
cultured for a further 5 days, passaged and seeded at 5 x 105 cells/mL onto 12-well 
ThinCert™ (Greiner Bio-One) membranes with a 0.4 µm pore size. Cultures were 
maintained with 500 µL medium in the apical chamber and 2 mL in the basal chamber. 
24 h after seeding, the exogenous calcium concentration was increased to 2 mM (near 
physiological) and cells cultured for a further 7-9 days, with medium changes every 2-3 
days. This differentiation protocol is summarised in Figure 6. 
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Figure 6: Diagram demonstrating the biomimetic approach for differentiation of NHU cells. 
Confluent NHU cells were cultured for 5 days in KSFMc + 5 % adult bovine serum (ABS). Cells 
were then passaged and seeded at a density of 5 x 105 cells/cm2 and further cultured in the 
presence of 5 % ABS for 24 hours. At this point the exogenous calcium concentration was 
increased to [2 mM] and cells cultured for a further 7 days, forming cell sheets. Differentiation 
was confirmed by the formation of a functional barrier which could generate transepithelial 
electrical resistance (see section 2.7.9 below). 
 
2.7.9 Transepithelial Resistance Readings 
For measurement of transepithelial resistance (TER), which is indicative of barrier 
formation associated with urothelial differentiation, an EVOM™ epithelial voltohmmeter 
(World Precision Instruments) was used on cells previously seeded onto 12-well 
ThinCert™ membranes. Prior to use the electrode was placed in a Universal tube 
containing 10 mL activated Cidex Plus (see Appendix; World Precision Instruments) for 
15min to allow sterilisation. The electrode was then washed once with appropriate culture 
medium (KSFMc supplemented with 5 % ABS and 2 mM CaCl2) and placed into another 
Universal tube containing fresh medium in order to calibrate. To perform the TER 
reading, the electrode was slowly lowered into the well until the longer probe made 
contact with the bottom of the basal chamber, meaning the shorter probe stopped just 
above the membrane. The electrode was then held in place until a settled reading was 
obtained on the Voltohmeter. For each well 3 separate readings were taken and averaged 
in order to give the most accurate reading in kΩ/cm2. A function barrier was considered 
to be a TER reading >0.5 kΩ/cm2. When finished, the electrode was washed in sterile 
H2O and allowed to air-dry on blue roll. 
2.7.10 AlamarBlue® Growth Assay 
AlamarBlue® (Serotec) is an indicator dye used to infer cell viability, based on the 
assumption that metabolic activity proportionately reflects cell number. It relies on the 
oxidative reduction of the compound resazurin (the active ingredient of AlamarBlue®) 
by cells to the flurorescent molecule rezorufin. Viable cells constantly facilitate this 
conversion and therefore the amount of fluorescence can be used to quantitate change in 
cell biomass. Proliferating NHU cells were seeded at the required experimental density 
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onto a Primaria™ 96-well plate at a volume of 200 µL/well. For each experiment 6 
technical repeats were included. The outside wells of the plate were filled with sterile 
water in order to prevent cultures from drying out. Once seeded, cells were left to adhere 
for 24 h before the addition of any treatments (day 0). On the day of treatment, medium 
change was performed and treatments added; no further medium change was conducted 
during the experiment. Absorbance readings were taken on days 1, 3, 5 and 7. On the day 
of each reading medium was removed from the cells and replaced by 200 µL 
AlamarBlue® diluted 1:10 with corresponding culture medium. Cells were left for 4 h to 
incubate with the solution. The 96-well plate was then transferred to a Multiskan Ascent 
96/384 Plate Reader (Thermo Scientific) and the optical density of each well (NHU cells 
and no cell controls) measured at test (570 nm) and reference (630 nm) wavelengths. 
Absorbance was directly proportional to mitochondrial activity within cells, and was 
therefore taken to be directly proportional to cell number. Percentage reduction in 
AlamarBlue® was calculated using the following equation: 
 
(
(34798 × 𝑁𝐻𝑈 𝐶𝑒𝑙𝑙𝑠570) − (80586 × 𝑁𝐻𝑈 𝐶𝑒𝑙𝑙𝑠630)
(155677 × 𝑁𝑜 𝐶𝑒𝑙𝑙𝑠630) − (5494 × 𝑁𝑜 𝐶𝑒𝑙𝑙𝑠570)
) ×100 
  
2.7.11 Organ Culture Sample Preparation 
All preparation took place under aseptic conditions. Ureteric samples were removed from 
a universal container and placed into a Transport medium-containing Petri-dish using 
sterile forceps. Surgical scissors were used to strip excess fat from the sample so that only 
the ureter remained. Scissors were the n used to cut along one side of the sample, 
revealing the urothelium. Ureter pieces were dissected into approximately 1 cm2 sections 
and kept in the Petri-dish in Transport medium until transfer to organ culture. 
2.7.12 Organ Culture Constructs 
Ureter pieces were placed urothelial side-up on cell culture inserts with 3 µM pore size 
(BD Falcon™) in a 6-well plate (Corning® Costar®). Samples were maintained in 
appropriate organ culture medium (described in 2.7.2) at a liquid:liquid interface, with 2 
mL medium in the basal chamber and a small amount of medium just covering the surface 
of the urothelium in the insert (approximately 4-5 drops from a Pasteur pipette). Medium 
was changed every 2-3 days to remove waste and provide nutrients. For exposure, 
cadmium was added to both chambers to maintain the concentration, as there was no 
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urothelial barrier present to prevent diffusion of solutes through the membrane. A 
diagram summarising the organ culture method can be found in Figure 7.   
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Figure 7: Diagram summarising the method for cadmium-exposed ureter organ culture. A 
small piece of healthy human ureter was cut open and laid flat to reveal the urothelium, which 
lies on top of stromal tissue. The ureter was placed urothelium-side up on a 3 µm pore-size 
membrane and cultured within a well. Both the apical and basal chambers were filled with 
medium supplemented with cadmium, with the apical medium just covering the surface of the 
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urothelium in order to maintain a liquid:liquid interface. For control conditions the same method 
applied but the medium did not contain cadmium. 
 
2.8 Histology 
2.8.1 Embedding of Cultured NHU Cell Sheets 
Differentiated NHU cell sheets that had been cultured on ThinCert™ membranes in wells 
were harvested intact for histological analysis. Medium was aspirated from cultures and 
the sheets were washed with pre-warmed (37 ºC) Dulbecco’s phosphate-buffered saline 
(D-PBS) solution (Gibco). D-PBS was aspirated and 2 % (w/v) Dispase II (Sigma D-
4693) added, as this is gentler than trypsin for cell disaggregation. 500 µL dispase was 
placed in the apical chamber and 2 mL in the basal chamber, and cultures were left to 
incubate at 37ºC for 30-45 min under frequent observation. When sheets began to lift the 
membrane was immediately placed in a Petri-dish containing pre-warmed D-PBS. A 
Pasteur pipette was then used in order to ‘float’ the cell sheet off the membrane and into 
a ‘Cell Safe’ histology cassette (CellPath) in the appropriate orientation. Cassettes were 
labelled, submerged in 10 % (v/v) formalin in PBS (see Appendix) for fixation and left 
for 24 h. After this time point cassettes were transferred into 70 % EtOH and stored until 
further processing. 
 To finish the embedding process, cassettes were transferred to fresh 70 % EtOH for 5 
min. They were then submerged in absolute EtOH for 3x5 min, isopropanol for 2x5 min 
and finally in xylene for 4x5 min. Cassettes were then transferred to molten paraffin wax 
at 60ºC (Fisher Scientific) for 4 separate incubations of 15 min. Cell sheets were removed 
from cassettes using forceps and placed into a metal mould. Sheets were then orientated 
correctly, the mould filled with wax, and the blocks placed to set on a cold table (RA 
Lamb). 
 For sectioning, pre-cooled wax blocks were cut into 5 µm thick sections using a Leica 
RM2135 microtome (Leica Microsystems) and placed into a 37 ºC water bath. Sections 
were collected on electrostatically charged Superfrost Plus™ microscope slides (BDH), 
allowed to air-dry and then baked for 1 h on a hot plate (RA Lamb) before further 
processing. 
2.8.2 Embedding of Tissue Samples  
Tissue specimens were placed into 10 % (v/v) formalin in PBS for at least 24 h depending 
upon the size of the sample. Samples were then transferred to 70 % EtOH (v/v) until 
further processing. 
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 Tissue samples were placed into a labelled ‘Cell Safe’ histology cassette and submerged 
in fresh 70 % (v/v) EtOH for 10 min. The cassettes were then submerged in absolute 
EtOH for 3x10 min washes on an orbital shaker. Following this, cassettes were 
submerged in isopropanol (Fisher Scientific) for 2x10 min washes, and further in xylene 
(Fisher Scientific) for 4x10 min washes; all of which took place inside an externally 
vented fume food. Samples were then placed sequentially in molten paraffin wax and 
embedded as described in section 2.8.1. 
2.8.3 Haematoxylin and Eosin (H&E) Staining 
H&E staining was used for histological analysis of embedded samples. Sections were de-
waxed in xylene (Fisher Scientific) using 4 sequential submersions of 10 mins, 10 min, 1 
min and 1 min duration. Sections were then re-hydrated in 3 sequential 1 min submersions 
in absolute EtOH, followed by a 1 min submersion in 70 % (v/v) EtOH and washing for 
1 min in tap water. For staining, sections were then sequentially submerged in 
haematoxylin (see Appendix) for 2 min, running tap water for 1 min, Scott’s tap water 
(see Appendix) for 1 min, running tap water for 1 minute, 1 % (w/v) Eosin (RA Lamb) 
for 30 secs and finally a 1 min wash in running tap water to remove any residual stain. 
Slides were de-hydrated by sequential submersions in 70% (v/v) EtOH (1 min), absolute 
EtOH (3x1 min) and xylene (2x1 min). Sections were then mounted using DPX fluid 
(CellPath) and sealed under cover slips (SLS). 
2.8.4 Immunolabelling 
To analyse protein expression in embedded tissue, immunohistochemical methods were 
used. Either an indirect streptavidin/biotin ‘ABC’ immunoperoxidase method or an 
amplified horseradish-peroxidase (HRP) polymer staining kit was used (see sections 2.8.7 
and section 2.8.8 respectively) as appropriate for the protein of interest. 
 Details of antibodies used for immunolabelling are given in Table 12. Antibodies were 
kept at 4 °C, -20 ºC or -80 ºC according to suppliers’ guidelines, with working stock 
solutions being kept at 4 ºC for up to 6 months. Working stocks were made up in either 
Tris-buffered saline pH 7.6 (TBS; see Appendix) or Tris-buffered saline supplemented 
with 0.1 % (v/v) Tween 20 (SLS) pH 7.6 (TBS-T; see Appendix) as appropriate for the 
immunolabelling method. Optimal antibody concentrations for each antibody were 
titrated using known negative and positive control tissues (Figure 8; see Table 13 for 
concentrations).
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Figure 8: Immunohistochemical labelling of ureter and kidney demonstrating MT-1/2 protein expression. For all antibodies used a range of dilutions were tested 
in order to determine the optimal working concentration. In this example, the E9 primary antibody was tested at 1:100, 1:200 and 1:400 dilutions on tissues with 
negative (ureter) and positive (kidney) target protein expression. 1:400 was selected as the optimum dilution. Scale bar: 25 µm. 
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 For all IHC experiments conducted, a number of experimental controls were included 
(Figure 9). A secondary antibody-only control was used on the sample in order to detect 
any non-specific background labelling. An antibody known to work on the sample was 
included as a positive method control. Lastly, a sample of tissue known to express the 
target protein was used to ensure the proficiency of the test antibody.
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Figure 9: Immunohistochemical labelling of ureter (Y1770) cultured in 10 µM CdCl2 for 7 days. For each IHC experiment a number of controls were included to 
ensure robustness of the primary result. (A) The primary antibody was used on the sample tissue. (B) A secondary antibody-only negative control was used to check 
for any non-specific background labelling, and (C) an antibody specific to a protein known to exist within the sample was used as a positive control to show that the 
method had worked. (D) Lastly, a sample known to express the target protein was included as an internal positive control in order to demonstrate the proficiency of 
the primary antibody. In this case, the control sample used was kidney tissue. Scale bar: 25 µm.
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2.8.5 Preparation of Sections and Endogenous Peroxidase Blocking 
Samples were de-waxed and re-hydrated prior to immunolabelling as described in section 
2.8.3. If samples contained vasculature and/or red blood cells endogenous peroxidase 
activity was blocked using 3 % (v/v) hydrogen peroxide (Fisher Scientific) for 10 min, 
followed by rinsing in running tap water for 10 min. 
2.8.6 Antigen Retrieval  
Antigenic sites can become masked during the tissue fixation process and can therefore 
be unable to bind antibodies (Arnold et al., 1996). To unmask antigens, thereby restoring 
antigen reactivity, a number of antigen retrieval methods were used: 
a) Heat-induced epitope retrieval (HIER) in appropriate buffer. Samples were placed 
in a 900 W microwave at full power for 13 min (to boil for 10 min) in either 10 
mM citric acid buffer pH 6 (see Appendix) or 1 mM EDTA pH 8 (see 
Appendices), using a Pyrex™ dish covered with perforated Clingfilm™. Dishes 
were then immediately placed on ice to accelerate the cooling down process. 
b) Enzymatic digestion (trypsinisation).  0.1 g trypsin from porcine pancreas (Sigma) 
was added to 0.1 % (w/v) pre-warmed calcium chloride pH 7.8 (see Appendix) to 
make a 0.1 % (w/v) trypsin solution. Slides were incubated in this solution at 37 
ºC for 10 min using a water bath. 
c) HIER combined with enzymatic digestion. Slides were incubated in the 0.1 % 
(w/v) trypsin solution in calcium chloride pH 7.8 at 37 ºC for 1 min before 
microwaving in citric acid buffer as described in a). 
After antigen retrieval, slides were rinsed in running tap water for 1 min. They were then 
placed in Shandon™ Sequenza™ cover-plates (Thermo Scientific) submersed in either 
TBS or TBST-T as appropriate for the immunolabelling method. 
2.8.7 Immunolabelling using Streptavidin/Biotin ‘ABC’ Method 
Endogenous avidin-binding sites were blocked using an avidin/biotin blocking kit 
(Vector). 100 µL avidin was added to each coverplate and incubated at ambient 
temperature for 10 min. Avidin was then removed by 2 washes with TBS and biotin 
applied to the slides. Slides were incubated at ambient temperature for 10 min, followed 
by 2 TBS washes. To minimise non-specific antibody binding, 100 µL 10% (v/v) serum 
(Dako) was incubated on the slides for 5 min. The serum used was dependent on the host 
of the secondary antibody; rabbit serum was used for rabbit secondary antibodies, and 
goat serum used for goat secondary antibodies. After blocking, 100 µL primary antibody 
was added at a pre-determined optimal dilution in TBS and slides were incubated at 4ºC 
Chapter 2: Materials and Methods 
86 
for 16 h. Negative control samples had an irrelevant antibody or did not have any primary 
antibody applied. 
After incubation, unbound primary antibody was removed by 3 washes with TBS. 100 
µL biotinylated secondary antibody (Dako) at a pre-determined dilution in TBS was 
incubated on the slides for 30 min at ambient temperature Unbound secondary antibody 
was removed by 2 TBS washes. A streptavidin-biotin-horseradish peroxidase (Strep-
HRP/ABC) complex (Vectastain Elite ABC Kit; Vector) was prepared according to the 
manufacturer’s instructions and 100 µL added to the slides for incubation at ambient 
temperature for 30 min. Slides were then washed twice with TBS and once with H2O. To 
visualise the antibody-bound complex a diaminobenzidine (DAB) substrate reaction was 
used. Sigma Fast™ DAB tablets were added to 5 mL H2O following the manufacturer’s 
instructions and the freshly-made solution added to the slides at a volume of 200 µL per 
slide. DAB solution was incubated on the slides for 12 min before removal with 2 H2O 
washes. Slides were counterstained in Haematoxylin for 5 secs, washed in tap water for 
at least 1 min and dehydrated/mounted as described in section 2.8.3. 
2.8.8 Immunoballeing using Polymer-Based Horseradish-Peroxidase (HRP) 
Amplification Method 
This method was used in order to improve the sensitivity of antibody labelling detection. 
The kit used was an Impress™ Excel staining kit (Vector) which is based on an 
enzymatic, non-biotin amplification system. The kit comes with ready-to-use affinity-
purified and cross-adsorbed reagents including an amplifier antibody and polymer 
reagent. 
 After placing slides in cover-plates submersed in TBS-T, 100 µL 2.5 % (v/v) normal 
horse serum was applied to block any non-specific background labelling. Serum was 
incubated at ambient temperature on the slides for 20 min. 100 µL primary antibody 
diluted in TBS-T was applied and incubated at 4 ºC for 16 h. Unbound antibody was 
removed by 3 washes with TBS-T and 100 µL secondary amplifier antibody incubated 
on the slides for 30 min at ambient temperature. Secondary amplifier was either directed 
against mouse or rabbit depending on the primary antibody used. Unbound amplifier 
antibody was removed by 2 TBS-T washes and 100 µL Impress™ Excell anti-IgG reagent 
incubated on the slides for 30 min at ambient temperature. Slides were washed twice with 
TBS-T and once with H2O before the addition of the ImmPACT™ DAB EqV reagent, 
which was used to visualise the bound antibody via the same reaction described above 
(section 2.8.7). DAB reagent was incubated for 5 min at ambient temperature and then 
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the slides were immediately washed once with H2O before being transferred to a metal 
rack and further rinsed in tap water. Slides were then counter-stained and mounted as 
described previously (section 2.8.3). 
2.9 Microscopy 
An Olympus BX60 microscope was used to view slides under bright-field illumination, 
using x20, x40 and x60 oil immersion objectives. Images were captured using an 
Olympus DP50 digital camera and Image-Pro Plus™ software version 4.5.1.29 (Media 
Cybernetics). 
2.10 Gene Expression Analysis 
All RNA work was carried out in a designated area of the lab, separate from polymerase 
chain reaction (PCR) work. The work area was cleaned by regular wiping with 70 % (v/v) 
EtOH, as well as RNaseZap® wipes (Fisher Scientific) which were used to remove any 
RNase enzymes on the bench, pipettes and tip boxes. Fresh gloves were worn and 
regularly changed and cleaned with the wipes throughout the protocols, as a measure to 
maintain sample RNA integrity and minimise the risk of RNase and/or genomic DNA 
contamination. Single use DNase and RNase-free 1.5 mL microfuge tubes (Ambion) and 
filter pipette tips (Starlab, Starstedt) were used to minimise contamination. All water used 
for gene expression analysis had been treated with 0.1 % (v/v) diethylpyrocarbonate 
(DEPC) to inactivate RNase enzymes, and then autoclaved. 
2.10.1 RNA Extraction 
All RNA extractions were carried out using Trizol™ reagent (Invitrogen) based on the 
single-step method of RNA extraction by acid guanidinium thiocyanate-phenol-
chloroform (Chomczynski and Sacchi, 1987). Medium was aspirated from cell cultures 
and 1 mL Trizol™ reagent added. Cultures were incubated at ambient temperature for 5 
min on an orbital shaker. Cells were then scrape-harvested (cell scrapers; Starstedt) into 
1.5 ml microfuge tubes, labelled and stored at -80 ºC until further processing. 
Samples were thawed on ice and then left at ambient temperature for 5 min to permit 
complete dissociation of nucleoprotein complexes. 200 µL chloroform (Fisher Scientific) 
was added to each tube, each of which were vortexed for 15 seconds and then left to 
incubate at ambient temperature for 2 min. Tubes were then placed in a Hettich Mikro 
200R refrigerating benchtop centrifuge (Hettich) and centrifuged at 12000 g for 15 min 
at 4 ºC. Following centrifugation, the RNA-containing aqueous supernatant was collected 
into fresh 1.5 ml microfuge tubes. 0.5 mL isopropanol (Fisher Scientific) was added to 
each tube, mixed by multiple inversions, and incubated at ambient temperature for 10 
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min. Tubes were then centrifuged at 12000 g for 20 min at 4 ºC. Following this, the 
supernatant was quickly removed by blotting onto blue roll. Two cycles of washing were 
carried out by adding 1 mL 75 % (v/v) EtOH, vortexing, centrifuging at 4 ºC for 5 min at 
7500 g and removing the supernatant by blotting. The resulting RNA pellets were left to 
air-dry for approximately 15 min, re-suspended in 30 mL DEPC-treated water and then 
transferred to a 0.5 mL microfuge tube. 
 To remove any DNase contamination all samples were treated with a DNA-free™ kit 
(Ambion) following the manufacturer’s recommendations. DNase 1 buffer was added at 
a dilution of 1:10 to each tube, along with 1 µL of the enzyme rDNase 1, and incubated 
at 37 ºC for 30 min. DNase inactivation reagent was thawed, re-suspended by vortexing 
and added to tubes at a dilution of 1:10. The tubes were incubated at ambient temperature 
for 2 min, and vortexed every 30 seconds. Following this tubes were centrifuged at 10000 
g for 1 min 30 seconds at ambient temperature and the supernatant collected into a fresh 
0.5 mL microfuge tube. RNaseOUT™ (Invitrogen) was added at a concentration of 40 
U/30 µL and samples stored at -80 ºC. 
2.10.2 cDNA Synthesis 
Prior to cDNA synthesis, RNA concentration and quality was measured using a 
NanoDrop® ND-1000 spectrophotometer (Fisher Scientific). cDNA first strand synthesis 
was performed using the Superscript™ II first strand synthesis system (Invitrogen) 
following manufacturers’ protocol. 1 µg RNA was added to two separate microfuge tubes 
for each sample; 1 tube for reverse transcriptase positive (RT +ve) and 1 tube for reverse 
transcriptase (RT -ve) reactions. 50 ng/µL random hexamers was added to each tube and 
incubated at 65 ºC for 10 min to anneal primers. Tubes were then cooled at 4ºC for 1 min 
and the contents collected by brief centrifugation. A master mix was prepared on ice so 
that each sample received 4 µL 5x First strand buffer, 2 µL 0.1 M DTT and 1 µL dNTPs 
(10 mM). Samples were then incubated at 25 ºC for 2 min. 1 µL (50 U) of the Superscript 
II reverse transcriptase enzyme was mixed into each RT+ tube but omitted from the RT- 
tubes. All samples were then incubated at 25 ºC for 10 min, 42ºC for 50 min, and finally 
70 ºC for 15 min to inactivate the enzyme. cDNA was stored at -20 ºC in the short-term 
and transferred to -80 ºC for long-term storage. Prior to use, RT +ve and RT -ve samples 
were assessed for transcript expression of the housekeeping gene GAPDH. This was to 
confirm equal quantities of cDNA in the samples, and to ensure the absence of DNA 
contamination (see Figure 10). 
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Figure 10: RT-PCR demonstrating the reverse transcriptase-negative and reverse transcriptase 
positive-controls used for every RT-PCR experiment. For every sample, two reactions were set 
up; one containing reverse transcriptase (RT +ve), one without (RT -ve). Once cDNA was 
synthesised, all samples were checked for the housekeeping gene GAPDH transcript expression 
in order to ensure equal cDNA/loading quantities (RT+ve) and to confirm the absence of genomic 
contamination (RT-ve). 
 
2.10.3 Primer Design 
For each gene, all transcript information was downloaded from the EMBL™ genome 
browser (http://www.ensembl.org/index.html). Primers were designed to detect all splice 
variants of a gene and were checked for specificity using the NCBI Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All primers were produced by 
Eurofins, reconstituted to 100 mM concentration in DEPC-treated water and stored at -
20 ºC. 
All primers were optimised for use prior to performing reverse-transcriptase polymerase 
chain reaction (RT-PCR). Optimisation involved a series of gradient PCR reactions at 
increasing annealing temperatures, using genomic DNA as a positive control (Promega). 
The optimal annealing temperature was selected as the temperature that gave the brightest 
singular band at the correct product size (Figure 11; see Table 11 for primer information). 
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Figure 11: Gradient RT-PCR was conducted to determine optimal primer annealing 
temperature. Each primer set was tested by performing RT-PCR over a range of temperatures 
using gDNA. The temperature demonstrating the brightest product band of the correct size with 
the least non-specific binding was deemed optimal and used in subsequent RT-PCRs. The above 
example of gradient PCR was performed using primers for MTF-1 transcript, which had a 
product size of 108 base pairs. The optimal primer annealing temperature (Ta) was selected as 
68 °C (demonstrated by the red rectangle).   
 
2.10.4 RT-PCR 
All PCR reactions were carried out in a T100 thermal cycler (Bio-Rad). For each target 
gene a master mix was made up so that each 20 µL sample reaction received 8.5 µL 
DEPC-treated water, 4 µL GoTaq buffer (Promega), 0.4 µL dNTPs (10mM; Invitrogen), 
2 µL MgCl2 (25mM; Promega), 2 µL forward primer, 2 µL reverse primer and 0.1 µL 
GoTaq polymerase (Promega). 1 µg/µL cDNA was added for each sample bringing the 
total volume up to 20 µL for each reaction. Genomic DNA was used as a positive control 
and a no-template negative DEPC-treated water (dH2O) control was also included (see 
Figure 12). 
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Figure 12: RT-PCR showing experimental controls included for every reaction. Negative 
controls (dH2O) were used to check for contamination, whereas positive controls (gDNA) were 
used to determine whether the reaction had been successful. 
 
 cDNA was initially denatured for 2 min at 95 ºC in the first cycle, changing to 
denaturation at 95 ºC for 30 seconds in subsequent cycles. After denaturation primers 
were annealed at a pre-determined optimum temperature for 30 seconds, followed by 
extension of template at 72 ºC for the required amount of time based on overall product 
size (30 seconds per 500 base pairs). A final cycle extension phase at 72 ºC for 5 min 
completed the reaction before cooling to 4 ºC. For each reaction 25 PCR cycles were 
performed. 
2.10.5 Gel Electrophoresis 
PCR products were visualised using gel electrophoresis and ultra-violet illumination. 2% 
flatbed gels were made using electrophoresis-grade agarose (Invitrogen) which was 
added to 1x Tris borate EDTA (TBE; see Appendix). The mixture was heated in a 
microwave for up to 3 min until the agarose had completely dissolved. The liquid was 
allowed to cool to approximately 60 ºC before the addition of SYBR® Safe DNA gel 
stain (Invitrogen) at a dilution of 1:10000. The molten gel was poured into a plastic gel 
case and allowed to set before being placed into an electrophoresis tank containing 1x 
TBE buffer. 
 18 µL from each PCR reaction was added to each well in order to ensure equal loading, 
and the gel run at 100 V until clear resolution of the DNA marker was achieved 
(approximately 1 h 30 min). The DNA marker used to track progress of the PCR products 
was HyperLadder™ 100bp (Bioline). Product bands were visualised using a Gene Genius 
Gel Imaging System (Syngene) and images captured using Genesnap software (Syngene). 
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2.11 Western Blotting  
2.11.1 Harvesting of Whole Cell Lysates 
Whole cell lysates were harvested from Cell+™ tissue culture flasks, Primaria™ 6-well 
plates or ThinCert™ membranes. The same protocol was used for all tissue culture-ware, 
however the amount of lysis buffer varied to account for overall cell number. 
Medium was aspirated from cultures and cells washed twice with pre-chilled PBS. 2x 
sodium dodecyl sulphate (SDS; see Appendix) lysis buffer was ‘completed’ shortly 
before use by the addition of 13 mM DTT and 1:100 dilution Protease Inhibitor Cocktail 
(catalogue #P8340; Sigma Aldrich). 75 µL, 50 µL and 30 µL lysis buffer was added to 
T75 Cell+™ tissue culture flasks, T25 Cell+™ tissue culture flasks/Primaria™ 6-well 
plates and ThinCert™ membranes respectively. A cell scraper was used to scrape-harvest 
cells and lysates were transferred to pre-chilled 1.5 mL microfuge tubes. Lysates were 
sonicated on ice for 2x 10 sec bursts with a 10 sec rest in between. A Sonifier® (Branson) 
was used, set to 25 W and 40 % amplitude. Lysates were then left to rest on ice for 30 
min, before centrifugation at 18000g for 30 min at 4 ºC. Supernatant was collected and 
placed in pre-chilled 0.5 mL microfuge tubes, and stored at -20 ºC. 
2.11.2 Protein Determination of Lysates 
A Coomassie protein assay reagent kit (Pierce) was used in order to determine the protein 
concentration of sample lysates. A 7-point protein standard was added in 10 µL duplicates 
to the wells of a 96-well plate (SLS) covering a range from 0-1 mg/mL, by dilution of 
bovine serum albumin (BSA) in H2O. Lysate samples were diluted 1:12.5 in H2O and 
also added in 10 µL duplicates to the plate. 200 µL Coomassie reagent (pre-warmed to 
ambient temperature) was added to each of the wells and absorbance read at test (570 nm) 
and reference (630 nm) wavelengths using a MRX II 96-well plate spectrophotomer 
(Dynex). A standard curve was produced using the Revelation™ software (Dynex) and 
the average absorbance of each duplicate sample was used to estimate protein 
concentration, correcting for the dilution factor. 
2.11.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
20 µg protein samples (diluted with H2O) were mixed with 10x NuPage™ reducing agent 
(Invitrogen) and 4x NuPage™ lithium dodecyl sulphate (LDS; Invitrogen) to a final 
reagent concentration of 1x. Samples were then heated for 10 min at 70 ºC and briefly 
centrifuged to collect contents. 
 Pre-cast 10- or 15-well 4-12 % Bis-Tris NuPage™ polyacrylamide gels (Invitrogen) 
were used for separation of proteins. Gels were placed in an XCell SureLock™ 
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(Invitrogen) tank, with both outer and inner tank chambers filled with appropriate 1x 
running buffer depending on target protein size. 3-(N-morpholino) propanesulfonic acid 
(MOPS) buffer was used for separation of larger proteins, and its structural analogue 2-
(N-morphilino) ethanesulfonic acid (MES) was used for smaller proteins (<10 kDa; 
buffers purchased ready-made from Life Technologies). 5 µL All-Blue Protein Precision 
Plus™ ladder (Bio-Rad) was loaded in the first well as a protein size reference (Figure 
13), and samples were loaded in the rest of the wells. Empty wells were loaded with the 
same amount of LDS as used for samples in order to ensure equal running. 200 µL 
NuPage™ antioxidant (Invitrogen) was added to the inner tank chamber to maintain the 
reduced proteins, and electrophoresis was performed at 200 V until the blue dye-front 
reached the foot of the gel (approximately 1 h).  
 
Figure 13: Western blot showing MT-1A protein expression in proliferating NHU cells (Y1270) 
exposed to 10 µM CdCl2 for 12 hours. For each Western blot performed a molecular weight 
ladder was included to determine whether the detected protein was at the same weight as the 
target protein’s estimated weight. Molecular weights are in kilodaltons (kDa). In this example, 
the predicted weight of MT-1A is ~6 kDa, and a protein band was detected at the correct estimated 
molecular weight. 
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2.11.4 Electrophoretic Protein Transfer 
Proteins were transferred from gels onto polyvinylfluoride (PVDF) membranes 
(Millipore) using the XCell II™ Blot Module (Invitrogen) following the manufacturer’s 
recommendations. 
 PVDF membrane was cut to an appropriate size and activated by dipping in methanol 
(Fisher Scientific) before washing in H2O. Prior to assembly E-PAGE™ blotting pads 
(Life Sciences), Whatman™ filter paper (cut to size) and PVDF membrane (cut to size) 
were all equilibrated in transfer buffer (see Appendix) for approximately 30 min. A gel 
membrane sandwich was then created in the order (from bottom to top); 2x blotting pads, 
filter paper, gel, PVDF membrane, filter paper, 3x blotting pads. The sandwich was 
placed in the blotting module and the inner chamber filled with transfer buffer, whereas 
the outside chamber was filled with tap water as a temperature buffer. The module was 
placed in an ice box and proteins were electrotransferred at 30 V for 3 h. 
To confirm successful transfer, the retrieved membrane was stained with 5 mg/mL 
Ponceau red in 1% (v/v) glacial acetic acid in H2O for a few seconds before washing in 
H2O until resolution of protein bands. 
2.11.5 Antibody Labelling 
Before probing with antibodies, membranes were incubated for 1 h at ambient 
temperature on a shaker with 10 mL TBS (see Appendix) and Odyssey blocking buffer 
(LI-COR®) in a 1:1 ratio. This is an optimised buffer for the LI-COR® system which 
reduces background fluorescence. After blocking, membranes were incubated with 5-8 
mL primary antibody at a pre-determined optimal dilution (Figure 14; see Table 12 for 
antibody concentrations) in a 1:1 mix of blocking buffer and TBS supplemented with 0.1 
% (w/v) Tween 20 (TBST; see Appendix) for 1 h at ambient temperature or 16 h at 4ºC 
on an orbital shaker. 
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Figure 14: Western blot demonstrating MT-1A protein expression in proliferating NHU cells 
(Y1531) exposed to 10 µM CdCl2 for 72h. For each antibody used for western blotting, a series 
of dilutions were tested on positive and negative controls in order to determine the optimal 
concentration. In this example, the negative samples were NHU cells grown in normal conditions, 
whereas the positive samples were NHU cells exposed to CdCl2. The MT-1A antibody was tested 
at 3 different concentrations; 0.5 µg/mL, 1 µg/mL and 2 µg/mL. 1 µg/mL was selected as the best 
working concentration. 
 
To remove unbound primary antibody membranes were washed 4x5 min in TBST on an 
orbital shaker. Secondary antibody was diluted 1:10000 in 1:1 blocking buffer and TBST 
and incubated with the membrane in the dark for 1 h at ambient temperature on a shaker. 
Either an Alexa Fluor® 680-conjugated anti-mouse secondary antibody (Invitrogen) or 
an IRDye 800-conjugated anti-rabbit secondary antibody (Tebu-Bio) was used depending 
on the primary host species. To remove unbound secondary antibody, membranes were 
washed 4x5 min in blocking buffer/TBST solution on a shaker. Finally, membranes were 
rinsed once with TBS to remove residual TBST and stored in TBS at 4 ºC. 
2.11.6 Membrane Imaging and Analysis 
Western blot membranes were scanned using an Odyssey® Sa Infrared Imaging System 
(LI-COR®), with laser excitation and emission wavelengths as appropriate for the 
fluorophores used. Images were captured and analysed using Odyssey® Image Studio™ 
software v5.0 (LI-COR®). A positive control where the target protein was known to be 
expressed was included for every western blot performed, in order to ensure successful 
completion of the protocol (see Figure 15). 
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Figure 15: Western blot showing MT-1A protein expression in proliferating NHU cells (Y1426) 
exposed to 10 µM CdCl2 for 72h. For all western blots conducted a positive (+ve) control was 
included, which was a sample known to have high expression of the target protein. In this case, 
the sample was from a different cell line chronically exposed to CdCl2 which had previously 
demonstrated high MT-1A protein expression. 
 
Rectangular bands were auto-drawn by the software around the correct-sized protein 
bands for each lane. An additional, same-sized rectangle was placed randomly on the 
membrane where no bands were present and defined as the background. This allowed the 
relative intensities of each band to be measured. Densitometry was performed by 
measuring band intensity for β-actin as a loading control on the same membrane (see 
Figure 16), and normalising protein loading in each lane to obtain accurate protein 
quantification. 
 
 
Figure 16: Western blot demonstrating use of the housekeeper β-actin protein expression as a 
loading control. Equal β-actin bands indicate accurate and equal protein sample loading into 
the gel. β-actin protein expression was included in every western blot performed. 
 
2.11.7 Stripping of Membranes for Re-use 
Membranes occasionally needed to be stripped before they could be probed with another 
antibody (e.g. if proteins of interest were of a similar molecular weight). Membranes were 
stripped by incubation with antibody stripping solution (Western Blot Recycling Kit; 
Source Bioscience Autogen) diluted 1:10 with H2O, for 30 min at ambient temperature 
on a shaker. Membranes were washed once with TBS and then re-scanned to ensure 
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stripping had been successful. Membranes were then re-blocked and re-probed as 
described in section 2.11.5. 
2.12 Direct Intracellular Metal Quantification  
Intracellular metal quantification was carried out using acid-digested biological samples 
and the spectroscopic technique inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). This involves plasma excitation of samples, and the resulting 
emission of light wavelengths can be used to determine what trace metals are present in 
the sample and their concentration. 
2.12.1 Digestion of Samples 
NHU cells were seeded onto Primaria™ 6-well plates and stimulated to differentiate for 
7 days using serum and calcium (as described in section 2.7.8). Once differentiation was 
confirmed by the formation of a functional barrier, cultures were treated with 10 µM 
CdCl2 for a further 7 days. At this point medium was aspirated and cells washed 3 times 
with PBS to remove any non-cellular metal. Concentrated nitric acid (Sigma) was sub-
boiled to 60 ºC using a water bath and 500 µL added to each well. Cells were incubated 
in acid at ambient temperature for 90 min to allow complete digestion of organic material. 
400 µL of the digested cell solution was taken from each well and 2 wells for each 
condition (control and CdCl2 exposure) were pooled together, resulting in a total of 800 
µL acid per sample. This was diluted to 16 mL with H2O to form 5 % (v/v) nitric acid in 
water and stored in Corning® 50 mL centrifuge tubes at 4 ºC until analysis. All work 
involving nitric acid was performed in a fume hood and safety glasses were worn at all 
times. 
2.12.2 Inductively-Coupled Plasma – Optical Emission Spectroscopy (ICP-OES) 
A range of CdCl2 standards was made up prior to running samples on the ICP-OES 
machine (iCAP 7000 Plus Series; Thermo Scientific). Standards consisted of CdCl2 
concentrations from 0 – 1 mG/L made up in H2O with 5 % (v/v) nitric acid, and were 
stored in Corning® 50 mL centrifuge tubes (required volumetric container for machine 
sampling). These standards and certified reference material were used in order to calibrate 
the machine. Accurate calibration was confirmed by a linear relationship between 
standard (predicted) and actual measurements (Figure 17). After calibration, samples 
were run on the machine and cadmium concentration of the digested cell solution 
calculated (taking into account the initial sample dilution). 2 technical repeats were 
included for each sample to ensure machine accuracy. 
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Figure 17: Graph demonstrating the linearity of the range of standards used to calibrate the 
ICP-OES equipment. When carrying out the ICP-OES procedure a known range of 
concentrations are input in order to calibrate the machine. The relationship between the standard 
(predicted) and actual concentrations should be linear in order to ensure the accuracy of 
readings, as demonstrated above. 
  
Once the acid-digested samples were entered into the ICP-OES machine they were 
combined with argon within a nebuliser, resulting in aeration of the sample. The sample 
was then passed to a spray chamber where a plasma torch excited the atoms and ions, 
producing specific wavelengths of light which were recorded by a receiver. This 
information was then used to determine which elements were present within the sample, 
and in what concentrations. Acid-washed equipment and wash buffers were utilised in 
order to avoid contamination. A summary of the ICP-OES workflow is provided in Figure 
18. 
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Figure 18: Schematic diagram summarising the process of Inductively Coupled Plasma-
Optical Emission Spectroscopy (ICP-OES). Biological samples entered the machine and were 
combined with argon within the nebuliser, resulting in aeration of the sample. The sample then 
travelled through the spray chamber and encountered a plasma torch, whose function was to 
excite the atoms and ions of the sample. This resulted in wavelengths of light being emitted which 
were received and recorded by the detector. The specific wavelengths of light were used to 
determine precisely which elements were present in the sample and their resultant quantities.  
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Chapter 3: Characterisation of Control and Cadmium-
Induced Metallothionein Isoform Expression in Normal 
Human Urothelium 
3.1 Chapter Aims 
The aim of this chapter was to characterise MT isoform expression in NHU cells under 
basal and cadmium-exposed culture conditions. Additionally, the use of novel MT 
isoform-specific antibodies was performed in order to discriminate between isoform 
expression at the protein level. 
3.1.1 Objectives 
1. Determine a human-relevant, non-cytotoxic cadmium concentration suitable for NHU 
cell culture. 
2. Assess baseline MT isoform transcript expression in a variety of human urothelial 
cell culture models, including proliferating NHU cells, differentiated NHU cells and 
urothelial cancer cell lines. 
3. Identify which, if any, MT isoform transcripts are induced in proliferating NHU cells 
exposed to cadmium and characterise this induction in relation to exposure time and 
cadmium concentration. 
4. Determine whether MT protein is induced in proliferating NHU cells exposed to 
cadmium using novel isoform-specific antibodies, and characterise expression of the 
same using immunohistochemistry to determine protein localisation and expression 
patterns. 
3.1.2 Experimental Approach 
1. Growth assays were performed using proliferating NHU cells either cultured under 
control conditions or exposed to a range of cadmium concentrations, so that toxicant 
cytotoxicity could be assessed. The range of CdCl2 concentrations selected was based 
on previous experiments in our laboratory, relevance to human exposure, and cell 
culture concentrations previously used in the literature (Chu et al., 1999; Takiguchi 
et al., 2003; Sens et al., 2004; Aimola et al., 2012; Fabbri et al., 2012; Mehus et al., 
2014; Zhou et al., 2012). An intermediate cadmium concentration of 10 µM (Luevano 
and Damodaran, 2014) was selected for further experiments, as this concentration had 
previously been suggested to most closely reflect in vivo human exposure (Aimola et 
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al., 2012) and had also been shown malignantly cellular transform the human prostate 
epithelial cell line RWPE-1 (Achanzar et al., 2001). Further growth assays were then 
performed using this specific concentration, with the aim of establishing whether 
altering NHU cell seeding density could facilitate comparable cell growth in control 
and cadmium-exposed cells. 
2. Before investigating MT isoform transcript induction by cadmium exposure it was 
important to determine baseline expression of their expression, as the literature had 
reported tissue-specific expression patterns (section 1.5.5.2; Jahroudi et al., 1990; 
Conway et al., 2010; Capdevila et al., 2012). Firstly, Next Generation Sequencing 
(NGS) data previously produced in the laboratory was mined for MT isoform 
expression using HT-seq gene analysis (Anders et al., 2015). NGS data was available 
for passage (P) 0 NHU cells (i.e. freshly isolated NHU cells that had not yet been 
passaged in vitro), proliferating (PRO) and differentiated (DIF) NHU cells. MT 
isoform transcript expression was normalised using housekeeping gene GAPDH 
transcription. Next, MT isoform transcript expression was assessed in proliferating 
and differentiated NHU cells grown in vitro, as well as three different urothelial 
cancer cell lines, using RT-PCR. Proliferating NHU cells and urothelial cancer cell 
lines were passaged prior to the experiment in order to maintain proliferation and then 
left to settle for 24 hours, before RNA was extracted at 12, 24 and 48 hour time-
points. Separate cultures of proliferating NHU cells were stimulated to differentiate 
using a biomimetic method (see section 2.7.8) prior to the experiment, and 
differentiation was confirmed by expression of the differentiation-associated marker 
ZO-1 (see section 8.7.1). Once differentiated, NHU cells were maintained in culture 
and RNA extracted at the same time-points as used for proliferating NHU cells and 
urothelial cancer cell lines. Extracted RNA was used to assess MT isoforms transcript 
expression via RT-PCR.  
3. Proliferating NHU cells were exposed to 10 µM CdCl2 and RNA extracted at multiple 
time points. RT-PCR was used to determine MT isoform transcript expression, 
allowing identification of highly induced isoforms for more detailed investigation in 
further experiments. To characterise the relationship between exposure and transcript 
induction proliferating NHU cells were then exposed to a range of cadmium 
concentrations over a variety of exposure times, and RT-PCR used to determine 
transcript expression.  
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4. Proliferating NHU cells were exposed to 10 µM CdCl2 for 72 hours, a time period 
previously shown as sufficient for MT protein translation (Wei et al., 2008; Urani et 
al., 2010; Mehus et al., 2014) and then underwent either protein extraction for 
subsequent western blotting or fixation for immunohistochemical analysis. Specific 
antibodies for two of the isoforms whose transcripts were highly induced by cadmium 
were obtained, titrated and then used to quantify and localise MT isoform protein 
induction in response to cadmium exposure.  
3.2 Results 
3.2.1 Identification of a Relevant Cadmium Concentration Suitable for In Vitro 
NHU Cell Culture 
Proliferating NHU cells were exposed to a range of cadmium chloride concentrations 
(CdCl2; 0.1 µM – 20 µM) and a growth curve generated over 7 days, using the 
AlamarBlue® cell biomass assay. For initial growth assays, the standard laboratory 
protocol for NHU cells was used, which indicates an NHU cell seeding density of 2 x 104 
cells/cm2. At this seeding density it was observed that exposure to CdCl2 concentrations 
above 3 µM was cytotoxic to proliferating NHU cells, and that even 0.1 µM CdCl2 was 
able to inhibit growth (Figure 19; n=1). As 0.1 µM CdCl2 is a very low concentration, it 
was decided that the initial cell seeding density would be increased in order to assess 
whether this could improve NHU cell tolerance to cadmium exposure.  
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Figure 19: AlamarBlue® assay demonstrating growth of NHU cells seeded at 2 x 104 cells/cm2 
and exposed to cadmium. Proliferating NHU cells (n=1; Y1470) were seeded and exposed to 
0.1, 1, 3, 7, 10 or 20 µM CdCl2 from day 0 for up to 7 days. Data points represent mean 
percentage reduction in AlamarBlue® ±S.D. (n=3; technical repeats). 
 
 At a seeding density of 4 x 104 cells/cm2 growth assays indicated that the highest 
concentration of 20 µM CdCl2 remained cytotoxic to the NHU cells, but that exposure to 
concentrations up to 3 µM CdCl2 did not appear to affect NHU cell proliferation (Figure 
20; n=1). However, treatment with 7 and 10 µM CdCl2 were observed to inhibit 
population growth, and exposure to 10 µM CdCl2 exerted a cytostatic effect. It was 
therefore decided to determine whether a further increase in cell seeding density could 
increase NHU cell tolerance to this concentration.  
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Figure 20: AlamarBlue® assay demonstrating growth of NHU cells seeded at 4 x 104 cells/cm2 
and exposed to cadmium. Proliferating NHU cells (n=1; Y1497) were seeded and exposed to 
0.1, 1, 3, 7, 10 or 20 µM CdCl2 from day 0 for up to 7 days. Data points represent mean 
percentage reduction in AlamarBlue® ±S.D. (n=3; technical repeats). 
 
 Final growth assays were performed using a cell seeding density of 6 x 104 cells/cm2. At 
this density, exposure to 20 µM CdCl2 remained cytotoxic to proliferating NHU cells 
(Figure 21A). However, exposure to 10 µM CdCl2 and lower no longer effected cell 
growth. Additionally, the growth curves indicated that NHU cells continued to proliferate 
throughout the experimental period, suggesting that confluency (and subsequent cell-cell 
contact inhibition) was not reached. To confirm these initial results the assays were 
repeated using NHU cells from a different patient donor and the data combined (Figure 
21B; n=2). This growth curve revealed a possible lag phase in NHU cell cultures exposed 
to cadmium between days 1 – 3; however, by day 5 the cells had recovered and 
demonstrated similar growth to control cells for the rest of the experiment. These results 
suggested that the human-relevant concentration 10 µM CdCl2 did not inhibit NHU cell 
growth when cells were seeded at a minimum density of 6 x 104 cells/cm2. 
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Figure 21: AlamarBlue® assays demonstrating growth of NHU cell cultures seeded at 6 x 104 
cells/cm2 and exposed to cadmium. (A) NHU cells (n=1; Y1497) were seeded and exposed to 0.1, 
1, 3, 7, 10 or 20 µM CdCl2 for 7 days. Data points represent mean percentage reduction in 
AlamarBlue® ±S.D. (n=3; technical repeats). (B) NHU cells (n=2; Y1497, Y1470) were seeded 
at a density of 6 x 104 cells/cm2 and exposed to 10 µM CdCl2 for 7 days. Data points represent 
mean percentage reduction in AlamarBlue®  ±S.D. from the two biological repeats. The mean of 
each biological repeat was calculated from three technical repeats (n=3; technical repeats). 
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 Phase contrast images were captured of proliferating NHU cell cultures exposed to 
cadmium in order to observe any morphological changes. The resultant images (Figure 
22A) revealed the formation of extended processes between the NHU cells at 24 and 48 
hours exposure, along with less defined cell borders compared to control cells (magnified 
in Figure 22B). These morphological alterations could be observed in NHU cell cultures 
from three independent donors exposed to 10 µM cadmium (n=3), and were also observed 
to present frequently in subsequent experiments. 
 
Figure 22: Representative phase contrast images of proliferating NHU cells cultured in 
cadmium for 48 hours. Three independent NHU cell lines (n=3; Y1089, Y1270, Y1426) were 
seeded at a density of 6 x 104 cells/cm2 and exposed to 10 µM CdCl2 for up to 48 hours. (A) Phase 
contrast images were captured at various time-points of control and cadmium-exposed cell 
cultures. (B) Magnified image of proliferating NHU cells exposed to 10 µM CdCl2 for 24 hours. 
Arrows indicate extended processes between cells. Scale bars = 50 µm. Representative NHU cell 
line was Y1089 (results from other cell lines are included in the Appendices). 
 
Chapter 3: Characterisation of Control and Cadmium-Induced Metallothionein 
Isoform Expression in Normal Human Urothelium 
107 
3.2.2 Baseline MT Transcript Expression in Normal Human Urothelium 
NGS data analysis revealed that the most highly expressed isoforms in P0, PRO and DIF 
NHU cells were MT-2A, and MT-1X (Figure 23). In general, MT isoform expression was 
observed higher in PRO NHU cells than P0 or DIF. The majority of MT-1 isoforms were 
expressed at such low levels that expression was neglibible and may have been below the 
limit of detection., particularly the MT-1A, MT-1H and MT-1M isoforms. MT-3 was also 
expressed at neglible levels, and MT-4 transcription was absent. 
 
Figure 23: Next Generation Sequencing (NGS) data analysis of MT isoform transcription in 
NHU cells. NGS data was previously collected from passage (P) 0 NHU cells (i.e. freshly isolated 
NHU cells that had not yet been passaged in vitro), proliferating (PRO) and differentiated (DIF) 
NHU cells. Data was mined using HT-seq gene analysis (Anders et al., 2015) and MT isoform 
transcription determined. All isoform splice variant transciption is shown individually. Transcript 
expression was normalised to housekeeping gene GAPDH transcription. 
 
The baseline expression of MT isoform transcripts was next established in both 
proliferating (n=1) and differentiated (n=1) NHU cells using RT-PCR (Figure 23). MT-
2A isoform transcript was constitutively highly expressed in both proliferating and 
differentiated NHU cells. However, many MT isoform transcripts were not expressed 
under control conditions in either NHU cell culture. This included a number of isoforms 
belonging to the MT-1 subfamily, such as MT-1B, MT-1G, MT-1H and MT-1M. The 
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MT-3 and MT-4 isoform transcripts were also absent in all NHU cell cultures. Other 
isoforms such as MT-1A demonstrated variable expression, appearing to alter with both 
differentiation state and time-point. Further, a number of isoforms showed increased 
transcript expression upon NHU cell differentiation, such as the MT-1E, MT-1F and MT-
1X isoforms. 
 
Figure 24: RT-PCR showing baseline MT isoform transcript expression in proliferating and 
differentiated NHU cells. Proliferating (n=1; Y1270) and differentiated (n=1; Y1456) NHU cell 
cultures were maintained under standard culture conditions for up to 48 hours and RNA 
extracted.  Differentiated NHU cells were induced to differentiate prior to the start of the 
experiment using the biomimetic protocol (see section 2.7.8) and differentiation was confirmed 
Chapter 3: Characterisation of Control and Cadmium-Induced Metallothionein 
Isoform Expression in Normal Human Urothelium 
109 
by the presence of a functional barrier (see Figure 31). PCR controls included genomic DNA as 
a positive control and dH2O as a negative control. GAPDH transcript expression was used as a 
loading control, and RT-ve samples confirmed the absence of genomic contamination.  
 
3.2.2.1 MT Transcript Expression in Urothelial Cancer Cell Lines 
MT isoform transcript expression was assessed in a number of urothelial cancer cell lines 
to determine how expression might change with malignancy (and/or the immortalisation 
process). Proliferating NHU cells were cultured in parallel with the EJ, RT112 and RT4 
urothelial cancer cell lines, and RNA extracted at 24 hours. As MT-4 transcript expression 
has only been reported in squamous tissue (section 1.5.2), and under basline conditions 
NHU cells did not express MT-4 transcript (Figure 24), this isoform’s expression was not 
assessed. Although NHU cells did not demonstrate MT-3 transcript expression it was 
decided to keep this isoform in the MT gene panel, as previous literature had suggested 
it is expressed in malignant urothelial cells (see section 1.5.6.3).  
 Consistent with the findings in NHU cells, under control conditions the urothelial cancer 
cell lines were negative for the majority of MT isoform transcript expression (Figure 25; 
n=1).  The RT-4 cell line in particular expressed no MT gene isoforms, apart from low 
expression of the MT-2A transcript. Interestingly, the MT isoforms with increased and/or 
constitutive transcript expression in proliferating and differentiated NHU cells (such as 
MT-1X and MT-2A) showed decreased expression in the malignant cell lines, especially 
in RT112 and RT4 cells. Lastly, MT-3 and MT-4 transcripts were found to be absent in 
all 3 urothelial cancer cell lines. 
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Figure 25: RT-PCR showing basal MT isoform transcript expression in NHU cells and three 
urothelial cancer cell lines. Proliferating NHU cells (n=1; Y1270) and 3 urothelial cancer cell 
lines (EJ, RT112, RT4; n=1; technical repeat) were cultured under standard growth conditions 
for 24 hours. RNA was then extracted and MT isoform transcript expression assessed. PCR 
controls included genomic DNA as a positive control and dH2O as a negative control. GAPDH 
transcript expression was used as a loading control, and RT-ve samples confirmed the absence 
of genomic contamination. 
 
3.2.3 Characterisation of MT Isoform Expression in NHU Cells Exposed to 
Cadmium 
RT-PCR results revealed induction of all but one of the MT-1 subfamily isoforms in 
proliferating NHU cells exposed to cadmium, particularly at the 12-hour time-point  
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(Figure 26; n=3). The only isoform unaffected by exposure was MT-1L. MT-1 isoform 
transcript induction was lost over time, as transcript expression of 5 isoforms returned to 
baseline expression after 48 hours continuous cadmium exposure. The isoform transcripts 
most prominently induced were MT-1A, MT-1G, MT-1H and MT-1M. MT-1X transcript 
was also highly induced in exposed cells, as there no obvious transcript expression in 
control cells; contradictory to results from other NHU cell lines where this isoform has 
been found to be highly expressed in control conditions (Figures 24, 74 and 75). By 
contrast, transcription of the other MT subfamilies did not appear to change with 
cadmium exposure. MT-2A transcript remained highly expressed under all conditions, 
and neither MT-3 or MT-4 transcripts were expressed. 
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Figure 26: Representative RT-PCR showing MT isoform transcript expression in proliferating 
NHU cells exposed to cadmium. Proliferating NHU cells (n=3; Y1270, Y1344, Y1426) were 
exposed to 10 µM CdCl2 for up to 48 hours, RNA extracted and MT isoform transcript expression 
assessed. PCR controls included genomic DNA as a positive control and dH2O as a negative 
control. GAPDH transcript expression was used as a loading control, and RT-ve samples 
confirmed the absence of genomic contamination. Representative cell line was Y1270 (results 
from other cell lines are included in the Appendices). 
 
 The dose-response relationship between cadmium exposure and MT isoform induction 
was then investigated. Proliferating NHU cells were exposed to the same range of 
concentrations as used in the growth assays (0.1 µM – 20 µM CdCl2; section 3.2.1) for 
12 hours and transcript expression assessed using RT-PCR. The results showed that MT-
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2A transcript expression remained constitutively expressed in all conditions and that MT-
3/MT-4 demonstrated no transcription (Figure 27), as observed in previous results. 
However, the MT-1 subfamily showed a striking dose-response induction of transcript, 
as isoform induction occurred in cells exposed to concentrations as low as 1 µM CdCl2 
(n=1). Once again the most prominently induced isoforms were MT-1A, MT-1G, MT-
1H and MT-1M. By contrast, MT-1B transcript was only minimally induced, and required 
exposure to at least 7 µM CdCl2 for expression to occur. Interestingly, in this cell line 
(Y1426) MT-1E and MT-1X transcripts were highly expressed in proliferating NHU cells 
under both normal and exposed conditions, which was also sporadically observed in NHU 
cell lines from other donors (see section 3.2.2). 
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Figure 27: RT-PCR showing the dose-response of MT isoform transcript induction in 
proliferating NHU cells exposed to cadmium. Proliferating NHU cells (n=1; Y1426) were 
exposed to 0.1, 1, 3, 7, 10 or 20 µM CdCl2 for 12 hours, RNA extracted and MT isoform transcript 
expression assessed. PCR controls included genomic DNA as a positive control and dH2O as a 
negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. 
 
 To further characterise the relationship between urothelial MT isoform induction and 
cadmium exposure, the timing of transcript induction was investigated. As the MT-1A, 
MT-1G, MT-1H and MT-1M isoforms had been observed to be consistently highly 
induced in response to cadmium exposure, it was decided to focus on these targets for 
subsequent experiments. Proliferating NHU cultures were exposed to 10 µM CdCl2 for 
up to 12 hours and RNA extracted at 1, 3, 6 and 12-hour time-points. RT-PCR once again 
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confirmed the prominent transcript induction of these isoforms in response to cadmium 
exposure (Figure 28). However, the results also showed that the isoforms differed in 
respect to their timing and extent of induction (n=1). MT-1G and MT-1M isoform 
transcript expression was induced as early as 1 hour into exposure, whereas MT-1A and 
MT-1H transcripts were not induced until 3 hours exposure. MT-1H transcript induction 
was decreased compared to the other isoforms, even after 12 hours exposure. MT-1A 
transcript expression was constitutively present at low levels in control cells, suggesting 
cadmium may not be the only inducer of this isoform. However, upon cadmium exposure 
MT-1A transcript expression increased strikingly, indicating that the metal is at least a 
highly potent inducer of this isoform.  
 
 
Figure 28: RT-PCR showing the time-response of MT isoform transcript induction in 
proliferating NHU cells exposed to cadmium. Proliferating NHU cells (n=1; Y1594) were 
continuously exposed to 10 µM CdCl2 and analysed at 1, 3, 6 and 12-hour time-points, RNA 
extracted and MT isoform transcript expression assessed. PCR controls included genomic DNA 
as a positive control and dH2O as a negative control. GAPDH transcript expression was used as 
a loading control, and RT-ve samples confirmed the absence of genomic contamination. 
 
3.2.4 Detection of Cadmium-Induced MT Isoform Protein Expression using Novel 
MT Isoform-Specific Antibodies  
It was next important to determine whether the prominent MT-1 isoform transcript 
inductions observed in cadmium-exposed NHU cells were translated to protein 
expression. However, as discussed earlier (section 1.5.5.4) the most specific MT antibody 
commercially available can only detect the MT-1/2 subfamily as a whole, and is therefore 
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also unable to discriminate between the the MT-1 isoforms. Determining individual 
isoform protein expression has therefore been problematic and previously only been 
attempted using mass-spectrometry in the literature (section 1.5.6.1). For this thesis, 
commercially untested isoform-specific antibodies were obtained, validated and 
optimised for use in a number of protocols (see Figures 8, 9, 14 and 15). The antibodies 
obtained were specific for the MT-1A and MT-1M isoforms, both of which had 
demonstrated high transcript induction in response to cadmium exposure. 
 Initial experiments were performed to determine whether MT-1A and MT-1M isoform 
protein induction could be detected using western blotting. Proliferating NHU cells were 
exposed to 10 µM CdCl2 for 72 hours, protein lysates extracted and western blotting 
performed using the newly optimised MT-1A and MT-1M antibodies. The results showed 
no expression of either MT-1A or MT-1M protein in NHU cells under control conditions 
(Figure 29), despite low MT-1A transcript expression having been observed in control 
cells. However, cadmium exposure caused a striking induction of both MT-1A (Figure 
29A) and MT-1M (Figure 29B) protein expression, which was observed in all three 
independent NHU cell lines tested (n=3). 
 To confirm these results, and to attempt localisation of MT isoform protein expression, 
immunohistochemistry was also performed. Proliferating NHU cells exposed to 10 µM 
CdCl2 for 72 hours were centrifuged to form cell pellets, which were then fixed and 
probed for MT-1A/MT-1M protein expression. Control cell pellets did not express either 
MT-1A and MT-1M protein, whereas cadmium-exposed cell pellets revealed strong 
immunolabelling for both protein isoforms (Figure 30; n=1). Interestingly, the isoforms 
showed differential protein localisation. MT-1A protein expression was observed to 
occur in both the cytoplasm and nucleus, forming punctate protein deposits (as indicated 
by the arrows). However, MT-1M protein was observed confined to the cytoplasm and 
did not form such distinguishable deposits, as localisation was observed to be more 
diffuse.  
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Figure 29: Western blot showing MT-1A and MT-1M protein expression in proliferating NHU 
cells exposed to cadmium. Proliferating NHU cells (n=3; Y1387, Y1097, Y1342 for MT-1A and 
Y1531, Y1426, Y1526 for MT-1M) were exposed to 10 µM CdCl2 for 72 hours, protein lysates 
extracted and western blotting performed. Protein expression of (A) MT-1A and (B) MT-1M was 
then determined using novel, isoform-specific antibodies. β-actin protein expression was used as 
a loading control. 
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Figure 30: Immunohistochemical labelling of MT-1A and MT-1M protein expression in 
proliferating NHU cells. Proliferating NHU cells (n=1; Y1497) were exposed to 10 µM CdCl2 
for 72 hours and centrifuged to form cell pellets. Pellets were then fixed and immunolabelled for 
MT-1A or MT-1M protein using novel isoform-specific antibodies. Arrows indicate punctate MT-
1A protein deposits visible within the cells. Scale bar = 25 µm. 
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3.3 Summary of Key Findings 
• 10 µM CdCl2, a concentration suggested to closely reflect human in vivo exposure, 
did not inhibit NHU cell proliferation at a minimum cell seeding density of 6 x 104 
cells/cm2.  
• Most MT-1 isoforms showed no or minimal transcript expression in NHU cells under 
baseline conditions, although MT-1A gene transcription was sporadically observed 
and MT-1X transcript constitutively expressed. MT-2A isoform transcript was also 
ubiqitously present. No expression of MT-3 isoform transcript was observed in either 
cadmium-exposed NHU cells or urothelial cancer cell lines. 
• NHU cell exposure to cadmium caused transcript induction of the majority of MT-1 
isoforms, with preferential induction of the MT-1A, MT-1G, MT-1H and MT-1M 
isoforms, which were the selected as target isoforms for study in subsequent 
experiments.  
• MT isoforms showed differential transcript induction depending on cadmium 
concentration and length of exposure. 
• MT-1A and MT-1M proteins were induced in proliferating NHU cells exposed to 
cadmium and demonstrated differential localisation and presentation. MT-1A protein 
formed punctate deposits throughout the cell, whereas MT-1M protein was observed 
as diffuse in the cytoplasm. 
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3.4 Discussion 
3.4.1 Development of Cell Culture Conditions for NHU Cell Cadmium Exposure 
When determining a human-relevant, non-cytotoxic concentration of cadmium for NHU 
cell exposure, it was observed that use of the standard cell seeding density for the 
proliferation assay resulted in cytotoxicity at the selected intermediate concentration 
10 µM CdCl2. It was therefore decided to determine whether an increased cell seeding 
density could increase NHU cell tolerance to this concentration. However, the density 
had to be remain low enough to still permit NHU cell proliferation for the duration of the 
experiment (i.e. without confluence being reached). Further experiments were successful 
in determining a minimum cell seeding density that permitted cellular proliferation 
throughout the experiment, yet eliminated cadmium-induced cellular cytotoxicity, 
resulting in proliferation of exposed NHU cells that did not significantly alter compared 
to proliferation by control cells. 
3.4.2 Cadmium-Induced NHU Cell Morphological Changes 
The development of extended processes between NHU cells exposed to cadmium (Figure 
22) has also been observed in other cadmium-exposed epithelial cell lines. One such study 
found that the rat liver cell line TLR1215 adopted a more fibroblastic morphology upon 
chronic cadmium exposure, a change which is often associated with the malignant 
transformation (Takiguchi et al., 2003). A similar morphological alteration has also been 
found in the human urothelial cancer cell line T24 upon exposure to cigarette smoke 
extract (Sun et al., 2017); a substance which is known to contain cadmium (section 
1.2.4.1). In this case the cells underwent a significant morphological change from a 
cobblestone-like to a spindle-like mesenchymal form, accompanied by increased 
expression of mesenchymal markers and decreased expression of epithelial markers. 
 Other carcinogenic heavy metals such as arsenic have also been shown to induce 
epithelial-to-mesenchymal transition (EMT); however, in this study the immortalised 
human lung peripheral epithelial cell line HPL-1D was used, not a urothelial one (Person 
et al., 2015). Of note, the authors also observed a significant increase in MT-1A and MT-
2A transcript expression in these cells, concluding that the results supported an 
association between MT expression and the development of a malignant cell phenotype. 
Based on these results, it is tempting to speculate that the formation of extended processes 
in NHU cells exposed to cadmium may be an early indicator of EMT. Further studies 
Chapter 3: Characterisation of Control and Cadmium-Induced Metallothionein 
Isoform Expression in Normal Human Urothelium 
121 
exposing NHU cells to cadmium for a prolonged time period would be required, 
combining morphological alterations with changes in gene expression (for example of 
epithelial and mesenchymal markers) in order to confirm whether cells may be 
undergoing EMT.  
3.4.3 MT Isoform Expression in NHU Cells  
RT-PCR assessment of MT isoform transcript expression in proliferating and 
differentiated NHU cells under control conditions revealed that the majority of MT-1 
isoforms were not expressed in baseline conditions, supported by the NGS data. However, 
these isoforms could be induced by cadmium exposure, consistent with literature 
suggesting that MT-1 is the inducible MT subfamily (Miles et al., 2000; Thirumoorthy et 
al., 2007; Capdevila et al., 2012). In proliferating NHU cells it was observed that both 
MT-1E and MT-1X transcription was variable, demonstrating constitutively high 
baseline expression in some NHU cells derived from certain donors, but having minimal 
or no expression in cells from others. NGS data partially supported these findings, 
demonstrating high MT-1E and MT-1X transcription in proliferating NHU cells. Variable 
expression could be linked to the high amounts of polymorphism observed in the MT-1 
subfamily  (Sigel et al., 2009; Capdevila et al., 2012) which can affect isoform expression 
and function (Yang et al., 2008; Raudenska et al., 2013; Starska et al., 2014). RT-PCR 
showed that MT-2A transcript was constitutively highly expressed in both proliferating 
and differentiated NHU cells from all donors, which was also found in the NGS data, 
consistent with literature which suggests that this is the most widely expressed MT 
isoform (section 1.5.2).  
 NHU cells derived from one patient donor demonstrated minimal transcript expression 
of the MT-1X isoform in control conditions, but a prominent upregulation of transcript 
expression was observed upon cadmium exposure. Results in NHU cells from other 
donors (see Appendices section 8.6.2) showed that MT-1X transcript expression was 
constitutively high in control conditions and remained unaffected by cadmium exposure. 
These contradictory results raise two questions; firstly, why does MT-1X baseline 
transcript expression vary between individuals? As suggested above, differential baseline 
transcription could be due to polymorphisms (e.g. single nucleotide polymorphisms), 
which could be further investigated using direct DNA sequencing. The second question 
is whether MT-1X transcript expression was still increased in individuals demonstrating 
high baseline transcription, but the increase was unobservable using RT-PCR due to PCR 
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band saturation. To answer this question quantitative PCR methods would need to be used 
to compare MT-1X transcript expression in cadmium-exposed NHU cells derived from 
different donors demonstrating either high or no MT-1X transcript expression under 
baseline conditions. The results would determine whether NHU cell lines demonstrating 
low baseline MT-1X transcript expression show a unique increased expression of MT-
1X in response to cadmium exposure.  
 As mentioned in the introduction (section 1.5.6.2) MT-3 transcript and protein 
expression has previously been reported in urothelial cancer specimens, and no obseravle 
expression in normal urothelial samples (Sens et al., 2000; Zhou et al., 2006b). Absent 
MT-3 expression in healthy urothelial controls is supported by the results from this thesis, 
as neither proliferating nor differentiated NHU cells  demonstrated MT-3 transcription. 
However in contradiction to previous findings, which suggested MT-3 as a potential 
biomarker of urothelial cancer (Sens et al., 2000), this thesis additionally found no 
detectable MT-3 transcript expression in any of the urothelial cancer cell lines analysed. 
This included the high-grade urothelial cancer cell line EJ, despite the study by Sens et 
al. having reported particularly elevated MT-3 expression in high-grade urothelial cancer. 
Moreover, in this thesis MT-3 transcript expression was also absent in proliferating NHU 
cells exposed to cadmium, despite a previous study having reported induction of MT-3 
in the urothelial cell line UROtsa after malignant transformation by chronic cadmium 
exposure (Zhou et al., 2006b). 
 Lack of MT-3 transcript expression in all human urothelial cells assessed in this thesis is 
supported by the widely held view that MT-3 expression is confined to neural tissue 
(Palmiter et al., 1992). It is therefore unclear why the studies by Sens et al. (2000) and 
Zhou et al. (2006b) observed positive MT-3 expression in urothelial cancer specimens. 
One possible explanation for the MT-3 transcript expression observed in urothelial cancer 
samples is that the transcript may have originated from other, non-urothelial cells. In 
order to perform RT-PCR the authors cut thick sections from paraffin-embedded tissue 
specimens, but did not attempt to isolate the urothelium, and thus the samples analysed 
most likely contained a mixture of cell types (e.g. stromal, lymphocyte). However, this 
does not explain why the authors were able to observe MT-3 protein expression in the 
urothelium of urothelial cancer specimens. A second possibility is that the antibody used 
was not specific for MT-3 protein expression. Clearly, further investigation is needed to 
establish whether MT-3 expression is truly associated with the presence of urothelial 
cancer. 
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 Lastly, commercially untested antibodies were able to successfully discriminate between 
cadmium-induced MT-1A and MT-1M protein expression (section 3.2.4). This was the 
first time that differentiation between MT-1 isoforms had been performed at the protein 
level using non-spectroscopic methods, and that localisation of the individual MT-1 
isoforms had been attempted. Differential localisation and protein expression 
characteristics of the isoforms was observed in cadmium-exposed NHU cells (Figure 30), 
not only suggesting that the antibodies could discriminate between the isoforms, but 
inferring that the different isoforms may possess distinct functions.
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Chapter 4: Cadmium Exposure and the Urothelial Barrier 
4.1 Chapter Aims 
The aim of this chapter was to determine whether cadmium could cross a functional, tight 
urothelial barrier, either by direct access or by compromising barrier function and thereby 
indirectly accessing the underlying urothelial cells. 
4.1.1 Objectives 
1. Determine whether exposure of differentiated NHU cells to a human-relevant 
concentration of cadmium alters barrier function over time. 
2. Assess whether cadmium exposure can cause MT transcript and protein induction in 
differentiated NHU cells despite the presence of a tight urothelial barrier. 
3. Directly quantify cadmium in exposed differentiated NHU cell sheets despite the 
presence of a tight urothelial barrier. 
4.1.2 Experimental Design 
1. To achieve the overall aim of determining whether cadmium could penetrate an intact 
tight urothelial barrier, it was first important to assess whether cadmium exposure 
compromised urothelial barrier function. To investigate this, proliferating NHU cell 
cultures were stimulated to differentiate using a biomimetic method (described in 
section 2.7.8). Differentiation was confirmed by expression of differentiation 
associated markers and/or the development of a functional barrier (determined using 
TER readings; section 2.7.9). Once differentiated, the cultures were exposed apically 
to 10 µM CdCl2 (Figure 31) in order to reflect in vivo exposure, where the apical 
surface of the urothelium would be exposed to cadmium in the urine. Differentiated 
NHU cells were exposed to cadmium for up to 72 hours and TER measured in 
triplicate at various time-points to monitor barrier function. 
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Figure 31: Diagram illustrating the set-up of a ThinCert™ membrane for culturing 
differentiated NHU cell sheets in the presence of cadmium. NHU cells were seeded onto the 
membrane and stimulated to differentiate (as described in section 2.7.8). For cadmium exposure, 
all medium was first aspirated from the wells. Normal medium was then placed in the basal well, 
and medium containing 10 µM CdCl2 was placed in the apical chamber in order to mimic in vivo 
exposure. 
 
2. The next step was to indirectly assess whether cadmium could penetrate the urothelial 
barrier. Based on the finding from Chapter 3 that MT-1 isoform transcript/protein 
induction appears a robust biomarker of cadmium exposure in NHU cells, 
differentiated NHU cell sheets demonstrating a tight urothelial barrier were exposed 
to 10 µM CdCl2 for up to 72 hours and MT isoform transcript and protein expression 
determined. TER was monitored throughout the experiment to ensure the continuous 
presence of a functional urothelial barrier. At the end of the experiment RNA and 
protein lysates were extracted for RT-PCR and western blotting respectively. 
Additionally, differentiated cell sheets were fixed and used for immunohistochemical 
labelling of MT protein.  
3. To further investigate and quantify any potential cadmium penetration through the 
urothelial barrier, inductively coupled plasma-optical emission spectroscopy (ICP-
OES) was performed to directly measure cadmium concentration in the underlying 
urothelial cells. Differentiated NHU cell sheets were taken from the above 
experiment, as they had maintained a tight urothelial barrier but still shown induction 
of the MT-1 isoforms post cadmium-exposure, suggesting cadmium may have 
penetrated the urothelium. The NHU cell sheets were washed, acid-digested and 
prepared for use in the ICP-OES machine (see section 2.12). Two separate NHU cell 
cultures from the same cell line were used for each condition (control and cadmium-
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exposed) to provide duplicate technical repeats. Cadmium concentration in digested 
cell solutions was then calculated, along with concentration per mm2 cell sheet.  
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4.2 Results 
4.2.1 Effect of Cadmium Exposure on Urothelial Barrier Function 
The results indicated that both control and cadmium-exposed differentiated NHU cells 
maintained a tight urothelial barrier throughout the experiment (Figure 32A). Moreover, 
TER readings remained similar between control and cadmium-exposed NHU cell 
cultures. In order to validate these findings, the experiment was repeated in NHU cells 
from 3 individual donors and the results combined. The data revealed that after 72 hours 
cadmium exposure differentiated NHU cells still retained a tight urothelial barrier with a 
TER reading >3 kΩ.cm2 (Figure 32B). This reading was not significantly different to 
control cells (p>0.05), suggesting that cadmium exposure did not alter urothelial barrier 
function (n=3 biological repeats, in experimental triplicates). 
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Figure 32: Transepithelial electrical resistance (TER) readings from differentiated NHU cell 
sheets exposed to cadmium. (A) Representative graph of differentiated NHU cells (n=1; Y1493) 
that were apically exposed to 10 µM CdCl2 for 24, 48 and 72 hours showing TER readings over 
time. Each data point represents mean electrical resistance from 3 technical replicates (kΩ.cm2) 
±S.D. (B) NHU cells from 3 independent donors (n=3; Y1493, Y1531, Y1456) were differentiated 
and exposed to 10 µM CdCl2 for 72 hours to determine whether exposure affected barrier 
function. Mean TER readings for each donor were calculated from 3 technical replicates. Each 
column represents the overall mean electrical resistance calculated from triplicate readings in 3 
independent donors (kΩ.cm2) ±S.D. 
Chapter 4: Cadmium Exposure and the Urothelial Barrier 
129 
4.2.2 MT Isoform Transcript and Protein Expression in Differentiated NHU Cells 
Exposed to Cadmium 
RT-PCR was performed for all MT-1 and MT-2 transcripts to examine possible induction 
of isoforms. KRT13 transcript expression was used as a marker of transitional 
differentiation (see Appendices section 8.4.1) and the presence of a functional barrier was 
also confirmed (see Figure 32B). Qualitatively, the results showed a strong induction of 
the majority of the MT-1 subfamily, although MT-1B and MT-1L demonstrated minimal 
induction (Figure 33; n=3). In support of previous findings (see section 3.2.3), the MT-
1A, MT-1G, MT-1H and MT-1M transcripts were the most highly induced. The data also 
indicated constitutively high expression of MT-1X and MT-2A transcripts, which had 
been previously observed (section 3.2.2). Despite its constitutive expression, MT-1X 
transcript also increased in expression with cadmium exposure.  
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Figure 33: Representative RT-PCR showing MT isoform transcript expression in differentiated 
NHU cells with functional barriers that were exposed to cadmium. NHU cells (n=3; Y1456, 
Y1493, Y1531) were differentiated and exposed to 10 µM CdCl2 for up to 72 hours. Differentiation 
was inferred by expression of the transitional epithelial marker KRT13 and confirmed using TER 
readings (see Figure 32B). PCR controls included genomic DNA as a positive control and dH2O 
as a negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. Representative cell line was Y1456 
(results from other cell lines are included in the Appendices). 
 
 Protein expression of the MT-1A and MT-1M isoforms was next determined. Western 
blotting revealed a prominent induction of MT-1A protein in differentiated NHU cells 
exposed to cadmium (Figures 34A and 34C; n=3). No MT-1A protein was expressed in 
control cells, despite the presence of low levels of transcript expression observed in 
control NHU cells previously (section 3.2.2). MT-1M protein induction could also be 
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detected in cadmium-exposed cells (Figure 34B; n=1), however not to the same extent as 
MT-1A protein. To confirm these findings, and attempt to localise the proteins within the 
differentiated cell sheets, immunohistochemistry was performed. The results showed 
immunolabelling for both MT-1A and MT-1M proteins in the exposed cell sheets (Figure 
35; n=1). In support of previous findings in proliferating NHU cells (section 3.2.4) MT-
1A protein was observed as punctate protein deposits, whereas MT-1M protein presented 
as diffuse immunolabelling. MT-1A protein expression also appeared  
much stronger than MT-1M, supporting the western blot results. 
 
 
Figure 34: Western blots demonstrating MT-1A and 1M protein expression in differentiated 
NHU cells with functional barriers that were exposed to cadmium. NHU cells were stimulated 
to differentiate and form a functional barrier, before exposure to 10 µM CdCl2 for up to 72 hours. 
Protein lysates were then extracted and MT protein expression determined. (A) MT-1A protein 
expression was assessed at multiple time-points to ensure exposure time was adequate for protein 
translation in differentiated NHU cells (n=1; Y1493). (B) Western blots showing MT-1A and MT-
1M protein expression (n=1; Y1531) and (C) MT-1A protein expression (n=1; Y1426) in 
differentiated NHU cells exposed to cadmium for 72 hours. 
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Figure 35: Immunohistochemical labelling of MT-1A and MT-1M protein expression in 
differentiated NHU cell sheets with functional barriers that were exposed to cadmium. NHU 
cells (n=1; Y1531) were differentiated forming cell sheets with a functional barrier. Cells were 
then apically exposed to 10 µM CdCl2 for 72 hours, and TER readings monitored throughout in 
order to ensure the continuous presence of a tight barrier (TER readings can be seen in Figure 
32B). NHU cell sheets were then fixed and immunolabelled for MT-1A and 1M protein 
expression. Control images were differentiated NHU cell sheets which had not undergone 
cadmium exposure.  Scale bar = 25 µm. 
 
These results demonstrated that cadmium could cause MT transcript and protein 
induction in differentiated NHU cell sheets despite the presence of a ‘tight’ urothelial 
barrier. This therefore suggested that cadmium was able to penetrate an intact urothelial 
barrier and enter urothelial cells, causing MT induction. However, this could only be 
inferred from the data indirectly, and thus a direct method of determining the presence 
of cadmium in differentiated urothelial cell sheets was additionally performed.  
4.2.3 Direct Quantification of Cadmium in Exposed Differentiated NHU Cell Sheets 
using Spectroscopic Methods 
Cadmium concentration readings of all solutions tested are shown in Figure 36A, which 
revealed that the cadmium concentration of the digested control cell solution was 
comparable to wash buffer concentrations; i.e. negligible. However, the digested cell 
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solution from cadmium-exposed NHU cells demonstrated a much higher cadmium 
concentration (n=1). When data from two technical repeats was combined and the means 
compared, it was found that the digested cadmium-exposed cell solution had an 
approximately 10 times higher mean cadmium concentration than the digested cell 
solution from control cells (0.08 µM and 0.94 µM, respectively; Figure 36A). Conversion 
of the data to cadmium concentration per mm2 NHU cell sheet supported these findings, 
with cadmium-exposed cells containing 0.008 µM/mm2 and control cells containing 
0.0007 µM/mm2 (Figure 36B).  
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Figure 36: ICP-OES was used to detect and quantify cadmium in differentiated NHU cells with 
a functional barrier that were exposed to cadmium. NHU cells (n=1; Y1531) were differentiated 
forming cell sheets with a functional barrier (see Figure 32B) and apically exposed to 10 µM 
CdCl2 for 7 days. Samples were then washed 3 times with PBS to remove extracellular metal, 
acid-digested and diluted for use in the ICP-OES machine. Dilutions were taken into account 
when calculating final measurements. (A) Cadmium concentrations in wash buffer solution, 
digested control and digested cadmium-exposed NHU cell solutions are shown. Each column 
represents mean cadmium concentration ±S.D. (n=2; technical repeats). (B) Cadmium 
concentration per mm2 cell sheet in control and cadmium-exposed differentiated NHU cells. Each 
column represents mean cadmium concentration ±S.D. (n=2; technical repeats). 
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4.3 Summary of Key Findings 
• Cadmium exposure did not compromise the urothelial cell barrier, yet it could still 
cause MT-1 subfamily transcript and protein induction in differentiated NHU cells; 
suggesting that cadmium could potentially penetrate the protective epithelial barrier. 
• Direct quantification of cadmium in the digested cell solution from exposed NHU cell 
sheets revealed an ~10-fold higher cadmium concentration compared to controls, 
despite the presence of a ‘tight’ urothelial barrier, further suggesting that cadmium 
could penetrate the protective urothelial barrier.  
 
  
Chapter 4: Cadmium Exposure and the Urothelial Barrier 
136 
4.4 Discussion 
4.4.1 The Ability of Cadmium to Penetrate an Intact Urothelial Barrier 
The results from this chapter suggest that cadmium is able to penetrate an intact urothelial 
barrier. This contradicts previous studies which have investigated the effect of cadmium 
exposure on barrier function of other epithelial cells. One publication observed that 
different cadmium concentrations had opposing effects on the TER of Sertoli cells, as 
intermediate to high concentrations caused a decrease in TER and low concentrations 
resulted in an increased TER reading (Janecki et al., 1992). Another study found that 
exposure of renal epithelial cells to cadmium decreased TER, especially when cadmium 
was applied to the apical surface (Faurskov and Bjerregaard, 1997). A limitation of these 
studies is that the cells used were not human, but instead originated from rats and toads 
respectively, questioning the applicability of the findings to in vivo human exposure. 
However, these findings are also supported by a recent study which used primary normal 
human bronchial epithelial cells (Cao et al., 2015). These cells were used to develop in 
an in vitro air-liquid-interface airway tissue model, which was exposed to non-cytotoxic 
concentrations of cadmium. The authors found that exposure caused a collapse of barrier 
function, as monitored by TER, as well as decreased expression of tight junction markers 
such as ZO-1 (see section 3.1.2).  
 There is the possibility that the discrepancy in these findings may be due to the difference 
in the type of epithelium being tested. Urothelial cells are known to form one of the 
tightest epithelial barriers in the human body so that they may protect the underlying 
tissue from harmful constituents of the urine (see Introduction section 1.1.3), and thus 
maintenance of this barrier is essential. While other epithelium could be susceptible to 
cadmium-induced damage, the urothelium may be unique in its resistance. However, it 
should be noted that ICP-OES analysis was only conducted on an NHU cell culture from 
one individual donor; cultures from at least another two independent donors should 
therefore be analysed to verify this finding. Further, although cadmium was only applied 
apically to differentiated NHU cells after the development of a tight urothelial barrier 
(section 4.1.2), it is still possible that some cadmium may have entered the bottom 
chamber via the cell sheet edges and penetrated the cell sheets basally. This would have 
circumnavigated the need to cross the urothelial barrier, and thus future experiments 
should aim to remove the possibility of basal urothelial penetration by cadmium as an 
extraneous variable.  
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Chapter 5: Specificity and Longevity of MT-1 Isoform 
Induction in Cadmium-Exposed NHU Cells. 
5.1 Chapter Aims 
The aims of this chapter were to investigate the specificity of MT-1 isoform induction in 
cadmium-exposed NHU cells, and to investigate how long this isoform induction 
persisted at both the transcript and protein level.  
5.1.1 Objectives 
1. Determine whether a variety of potential inducers can stimulate MT-1 isoform 
transcript and protein expression in NHU cells.  
2. Compare MT-1 isoform transcript and protein induction caused by extraneous factors 
from Objective 1 to induction caused by cadmium, focusing on isoform specificity 
and extent of induction.  
3. Analyse the arrangement of MTF-1 binding sites in MT-1 isoform genes as a potential 
mechanism of induction specificity. 
4. Determine how long MT-1 isoform transcript and protein induction persists in NHU 
cells post-exposure to cadmium. 
5.1.2 Experimental Approach 
1. As reviewed in section 1.5.5.3, it has been suggested that the MT isoforms show 
differential induction depending on the causative agent. In order to determine the 
cadmium-specificity of the MT-1 target isoform induction identified in Chapters 4 
and 5, it was important to establish whether other extraneous factors could also 
regulate MT-1 isoform expression. This was especially important for the MT-1A 
isoform, which had already demonstrated varied expression in control cells, 
suggesting factors other than cadmium exposure were able to regulate its transcript 
expression. Positive control genes were used to ensure NHU cell exposure to effective 
treatment concentrations where necessary (see Appendices section 8.4.1). A number 
of potential inducers identified from the literature (see section 1.5.5.3) were tested to 
determine their ability to induce MT-1 isoform transcript expression. If transcript 
expression was observed to be altered, protein expression was also investigated. All 
results from candidate inducers are summarised in section 5.2.2, Table 7. The 
‘inducers’ tested and the experimental approach taken are summarised below: 
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a. Cell Culture Conditions – MT-1A transcript expression had varied under 
control conditions in previous experiments (see sections 3.2.2 and 3.2.3), and 
thus it was important to determine whether standard cell culture procedures 
such as medium change and passage may be able to influence MT-1 isoform 
expression. Proliferating NHU cells were cultured under standard conditions 
and underwent either a medium change or passage every 24 hours for 3 days. 
After the last passage, cells were left for 12 hours in order to allow them to 
adhere, meaning the total experimental time was 84 hours. A separate culture 
of NHU cells was exposed to 10 µM CdCl2 throughout this time period 
without undergoing any cell culture procedures, so that MT-1 isoform 
induction could be compared between cadmium exposure and the cell culture 
procedures. At the end of the experiment RNA and protein were extracted for 
analysis using RT-PCR and western blotting. A flow chart summarising the 
experimental plan is shown below in Figure 37.
Chapter 5: Specificity and Longevity of MT-1 Isoform Induction in 
Cadmium-Exposed NHU Cells. 
139 
 
 
Figure 37: Flow diagram summarising the experimental plan for assessing the ability of standard cell culture procedures to influence MT-1 isoform transcript 
induction. Three proliferating NHU cell cultures were seeded and left to adhere for 24 h. One cell culture underwent medium change every 24 h and one cell culture 
underwent passage every 24 h. This was performed for 72 h, and cells were then left for 12 h post final medium change/passage so that passaged cells could adhere 
before lysis. This resulted in a total experimental timeline of 84 h. A third cell culture was exposed to 10 µM CdCl2 continuously throughout the experiment. At 84 h 
all cell cultures were lysed and RNA and protein extracted.   
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b. Reactive Oxygen Species - The ability of reactive oxygen species (ROS) to 
induce MT isoform expression was determined. This was particularly 
important to establish, as cadmium exposure is reported to indirectly induce 
ROS via inhibition of the mitochondrial electron transfer chain (Wang et al., 
2004; Heyno et al., 2008). Therefore, it was essential to determine whether 
MT isoform induction in cadmium-exposed NHU cells was due to increased 
cellular ROS, or due to cadmium itself. To investigate this, the ROS-inducing 
chemical sulforaphane was titrated using NHU cell cultures in order to 
identify a concentration that induced similar levels of ROS to cadmium 
exposure (5 µM; see Appendices section 8.6.2). ROS induction was inferred 
using transcript expression of the ROS-sensitive heme oxygenase-1 
(HMOX1) gene (Ryter and Choi, 2005; Sarma et al., 2011). Proliferating 
NHU cells were then exposed to either 10 µM CdCl2 or 5 µM sulforaphane 
for 12 hours, and RNA extracted for RT-PCR analysis. To further determine 
whether ROS could cause MT-1 subfamily induction, a second experimental 
approach was taken. This involved exposure to cadmium in the presence of 
the ROS-scavenger ascorbic acid.  The ascorbic acid concentration was based 
on preliminary titration work that identified a concentration that could inhibit 
cadmium-induced ROS (25 µg/mL; see Appendices section 8.7.2), as inferred 
by HMOX1 transcript expression. Proliferating NHU cells were then exposed 
to 10 µM CdCl2 either alone or in combination with 25 µg/mL ascorbic acid 
for 12 hours and RNA extracted.  
c. Hypoxia - Another factor that has been proposed to induce MT expression is 
hypoxia (see section 1.5.5.3). To investigate whether hypoxic conditions 
could induce MT-1 subfamily expression, proliferating NHU cells were 
cultured in a hypoxic incubator where atmospheric oxygen (O2) was 
maintained at 2 %. A separate NHU cell culture was exposed to 10 µM CdCl2 
under normal cell culture conditions, and after 12 hours RNA was extracted 
from both cultures for analysis. HIF-1α gene transcript expression was used 
as a positive control for hypoxia (see Appendices section 8.4.1). 
d. Steroids and Hormones - The literature has also suggested that both 
glucocorticoids and cytokines may be able to induce MT expression (see 
section 1.5.5.3). To assess whether these factors could cause MT-1 subfamily 
expression, proliferating NHU cells were exposed to two reported inducers; 
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either the glucocorticoid dexamethasone (Dex) or the cytokine interleukin-1β 
(IL-1β). Both these substances were titrated prior to use (see Appendices 
section 8.4.2) in order to determine functional concentrations capable of 
altering target gene expression (Figure 43A). Cells were either exposed to one 
of these agents or 10 µM CdCl2 for 12 hours and RNA extracted for RT-PCR 
analysis. 
e. Essential Metals – Previous studies had reported that some essential metals 
such as zinc were able to induce MT-1 isoform expression. The next step was 
therefore to determine whether the addition of essential metals at the same 
exogenous concentration as cadmium (10 µM) could induce MT-1 isoform 
expression, and if so, whether to the same extent. Proliferating NHU cells 
were exposed to either 10 µM cadmium (CdCl2), copper (CuSO4), iron 
(FeSO4) or zinc (ZnCl2) for 12 hours and RNA extracted. 
f. Other Heavy Metals - As it is well documented that heavy metals can cause 
induction of MT (section 1.5), it was decided to investigate whether exposure 
to other occupationally-related carcinogenic heavy metals could also induce 
transcript expression of the MT-1 target isoforms, and whether induction was 
comparable to that caused by cadmium exposure. Proliferating NHU cells 
were exposed to a range of non-cytotoxic concentrations of either sodium 
arsenite (NaAsO2; 0.25 – 2 µM) or nickel (NiCl2; 25 – 200 µM; Dally and 
Hartwig, 1997; Gadhia et al., 2012; Severson et al., 2012; Treas et al., 2012; 
also determined by previous experiments in the laboratory) for 12 hours and 
RNA extracted. 
2. To confirm the specificity of MT-1 isoform transcript induction, and to determine 
whether these changes were translated to protein expression, all factors that were 
capable of inducing MT-1 isoform transcript expression were compared in the same 
experiment. Proliferating NHU cells were exposed to either 10 µM CdCl2, 10 µM 
CuSO4, 10 µM FeSO4, 10 µM ZnCl2, 2 µM NaAsO2, 200 µM NiCl2 or 5 µM 
sulforaphane for 72 hours. RNA and protein were then extracted for analysis.  
3. To further investigate the initial findings of differential MT-1 isoform induction, and 
potentially identify a regulatory mechanism, bioinformatics was used to determine 
the presence and spatial arrangement of MTF-1 binding sites in the non-coding DNA 
region upstream of MT-1 isoform genes (see section 1.5.3). The rVISTA (v. 2.0) 
computer web tool was used for this approach 
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(http://genome.lbl.gov/vista/index.shtml). The tool works by identifying all 
transcription factor binding sites (TFBSs) in target genes using positional weight 
matrices from the TRANSFAC® database (Figure 38). TFBSs are then selected based 
on criteria such as local alignment and high DNA conservation, and the tool produces 
a list of transcription factors (TFs) that have binding sites within the target genes. The 
user then selects which TF(s) they are interested in, and the programme produces a 
graphical display of the TFBSs for this selected TF(s) within the target genes. These 
displays can then be used to compare target genes and identify shared and unique 
TFBSs for the specific TF(s) in question. For this thesis, MTF-1 binding sites were 
compared between the MT-1 target isoforms (MT-1A, MT-1G, MT-1H, MT-1M), 
focusing specifically on the MT-1A and MT-1M isoforms. MT-1A and MT-1M were 
each compared to the other MT-1 isoforms individually as ‘cases’, with the aim of 
identifying any unique MTF-1 binding sites in the gene promoters. Unique MTF-1 
binding sites were identified in each case by comparing the location of all MTF-1 
binding sites (denoted by MTF1_all) to the location of shared binding sites (denoted 
by MTF1_aligned and MTF1_conserved). Any unique binding sites observed in the 
individual cases were then compared to MTF-1 binding sites from all cases, to 
confirm if they were truly unique and not present in any of the other isoforms. 
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Figure 38: Diagram showing the workflow for using the rVISTA (v. 2.0) web tool. The purpose 
of the web tool is to identify transcription factor (TF) binding sites (TFBSs) in target genes, 
allowing gene comparisons and unique binding sites to be found. The tool firstly identifies all 
TFBSs in the target genes using positional weight matrices (PWM) obtained from the 
TRANSFAC® database. TFBSs are then filtered using local alignment and DNA conservation. 
The programme then provides the user with a list of TFs that have binding sites within the target 
genes, and the user can select which TF(s) they wish to analyse. Graphical displays are produced 
which show all TFBSs for the TF(s) in question within the non-coding DNA of target genes, 
allowing comparisons of TFBSs to be made. Website: http://genome.lbl.gov/vista/index.shtml.  
 
4. The longevity of MT-1 target isoform induction was investigated in order to 
determine whether expression persisted post-cadmium exposure. This was important 
to investigate in order to assess their potential use as biomarkers of cadmium 
exposure, as not all occupational heavy metal exposure is current. Longevity of MT-
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1 isoform expression was determined in both proliferating and differentiated NHU 
cells as both cell phenotypes are found in vivo in human urothelium (see Introduction; 
section 1.1.2), and additionally that any dilutive effects caused by cell division could 
be observed and eliminated as an extraneous effect.  
a. Transcript Expression - MT-1 isoform transcript longevity was first 
assessed. Proliferating NHU cells were pre-exposed to 10 µM CdCl2 for 24 
hours before removal of cadmium (time-point 0 h). Cells were then further 
cultured for 48 hours, and RNA extracted at various time-points. MT-1 
isoform transcript expression post-cadmium exposure was also assessed in 
differentiated NHU cells. To achieve this, differentiated NHU cell cultures 
were apically exposed to 10 µM CdCl2 for 3 days (0 d), before removal of 
exposure and continued culturing for up to 11 days. A description of the 
method used for NHU cell differentiation and apical cadmium exposure can 
be found in Chapter 5 (section 5.1.2). RNA was extracted at various time-
points for RT-PCR analysis.  
b. Protein Expression - The next step was to determine the longevity of MT-
1A and MT-1M protein induction post-exposure to cadmium. This was firstly 
investigated in undifferentiated NHU cells; proliferating NHU cells that had 
been allowed to reach confluence prior to exposure. The purpose of allowing 
confluence to be reached was to prevent protein dilution due to cell 
proliferation post-exposure, as protein dilution could be falsely interpreted as 
a decrease in protein expression. Once NHU cells had reached confluence they 
were exposed to 10 µM CdCl2 for 72 hours, before removal of exposure and 
continued culturing for a further 5 days. Protein was then extracted and 
western blotting performed. The longevity of MT protein expression was also 
investigated in differentiated NHU cell cultures. Upon differentiation 
(confirmed by TER measurements), NHU cell cultures were apically exposed 
to 10 µM CdCl2 for 3 days (0 d time-point). Cadmium was then removed from 
the medium and the differentiated cell sheets cultured for another 4 days. 
Protein lysates were extracted both before and after removal of exposure and 
MT-1A and MT-1M protein expression determined. Immunohistochemistry 
was also performed to assess MT-1A and MT-1M protein longevity. 
Differentiated NHU cells were apically exposed to 10 µM CdCl2 for 3 days 
before removal of exposure and continued culturing for 4 days. NHU cell 
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sheets were then fixed and immunolabelled for MT-1A and MT-1M protein 
expression. 
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5.2 Results 
5.2.1 Effect of Candidate Inducers on MT-1 Isoform Expression to Investigate 
Isoform Specificity  
5.2.1.1 Cell Culture Conditions 
NHU cell culture medium change caused induction of all MT-1 transcripts, although 
induction of the MT-1H and MT-1M transcripts was minimal (Figure 39A; n=1). 
However, induction of all isoforms was not as prominent as when NHU cells were 
exposed to cadmium. The results also indicated that passage resulted in downregulation 
of MT-1A transcript expression. Despite these changes in MT-1A transcript expression, 
MT-1H and MT-1M isoforms were unaffected by cell culture procedures, and transcript 
induction only induced by cadmium exposure. 
 As MT-1A transcript expression was altered by both medium change and passage, it was 
important to determine whether these changes were translated to MT-1A protein 
expression. Western blotting indicated low relative levels of MT-1A protein in both 
control and medium change cell cultures, and a slight upregulation of protein expression 
in the passaged cell culture (Figure 39B; n=1). However, quantification of protein 
expression using densitometry revealed that both medium change and passage were 
unable to increase MT-1A protein expression (Figure 39C; n=1). By contrast, western 
blotting clearly demonstrated a high induction of MT-1A protein expression in cells 
exposed to cadmium, which was supported by densitometry analysis. 
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Figure 39: The effects of cell culture conditions on MT isoform transcript and protein 
expression in NHU cells. Proliferating NHU cells (n=1; Y1483) were cultured in vitro, and were 
either medium changed or passaged every 24 hours for a total of 3 days. After the final subculture, 
cells were allowed to settle and adhere for 12 hours before RNA and protein extraction, meaning 
the total experimental period was 84 hours. A parallel NHU cell culture was continuously 
exposed to 10 µM CdCl2 in order to compare MT-1 isoform transcript and protein expression. 
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(A) Transcript expression was assessed by RT-PCR for MT-1 target isoforms. PCR controls 
included genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination. (B) MT-1A transcript changes were investigated at the protein level by western 
blotting, and (C) densitometry was performed to quantify MT-1A protein expression. 
 
5.2.1.2 Reactive Oxygen Species 
HMOX1 gene transcription was induced by both cadmium and Sulforaphane, suggesting 
that ROS was induced by both treatments (Figure 40A; n=3). Sulforaphane-induced ROS 
caused induction of both MT-1A and MT-1G transcription . However, this induction was 
decreased in comparison to cadmium-induced transcription. MT-1H and MT-1M 
transcription also showed some transcript induction in response to ROS exposure, 
however this was only minimal, and once again cadmium demonstrated a more striking 
induction of transcription.  
 It was important to determine whether the induction of MT-1A transcript expression by 
ROS was translated to MT-1A protein expression. To achieve this, proliferating NHU 
cells were exposed to 5 µM Sulforaphane for 72 hours (allowing sufficient time for 
protein translation) and protein extracted for analysis. Western blotting of protein lysates 
showed that ROS exposure did not cause induction of MT-1A protein expression (Figure 
40B; n=2). This observation was further supported when the immunoblot was analysed 
by densitometry and corrected for loading, as MT-1A protein expression was observed to 
slightly decrease in ROS-exposed cells (Figure 40C). However, in cadmium-exposed 
NHU cells there was a high induction of MT-1A protein expression, as observed in 
previous results (sections 3.2.4 and 4.2.2). This suggested that although ROS was capable 
of inducing MT-1A transcript expression, these changes were not translated to protein 
expression (n=2). 
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Figure 40: The effect of reactive oxygen species (ROS) on MT-1 isoform transcript and protein 
expression in NHU cells. (A) Representative RT-PCR showing the effects of ROS on MT isoform 
transcript expression. The chemical sulforaphane (SF) was used to induce ROS, having been 
titrated to a concentration that mimicked the amount of cadmium-induced ROS (determined by 
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transcript expression of the target gene HMOX1; section 8.4.1). Proliferating NHU cells (n=3; 
Y1426, Y1344, Y1526) were treated with either 10 µM CdCl2 or 5 µM Sulforaphane for 12 hours 
and RNA extracted for analysis. The production of ROS was confirmed using HMOX1 gene 
transcript expression. PCR controls included genomic DNA as a positive control and dH2O as a 
negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. A positive genomic DNA control for 
HMOX1 expression was not possible due to intron-spanning primers (N/A; not applicable). 
Representative NHU cell line was Y1426 (results from other cell lines are included in the 
Appendices). (B) Representative western blot showing the effects of ROS on MT-1A protein 
expression. Proliferating NHU cells (n=2; Y1426, Y1526) were treated with 5 µM Sulforaphane 
or 10 µM CdCl2 for up to 72 hours and western blotting performed. Representative NHU cell line 
was Y1426 (results from other cell lines are included in the Appendices). (C) Densitometry was 
performed in order to quantify and compare MT-1A protein expression induced by ROS and 
cadmium (n=2; Y1426, Y1526).  
 
 To further determine whether ROS could cause MT-1 subfamily induction, the ROS-
scavenger ascorbic acid was used to inhibit cadmium-induced ROS, and MT-1 isoform 
induction assessed. RT-PCR confirmed successful inhibition of cadmium-induced ROS, 
as indicated by the reduction in HMOX1 transcript expression (Figure 41). The results 
also suggested that a reduction in cadmium-induced ROS did not inhibit induction of MT-
1 isoform transcript expression (n=1). All isoforms showed high transcript induction in 
both conditions, and this expression did not change with ROS inhibition. 
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Figure 41: RT-PCR showing the effects of inhibition of cadmium-induced reactive oxygen 
species (ROS) on MT-1 isoform transcript expression. Proliferating NHU cells (n=1; Y1526) 
were exposed to 10 µM CdCl2 for 12 hours either alone or in combination with 25 µg/mL ascorbic 
acid. Ascorbic acid is a ROS scavenger and was previously titrated to a concentration that 
inhibited ROS induction by cadmium exposure (see Appendices, section 8.4.2). Transcript 
expression of the ROS-sensitive gene HMOX1 was used to infer ROS production. PCR controls 
included genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination.  
 
5.2.1.3 Hypoxia 
RT-PCR showed that whereas cadmium could cause a prominent induction of all MT-1 
isoform target genes, hypoxia was unable to induce expression of any of these genes 
(Figure 42; n=1). Hypoxia was confirmed by induction of the hypoxia-sensitive HIF-1α 
gene.  
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Figure 42: RT-PCR showing the effects of hypoxia on MT-1 isoform transcript expression in 
NHU cells. Proliferating NHU cells (n=1; Y1594) were exposed to either hypoxia (2 % O2) or 
10 µM CdCl2 for 12 hours, and MT-1 isoform transcript expression assessed. HIF-1α gene 
expression was used to confirm hypoxic conditions (see Appendices, section 8.4.1). PCR controls 
included genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination. A positive genomic DNA control for HIF-1α expression was not possible due to 
intron-spanning primers (N/A; not applicable). 
 
5.2.1.4 Dexamethasone (Glucocorticoid) and Cytokine IL-1β (Hormone)  
Successful treatment of NHU cells with functional concentrations of both 
Dexamethasone and IL-1β was confirmed using target gene transcript expression (Figure 
42A). The usual induction of MT-1 isoform transcript expression by cadmium exposure 
was observed, however treatment with Dexamethasone or IL-1β demonstrated no 
induction of the isoforms (Figure 43B; n=1). The results therefore suggested that this 
specific glucocorticoid and cytokine were unable to induce MT-1 isoform target gene 
expression.  
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Figure 43: RT-PCR showing the effects of glucocorticoid and cytokine treatment on MT-1 
isoform transcript expression in NHU cells. Proliferating NHU cells (n=1; Y1426) were 
cultured with either 10 µM CdCl2, 10 µM Dexamethasone (Dex; glucocorticoid) or 1 nG/mL IL-
1β (cytokine) for 12 hours. As the vehicle for dexamethasone, dimethyl sulphoxide (DMSO) 
treatment was included as a control. (A) Dexamethasone and IL-1β were titrated prior to use (see 
Appendices, section 8.4.2) in order to determine functional concentrations that were capable of 
altering target gene transcript expression. (B) MT-1 isoform transcript expression was assessed 
to determine whether either Dexamethasone or IL-1β could cause induction comparable to 
cadmium exposure. PCR controls included genomic DNA as a positive control and dH2O as a 
negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. 
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5.2.1.5 Essential Metals 
RT-PCR analysis indicated that the MT-1 isoforms demonstrated differential induction 
depending upon the specific metal exposure (Figure 44; n=2). For example, MT-1G 
transcript expression was induced by both copper and zinc treatment, but not iron. 
Moreover, zinc was capable of inducing MT-1G transcript expression to a similar extent 
to cadmium exposure. Zinc was also the only essential metal able to induce either MT-
1H or MT-1M transcript expression, but this induction was minimal compared to 
cadmium-induced expression. Lastly, all the essential metals tested were able to 
upregulate MT-1A transcript expression, although not to the same extent as cadmium 
exposure. 
 
 
Figure 44: RT-PCR showing the effects of essential metal exposure on MT-1 isoform transcript 
expression in NHU cells. Essential metals copper, iron or zinc were added to NHU cell culture 
at the same exogenous concentration as cadmium, in order to determine whether they could also 
induce MT-1 isoform transcript expression. Proliferating NHU cells (n=2; Y1426, Y1526) were 
exposed to either 10 µM CdCl2, 10 µM CuSO4, 10 µM FeSO4, or 10 µM ZnCl2 for 12 hours and 
RNA extracted for RT-PCR. PCR controls included genomic DNA as a positive control and dH2O 
as a negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. Representative cell line was Y1426 
(results from the other cell line are shown in Figure 46).  
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5.2.1.6 Other Heavy Metals 
RT-PCR showed that the NHU cell line used in this experiment demonstrated constitutive 
expression of MT-1A transcript, which remained unaffected by exposure to either 
arsenite or nickel (Figure 45). However, MT-1G, MT-1H and MT-1M transcript 
expression demonstrated a dose-response relationship to both arsenite and nickel 
exposure (n=1). Preferential metal induction of MT-1 isoforms was again observed, as 
exposure to the highest non-cytotoxic concentration of nickel was capable of inducing 
MT-1H and MT-1M transcripts to a greater extent than the highest non-cytotoxic 
concentration of arsenite. Indeed, MT-1M transcript expression remained largely 
unaffected by arsenite exposure (n=2). 
 
 
Figure 45: Representative RT-PCR showing the effects of exposure to the carcinogenic metals 
arsenite and nickel on MT-1 isoform transcript expression in NHU cells. Proliferating NHU 
cells (n=2; Y1344, Y1526) were exposed to a range of non-cytotoxic concentrations of arsenite 
(0.25 µM – 2 µM; NaAsO2) and nickel (25 µM – 200 µM; NiCl2) for 12 hours and MT-1 isoform 
transcript expression assessed. Non-cytotoxic concentrations were established using the 
literature (see section 5.1.2) and previous experiments in the laboratory. PCR controls included 
genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination. Representative NHU cell line was Y1344 (results from the other cell line are 
shown in Figure 46). 
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5.2.2 Comparison of MT-1 Isoform Induction by Cadmium and other Candidate 
Inducers   
The RT-PCR results further supported differential induction of the MT-1 isoforms 
(Figure 46A; n=2). For example, MT-1G transcript was induced by cadmium, zinc, nickel 
and SF-induced ROS. By contrast, MT-1M transcript expression was only strongly 
induced by cadmium exposure, although there was minimal induction by zinc. MT-1A 
isoform transcription was constitutively minimal, but similar to MT-1M, could only be 
strongly upregulated by cadmium and zinc. MT-1H showed high induction by cadmium, 
but also some minimal induction by both zinc and SF-induced ROS. Neither of the heavy 
metals tested were observed able to induce transcript expression of MT-1A, MT-1H or 
MT-1M (n=1), which contradicts the previous findings (Figure 45). Overall the RT-PCR 
data further suggested that MT-1M transcript expression was highly specific to cadmium 
exposure, and though MT-1A transcript expression appeared less specific, it 
demonstrated preferential induction by cadmium.  
 Initial MT-1A protein expression results had suggested that the transcript expression 
changes caused by candidate inducers were not translated (Figures 39 and 40). It was 
important however to determine the specificity of both MT-1A and MT-1M protein 
expression as well as transcript. Western blotting showed that low amounts of MT-1A 
protein could be detected in control, zinc, arsenite and SF-induced ROS conditions; 
however, protein expression was also strikingly high in cadmium-exposed cells (Figure 
46B; n=2). MT-1M protein exposure also showed prominent induction in NHU cells 
exposed to cadmium. However, in contrast to MT-1A protein, no expression of MT-1M 
protein was detected under other conditions. Densitometry was therefore only performed 
to quantify and compare MT-1A protein expression between the conditions (Figure 46C; 
n=2). Densitometry revealed that MT-1A protein was minimally expressed under 
baseline conditions, and that no treatments other than cadmium could increase its 
expression, which caused ~6 times higher MT-1A protein abundance.  
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Figure 46: A comparison of MT-1 isoform expression in NHU cells exposed to a variety of 
potential inducers. Factors that had been found capable of inducing MT-1A or MT-1M isoform 
transcript expression in previous experiments were assessed in order to compare transcript 
induction and determine if changes were translated to protein expression. Proliferating NHU 
cells were exposed to either CdCl2 (10 µM), CuSO4 (10 µM), FeSO4 (10 µM), ZnCl2 (10 µM), 
NaAsO2 (2 µM), NiCl2 (200 µM), or SF (5 µM) for 72 hours, and RNA and protein extracted. (A) 
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Representative RT-PCR showing MT-1 target isoform transcript expression in NHU cells. PCR 
controls included genomic DNA as a positive control and dH2O as a negative control. GAPDH 
transcript expression was used as a loading control, and RT-ve samples confirmed the absence 
of genomic contamination. Representative NHU cell line was Y1526 (results from other cell lines 
can be seen earlier in the chapter in Figures 44 and 45). (B) Representative western blot showing 
MT-1A and MT-1M protein expression in NHU cells. Representative NHU cell line was Y1426. 
(C) Densitometry was performed in order to quantify and compare MT-1A protein expression 
between the different potential inducers (n=2; Y1426, Y1526).  
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Table 5: Summary of MT-1 isoform potential inducers. Table showing the different factors 
tested for their ability to induce MT-1A, MT-1G, MT-1H and MT-1M isoform expression. The 
concentration of each factor is given (where appropriate), and whether it could influence MT-1 
isoform expression at the transcript and/or protein level. For each result the ‘n’ number 
(biological repeats) is provided. Results which are starred (*) denote mixed findings.  
Potential Inducer Concentration 
Used 
Isoform(s) with 
Altered 
Transcript 
Expression  
Isoform(s) with 
Altered Protein 
Expression 
Medium Change N/A; 4x MT-1A, MT-1G 
(n=1)  
None (n=1) 
Passage N/A; 4x None (n=1) None (n=1) 
ROS  
1. Induction 
(sulforaphane) 
2. Inhibition 
(ascorbic acid) 
 
1. 5 µM  
2. 25 µg/mL 
 
1. MT-1A, MT-
1G (n=3) 
2. None (n=1) 
 
 
1. None (n=2) 
2. Not tested 
Hypoxia N/A; 2 % O2 None (n=1) Not tested 
Dexamethasone 
(Glucocorticoid) 
10 µM None (n=1) Not tested 
IL-1β (Cytokine) 1 ng/mL None (n=1) Not tested 
Copper (CuSO4) 10 µM MT-1A, MT-1G 
(n=2) 
None (n=2) 
Iron (FeSO4) 10 µM MT-1A (n=2) None (n=2) 
Zinc (ZnCl2) 10 µM MT-1A, MT-1G, 
MT-1H, MT-1M 
(n=2) 
None (n=2) 
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Arsenite (NaAsO2) 2 µM *MT-1G, MT-1H, 
MT-1M (n=1) 
None (n=1) 
None (n=2) 
Nickel (NiCl2) 200 µM *MT-1G, MT-1H, 
MT-1M (n=1) 
None (n=1) 
None (n=2) 
Cadmium (CdCl2) 10 µM MT-1A, MT-1G, 
MT-1H, MT-1M 
(n= >3) 
MT-1A, MT-1M 
(n= >3) 
 
5.2.3 Presence and Spatial Arrangement of MTF-1 Binding Sites in MT-1 Isoform 
Genes as a Potential Mechanism of Differential Induction 
Analysis of MTF-1 binding sites in the X1000 bp upstream non-coding DNA of the MT-
1A isoform gene showed that it contained 1 unique TFBS compared to MT-1G, no unique 
TFBSs compared to MT-1H, and 4 unique TFBSs compared to MT-1M (Figure 47A). 
However, upon comparison of TFBSs from all isoforms combined, it was found that no 
TFBSs were truly unique to MT-1A. MT-1M analysis revealed that its non-coding DNA 
contained 13 unique TFBSs compared to MT-1A, 10 unique TFBSs compared to MT-
1G, and 9 unique TFBSs compared to MT-1H (Figure 47B). Upon comparison to the 
TFBSs from all isoforms, it was found that MT-1M contained 9 truly unique MTF-1 
binding sites in its gene promoter. Moreover, MT-1M contained 29 MTF-1 binding sites 
overall, whereas MT-1A only contained 17. 
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Figure 47: rVISTA (v. 2.0) analyses showing shared and unique MTF-1 binding sites in MT-
1 isoform non-coding DNA. (A) MT-1A isoform was compared to MT-1G, 1H and 1M isoforms. 
(B) MT-1M isoform was compared to MT-1A, 1G and 1H isoforms. Unique MTF-1 binding sites 
were identified by comparing shared (MTF1_aligned; red, and MTF1_conserved; green) and all 
(MTF1_all; blue) TFBSs present in the target isoform. Any unique binding sites found between 
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two isoforms was then compared to all other isoforms in order to check if it was truly unique. 
Website: http://genome.lbl.gov/vista/index.shtml. 
 
 Overall, the data obtained from performing these analyses indicated that the MT-1 
isoforms have differential arrangement and total number of MTF-1 binding sites within 
their non-coding DNA, which could be seen from the graphical comparisons. Moreover, 
the data  indicated that the MT-1M isoform contains up to 9 unique MTF-1 binding sites 
and possesses 12 additional sites compared to MT-1A.  
 
5.2.4 Longevity of MT-1 Isoform Expression Post-Exposure to Cadmium 
5.2.4.1 Transcript Expression 
RT-PCR analysis showed that cadmium exposure caused transcript induction of all MT-
1 isoforms, as previously observed (Figure 48). However, once cadmium exposure was 
removed and cells cultured under standard conditions, transcript induction began to 
recede over time (n=1). The rate of this reduction was observed to be dependent on the 
isoform. For example, MT-1A transcript expression returned to control levels by 24 hours 
post-exposure, whereas MT-1G and MT-1H transcript expressions remained elevated up 
to 48 hours post-exposure. By contrast, at 48 hours post-exposure MT-1M transcript 
induction had dissipated and expression was comparable to controls.  
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Figure 48: RT-PCR showing MT-1 isoform transcript expression in NHU cells post exposure 
to cadmium. Proliferating NHU cells (n=1; Y1270) were exposed to 10 µM CdCl2 for 24 hours 
before removal of cadmium and further culturing for 48 hours. RNA was extracted at regular 
time points and MT isoform transcript expression assessed. PCR controls included genomic DNA 
as a positive control and dH2O as a negative control. GAPDH transcript expression was used as 
a loading control, and RT-ve samples confirmed the absence of genomic contamination. 
 
 In differentiated NHU cells, high induction of all MT-1 isoform transcripts pre-exposed 
to cadmium was observed, as in previous experiments (Figure 49). However, transcript 
induction again receded once cadmium exposure was removed, albeit at a slower rate 
than proliferating NHU cells (n=1). For example, MT-1M transcript expression remained 
highly induced at 4 days post-exposure in differentiated cells, whereas in proliferating 
cells transcript expression returned to control levels after only 48 hours. The rate of 
transcript de-induction also differed between the isoforms, as observed in proliferating 
cells. MT-1A transcript induction was the most transient, showing loss of induction by 4 
days post-exposure, whereas MT-1G transcript induction was still present up to 11 days 
post-exposure. 
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Figure 49: RT-PCR showing MT-1 isoform transcript expression in differentiated NHU cells 
post exposure to cadmium. NHU cells (n=1; Y1531) were differentiated and pre-exposed to 10 
µM CdCl2 for 3 days. Cadmium was then removed (0 d) and cells further cultured for 11 days. 
RNA was extracted at various time-points and MT-1 isoform transcript expression assessed. 
Differentiation of cells was confirmed by formation of a ‘tight’ urothelial barrier, and transcript 
expression of the differentiation marker ZO-1 (see Appendices, section 8.4.1). PCR controls 
included genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination. 
 
5.2.4.2 Protein Expression 
The results from undifferentiated NHU cells revealed high protein expression of both 
MT-1A and MT-1M isoforms that could be detected up to 5 days post exposure to 
cadmium, and no protein expression detected in control cells (Figure 50; n=1). This 
suggested that MT-1 isoform protein expression was more stable than transcript 
expression in undifferentiated NHU cells, at least for the MT-1A and MT-1M isoforms. 
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Figure 50: Western blot showing MT-1A and MT-1M protein expression in confluent 
undifferentiated NHU cells post exposure to cadmium. Proliferating NHU cells (n=1; Y1277) 
were cultured until confluence was reached, and then exposed to 10 µM CdCl2 for 72 hours. 
Cadmium exposure was then removed and cells further cultured for another 5 days. Protein 
lysates were extracted and MT-1A and MT-1M protein expression determined. 
 
 Western blotting from differentiated NHU cell cultures showed that both MT-1A and 
MT-1M proteins were induced after 72 h cadmium exposure (0 d), although MT-1M 
protein expression was not induced to the same extent as MT-1A (Figure 51). Both 
proteins could still be detected 4 d post-exposure, and expression did not significantly 
decrease during this time-period (n=1).   
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Figure 51: Western blot showing MT-1A and MT-1M protein expression in differentiated NHU 
cells post exposure to cadmium. NHU cells (n=1; Y1531) were differentiated and then apically 
exposed to 10 µM CdCl2 for 3 days (0 d time-point). Cadmium was then removed and cells 
cultured for a further 4 days. Protein was extracted at 0 d and 4 d post exposure, and MT-1A and 
MT-1M protein expression assessed. Differentiation was confirmed by the presence of a ‘tight’ 
urothelial barrier and transcript expression of a differentiation-associated marker (see 
Appendices section 9.4.1). 
 
 Both MT-1A and MT-1M protein expression was detectable in cell sheets at 4 d post 
cadmium exposure (Figure 52; n=1), supporting the western blot data. MT-1A protein 
formed punctate deposits, whereas MT-1M protein demonstrated a mainly diffuse 
expression pattern, both of which have been observed in previous results (sections 3.2.4 
and 4.2.2). These results further suggest that MT-1 isoform protein expression was more 
stable than transcript expression, as protein induction persisted post cadmium exposure 
for a longer time period.
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Figure 52: Immunohistochemical labelling of MT-1A and MT-1M protein expression in 
differentiated NHU cell sheets post exposure to cadmium. NHU cells (n=1; Y1426) were 
differentiated and then apically exposed to 10 µM CdCl2 for 3 days, before removal of cadmium 
exposure and further culturing for 4 days. Cell sheets were harvested, fixed and prepared for 
immunohistochemical labelling to determine MT-1A and MT-1M protein expression. NHU cell 
differentiation was confirmed by the presence of a ‘tight’ urothelial barrier and transcript 
expression of a differentiation-associated marker (see Appendices section 8.4.1). Scale bar = 
25 µm.
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5.3 Key Findings 
• MT-1 target isoforms showed differential transcript induction. 
• Comparison of MTF-1 binding sites in MT-1 isoforms revealed differences in the 
spatial arrangement and total number of MTF-1 binding sites. The MT-1M isoform 
was the only isoform to demonstrate uniquely located MTF-1 binding sites, and 
contained an additional 12 sites compared to MT-1A.  
• MT-1A transcript expression could be induced by a number of factors; however, these 
changes were not usually translated to protein, and only cadmium exposure was able 
to cause high induction of MT-1A protein expression. 
• MT-1M transcript and protein expression were highly specific to cadmium exposure. 
• MT-1 isoform transcript induction was transient, and a loss of induction was observed 
after cessation of cadmium exposure; moreover, this reduction occurred at different 
rates depending on the gene isoform. 
• MT-1A and MT-1M protein expression was observed to persist for prolonged time 
periods post-cadmium exposure, suggesting protein induction was more stable than 
transcript. 
 
  
Chapter 5: Specificity and Longevity of MT-1 Isoform Induction in 
Cadmium-Exposed NHU Cells. 
171 
5.4 Discussion 
5.4.1 Specificity of MT Isoform Induction 
As explored in the Introduction (section 1.5.5.3), the MT isoforms are thought to show 
differential induction depending on the specific inducer present, and a range of potential 
factors have been suggested as capable of inducing MT-1 isoform expression. However, 
this was the first time that these potential inducers have been studied using a normal 
human urothelial cell model. The results revealed the extent to which urothelial MT 
isoforms can differ in their individual expression, as specific isoforms were induced by 
different factors and to differing extents (sections 5.2.1. and 5.2.2). These findings 
support the hypothesis of differential induction of MT isoforms, and demonstrate the 
importance of discriminating between individual isoforms. 
 Standard cell culture procedures such as passage and medium change were able to alter 
MT-1A transcript expression. Moreover, medium change was observed to cause a slight 
induction of all MT-1 isoforms (section 5.2.1.1). The reasons for this are currently 
unclear, and to the author’s knowledge these results have not been reported before. 
However, there is the possibility that these changes in isoform transcription were due to 
altered levels of cellular stress caused by medium change (Garcia-Montero et al., 2001). 
They could also be linked to changes in cellular proliferation, which is known to be 
significantly reduced after passage and reseeding (known as the ‘lag’ phase; Freshney, 
2016). Further work would be required to elucidate the mechanism(s) by which standard 
cell culture may be capable of inducing MT-1 isoform transcript induction, particularly 
MT-1A.  
 Several of the potential inducers tested were unable to induce any MT-1 isoform 
expression, an observation which was particularly evident with the non-metal factors 
tested (sections 5.2.1.3 and 5.2.1.4). Neither dexamethasone, hypoxia nor IL-1β were able 
to cause MT isoform transcript induction. A possible reason why these proposed inducers 
failed to induce MT-1 isoform expression is that no previous studies have specifically 
studied MT induction by these factors in normal human urothelium, and as explored in 
the Introduction (section 1.5.5.2), MT isoform expression and induction appears to be 
highly tissue-specific. Moreover, most previous studies using these potential inducers 
have not attempted to discriminate between the MT-1 isoforms, and thus it is unclear 
which isoform(s) may have been responsible for the reported increase in MT expression. 
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 It was particularly important to determine whether the MT-1 isoform induction observed 
in response to cadmium exposure was due to cadmium itself, or the ROS produced as a 
by-product of exposure. The results from this thesis suggested that although SF-induced 
ROS was able to induce transcript expression of MT-1A and MT-1G, these changes were 
not translated to MT-1A protein expression (section 5.2.1.2). These findings contradict 
previous studies which have demonstrated increased MT transcript and/or protein 
expression in response to ROS (Futakawa et al., 2006; Mita et al., 2008; Cortese-Krott et 
al., 2009; Kadota et al., 2010). However, these studies did not discriminate between the 
isoforms of the MT-1 subfamily. Discrimination between the MT-1 and MT-2 
subfamilies was performed at most, and even then was only completed at the transcript 
level; and additionally did not include all functional isoforms (Kadota et al., 2010). 
Moreover, when increased MT protein was detected, only total cellular MT protein was 
analysed (Futakawa et al., 2006); meaning any of the MT isoforms from any subfamily 
could have been responsible. The results from this thesis therefore may not be 
contradictory to previous studies, only more comprehensive due to discrimination 
between isoforms. This further demonstrates the importance of differentiating between 
the MT isoforms at both the transcript and protein level, so that individual specificities 
and expression of the isoforms may be determined. 
 The results obtained using inhibition of ROS (Figure 41) slightly contradict the original 
ROS-induction experiment (Figure 40). If SF-induced ROS was able to induce MT-
1A/1G isoform expression, inhibition of ROS should have been able to inhibit their 
cadmium-induced expression, yet did not appear able to. However, it is possible that SF 
and cadmium may induce different types of ROS, which could cause differential 
induction of the MT-1 isoforms and account for the apparent discrepancy in results. 
Cadmium has been reported to induce both superoxide anion and hydrogen peroxide 
(Hassoun and Stohs, 1996 and Heyno et al., 2008 respectively), whereas the type of ROS 
induced by SF remains unclear. Further, it appears that cadmium and SF may induce ROS 
via different mechanisms; cadmium has been reported to generate ROS via the 
mitochondria (section 5.1.2), whereas SF been shown to deplete intracellular glutathione 
levels and thus is thought to induce ROS via a non-mitochondrial mechanism (Singh et 
al., 2005).  
 Exposure of proliferating NHU cells to both essential and heavy metals illustrated metal-
specific induction of the MT-1 isoforms (sections 5.2.1.5 and 5.2.1.6). This metal 
specificity supports previous research conducted in other cell types which have also 
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demonstrated metal-dependent differential induction (section 1.5.5.3). Moreover, metal-
specificity has been shown as tissue-specific; in a previous study using HeLa cells copper 
was unable to induce MT-1A transcript expression (Miura and Koizumi, 2007), whereas 
in this thesis copper was observed to induce MT-1A transcript expression in NHU cells. 
These results further demonstrate the need to study the metal specificity of MT isoform 
induction within the specific cell type being investigated, as results from a different tissue 
type cannot necessarily be applied to other tissues. 
 Comparison of MT-1 isoform transcript and protein expression in response to the 
potential inducers revealed that although MT-1A transcript expression could be induced 
by several factors, only cadmium could induce strong protein expression (section 5.2.2). 
Although low MT-1A protein expression could be detected under other conditions (such 
as zinc exposure), cadmium was by far the most potent inducer, suggesting preferential 
activation. MT-1M transcript induction was highly specific to cadmium, as the only other 
treatment able to cause induction was zinc, and induction was minimal (section 5.2.1.5). 
Low transcript induction was not translated to protein, and only cadmium exposure could 
cause MT-1M protein expression, suggesting that MT-1M protein induction is highly 
cadmium-specific.   
 The reasons for the poor translation of MT-1A transcript to protein under non-cadmium 
conditions are unknown. However, it is possible that MT-1A transcript generally has a 
poor translation efficiency (Tian et al., 2004; Vogel et al., 2010), and subsequently 
translation may require high amounts of transcript in order for protein expression to be 
detectable. As cadmium was a potent transcript inducer, this could explain why MT-1A 
protein expression was only detectable in cadmium-exposed NHU cells. Alternately, the 
translational efficiency of MT-1A transcript may be inducer-specific, with different 
inducers potentially utilising different post-transcriptional controls (reviewed by Day and 
Tuite, 1998).   
 A limitation of these MT isoform specificity results is that for factors which were not 
observed to alter MT-1 isoform transcript induction (such as hypoxia), NHU cells from 
only one donor were used. To truly demonstrate whether these factors are unable to 
induce MT-1 isoform expression, the experiments would need repeating in NHU cells 
derived from at least another two individual donors. A further limitation is that only 
qualitative methods were used to assess isoform transcript expression (RT-PCR). These 
methods were adequate for investigating initial isoform transcript induction as a series of 
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pilot experiments, but for in-depth comparison between inducing factors and assessment 
of individual isoform expression, a quantitative method such as real-time PCR should be 
used. With regards to cytokine treatment, it should also be noted that only IL-1β was 
tested, whereas IL-1α has specifically been suggested to induce MT isoform transcript 
expression (Kikuchi et al., 1993). However, studies have suggested that the IL-1 family 
as a whole can induce MT expression (Karin et al., 1985), and have also shown that IL-
1α specifically requires the addition of zinc to be able to cause MT-1 isoform induction 
(Alvarez et al., 2012). 
 The unique number and spatial arrangement of MTF-1 binding sites found in the MT 
isoforms supports the hypothesis of differential induction (section 1.5.5.3). However, the 
exact mechanism(s) behind this is not clear. Previous studies have observed that MTF-1 
can bind to different non-overlapping genomic regions depending on the specific type of 
metal treatment used in D. melanogaster (Sims et al., 2012). A similar mechanism was 
reported in a human hepatocarcinoma cell line, where MTF-1 was observed to bind to a 
different combination of MTF-1 binding sites depending on the type of metal exposure 
(Balesaria et al., 2010). Although MTF-1 binding sites are composed of MREs, other 
transcription factors are also able to bind to these sites (such as MREBP), and it has been 
suggested that cadmium induces MT expression via its own unique mechanism that is 
independent of MTF-1 yet still dependent on MREs (section 1.5.3). It is therefore possible 
that transcription factors other than MTF-1 may bind to the MREs, resulting in cadmium-
specific induction. Further work analysing MREs should be conducted in order to 
determine what factors may bind to these sites under normal and cadmium-exposed 
conditions. To achieve this, one possible approach would be to perform a DNA pull-down 
assay based on the principles of reverse ChIP, where a DNA probe is used to isolate the 
DNA region of interest and mass-spectrometry performed to identify the proteins bound 
to it (Rusk, 2009). Reverse-ChIP would allow the identification of TFs bound to the MT-
1 isoform MREs under cadmium-induced activation, determining whether MTF-1 is 
involved or whether other potentially novel TFs may also play a role.    
5.4.2 MT Induction Longevity after the Cessation of Cadmium Exposure 
The results from this thesis indicated that cadmium-induced MT-1 isoform transcript 
induction was transient, as removal of exposure caused a gradual return to control 
expression. These findings are consistent with results from previous research (Waalkes 
et al., 1984; Morris and Huang, 1987; Garrett et al., 2002); however, discrimination 
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between the MT isoforms was not performed in these studies. The experiments in this 
thesis differentiated between the MT-1 isoforms, which revealed that the rate of de-
induction appeared to be isoform-specific. These MT isoform-specific differences in 
transcript longevity have not been reported before, presumably due to a lack of 
discrimination, further showing the need to determine individual isoform expression. The 
isoform-specific rates of transcript de-induction also lend support to the hypothesis that 
individual isoforms may have different roles within the cell.  
 To the author’s knowledge, longevity of MT protein expression post-cadmium exposure 
has not been investigated in a human cell system before, although some exploratory 
studies have been conducted in rats (Liang et al., 2010; Madejczyk et al., 2015). The 
results from this thesis found that high MT-1A and MT-1M protein expression could still 
be detected in undifferentiated NHU cells up to 5 days post-cadmium exposure, despite 
de-induction of transcript generally occurring within 48 hours. This suggests that protein 
expression is longer-lived and may persist within the cell for a prolonged period post-
cadmium exposure, warranting further investigation into the use of MT protein as a 
biomarker of cadmium exposure. 
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Chapter 6: Translation of In Vitro Findings to Ex Vivo Organ 
Culture. 
6.1 Chapter Aims 
The main aim of this chapter was to determine whether the cadmium-induced MT-1 
isoform protein expression previously observed in in vitro NHU cell cultures could also 
be observed in the urothelium of ex vivo ureter organ culture. The advantages of using 
this type of 3-dimensional model are explained in detail in section 1.1.5, but one of the 
primary reasons to use organ culture is that it is more reflective of in vivo conditions. 
Therefore, if the MT-1A and MT-1M proteins could be found induced in this model, it 
would suggest these proteins may also be found induced in situ in the urothelium of a 
cadmium-exposed human.  
 A further aim of this chapter was to determine whether cadmium exposure could affect 
the expression of various other proteins whose expression had previously been reported 
to be altered by exposure. These target proteins were as follows; 
• CK13 - protein expression of the differentiation-associated marker CK13 was 
determined in order to assess transitional differentiation of urothelium (Varley et al., 
2004; Southgate et al., 2007). Although this protein has not been reported as directly 
altered by cadmium, a loss of tissue differentiation has been associated with exposure 
(Achanzar et al., 2001; Qu et al., 2012).  
• FOXA1 – a second marker of urothelial differentiation was also assessed in order to 
further investigate the potential effect of cadmium exposure on loss of tissue 
differentiation (Varley et al., 2009).  
• CK5 - CK5 protein expression was investigated as its expression has been reported 
as increased by cadmium-induced malignant cellular transformation (Benbrahim-
Tallaa et al., 2009), and it is also a well-characterised marker of basal urothelial cells 
(Reis-Filho et al., 2003; Castillo-Martin et al., 2010). Thus, characterising its 
expression could help to determine the phenotype of urothelial cells in cadmium-
exposed ureter organ culture.  
• Ki67 - protein expression of the cellular proliferation marker Ki67 (Gerdes et al., 
1983) was assessed, as previous studies have reported increased cellular proliferation 
due to cadmium exposure (Takiguchi et al., 2003; Kundu et al., 2011; Lacorte et al., 
2011).  
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• H3K27me3 – protein expression of the histone post-translational modification 
H3K27me3 was determined, having been previously reported as increased in 
cadmium-exposed UROtsa cells (Somji et al., 2011b). This epigenetic mark is 
strongly repressive, and as such is often found associated with genetic silencing 
(Filion et al., 2010; Kharchenko et al., 2011; Li, Huang, Bickel, & Brenner, 2014).  
6.1.1 Objectives 
1. Determine whether MT protein is induced in the urothelium from ureter organ 
cultures acutely and chronically exposed to cadmium. 
2. Investigate whether MT protein expression persists in the urothelium of ureter organ 
cultures post-acute exposure to cadmium. 
3. Assess whether cadmium exposure can alter the protein expression of several 
candidate targets identified from the literature. 
6.1.2 Experimental Approach 
6.1.2.1 Use of the MT-1/2 (E9) Antibody 
In addition to the MT-1A and MT-1M antibodies, the commercially available E9 antibody 
was also used for these experiments. As explained earlier (section 1.5.5.4) this antibody 
detects all MT-1/2 proteins and does not discriminate between the isoforms. This 
antibody was therefore included to ensure that any changes in gross MT protein 
expression were not missed due to only focusing on MT-1A and MT-1M isoform protein 
expression. Results using all 3 antibodies to determine MT protein expression in 
cadmium-exposed ureter organ culture can be found summarised in section 6.2.2, Table 
9. 
6.1.2.2 Ureter Organ Culture  
The detailed protocol used for ureter organ culture can be found in section 2.7.12. It is 
important to note that exposure of ureter to cadmium was both apical and basal, the 
reasons for which are explained in the Materials and Methods (also section 2.7.12).  
1. In order to determine whether any changes in MT protein expression could be 
detected in the urothelium of ureter organ cultures acutely exposed to cadmium, 
ureter was continuously exposed to 10 µM CdCl2 for 3, 7 or 14 days. The pieces 
of ureter were then fixed, sectioned and immunolabelled for MT-1/2, MT-1A and 
MT-1M protein expression. 
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2. The next experiment was designed to fulfil Objectives 2 and 3, and the second 
half of Objective 1. Ureter from one individual donor was exposed to 10 µM 
CdCl2 for either 7 days (acute exposure) or 56 days (chronic exposure). A further 
culture was exposed for 14 days (found to be sufficient for MT protein induction; 
section 6.2.1) before removal of cadmium and continuous culturing for 42 days 
(post-exposure). Ureter sections were then used to achieve the Chapter’s 
Objectives in the following ways; 
a. Objective 1 (partial) – the effect of chronic cadmium exposure on MT 
protein expression was assessed by immunolabelling ureter sections for 
MT-1A, MT-1M and MT-1/2 protein expression. 
b. Objective 2 – post-exposure ureter sections were immunolabelled for 
MT-1A, MT-1M and MT-1/2 protein expression in order to determine 
whether expression could be detected post-cadmium exposure. 
c. Objective 3 - acutely and chronically exposed ureter sections were 
immunolabelled to determine the protein expression of several other 
potential targets of cadmium. Post-exposure samples were included as 
they had the potential to support any changes found in chronically exposed 
urothelium, and could possibility indicate whether cadmium-induced 
alterations persisted even after cadmium exposure. 
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6.2 Results 
6.2.1 MT Protein Expression in the Urothelium of Cadmium-Exposed Ureter Organ 
Culture 
The urothelium from control cultures was largely negative for MT-1/2 protein expression, 
showing only faintly diffuse immunolabelling at the apical surface of superficial cells 
(Figure 53). By contrast, after 7 days continuous cadmium exposure there was a strong 
induction of MT-1/2 protein expression in the urothelium, which was both nuclear and 
cytoplasmic. Protein expression was observed in all 3 urothelial cell zones, although 
expression was strongest in the superficial urothelial cells. The stromal cells underlying 
the urothelium also showed an increase in MT-1/2 protein expression upon cadmium 
exposure, although this was confined to nuclear expression.  
 
 
Figure 53: Immunohistochemical labelling of MT-1/2 protein expression in ureter organ 
culture exposed to cadmium. Ureter pieces (n=1; Y1770) were continuously exposed to 10 µM 
CdCl2 for 7 days and MT-1/2 protein expression determined. Scale bar = 25 μm. 
 
 The next step was to determine whether the MT-1A and/or MT-1M proteins were 
specifically induced. To achieve this, ureter sections were continuously exposed to 10 
µM CdCl2 for 3 or 7 days and immunolabelled for MT-1A and MT-1M protein 
expression. By day 3 there was strong immunolabelling for the MT-1A protein in exposed 
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urothelium, which could be seen in both the nucleus and cytoplasm in the majority of 
cells, and in all 3 urothelial cell zones (Figure 54). By contrast, MT-1M protein 
expression was barely detectable after 3 days exposure, and most cells were negative for 
expression. After 7 days exposure, MT-1A protein expression was still present, remaining 
expressed in both the nucleus and cytoplasm. MT-1M protein expression was also 
observed highly induced by this time-point, demonstrating a diffuse expression pattern. 
MT-1M protein expression was mainly confined to superficial urothelial cells, although 
sporadic intermediate cells also showed expression. Additionally, MT-1M protein 
induction only occurred in the cytoplasm, and no nuclear immunolabelling was observed.  
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Figure 54: Immunohistochemical labelling of MT-1A and 1M protein expression in ureter organ culture exposed to cadmium. Ureter pieces (n=1; Y1566) were 
continuously exposed to 10 µM CdCl2 for 3 or 7 days and immunolabelled for MT-1A and MT-1M protein expression.  Scale bar = 25 μm. 
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 Ureter continuously exposed to 10 µM CdCl2 for 14 days was also immunolabelled for 
MT-1A, MT-1M and MT-1/2 protein expression. After 14 days exposure a strong 
induction of MT-1/2 protein expression was observed, which occurred throughout the 
urothelium as well as the stroma, as observed previously (Figure 55; n=2). However, in 
this organ culture the difference in immunolabelling intensity between the individual 
urothelial cell zones was more prominent; MT-1/2 protein expression decreased with 
penetration through the cell zones, from superficial to basal cells. MT-1A protein 
expression was also induced after cadmium exposure in all cell zones, supporting the 
initial findings (n=2). However, in contrast to the previous experiment, MT-1A 
immunolabelling was confined to nuclei throughout the urothelium and also presented in 
stromal cells. Lastly, MT-1M protein expression was found sporadically induced in 
urothelial cells after exposure to cadmium (n=2). As observed previously, protein 
expression presented as diffuse in the cytoplasm, and was mainly confined to the 
superficial and intermediate cell zones.  
Chapter 6: Translation of In Vitro Findings to Ex Vivo Organ Culture. 
183 
 
Figure 55: Immunohistochemical labelling of MT-1/2, MT-1A and MT-1M protein expression 
in ureter organ culture exposed to cadmium. Ureter pieces (n=1; Y1644) were continuously 
exposed to 10 µM CdCl2 for 14 days and immunolabelled for MT-1A, MT-1M and MT-1/2 
proteins.  Scale bar = 25 μm. 
  
6.2.2 MT Protein Expression in Ureter Organ Cultures Chronically Exposed or 
Post-Acute Exposure to Cadmium 
6.2.2.1 Chronic Cadmium Exposure 
From this single specimen, all long-term organ cultures showed a high number of nuclear 
fragments in the urothelium which resembled apoptotic bodies (Figures 56 and 57). The 
reasons for this prominent urothelial cell death are unknown, but may be associated with 
the prolonged (56 day) organ culture. Additionally, the width of the urothelium varied 
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greatly between control and chronically exposed ureters, as the width of the latter 
appeared approximately 3-fold narrower than control. 
 After 56 days continuous cadmium exposure a strong induction of MT-1/2, MT-1A and 
MT-1M protein expression was observed in the urothelium (Figure 56; n=1). 
Immunolabelling of these proteins occurred in all three cell zones, in both the nucleus 
and cytoplasm. These results differed from previous experiments which suggested that 
MT-1A protein expression was nuclear and MT-1M protein expression confined to the 
cytoplasm. Additionally, MT-1/2 protein was equally expressed throughout all cell zones, 
whereas in acutely exposed ureter it was observed to be strongest in the superficial 
urothelial cells. In general, after 56 days’ cadmium exposure immunolabelling of all 3 
different MT proteins was quite similar. The most obvious difference was that a number 
of urothelial cells did not express MT-1M expression, whereas nearly all cells 
demonstrated immunolabelling for MT-1A and MT-1/2 protein expression.  
6.2.2.2 Post-Acute Cadmium Exposure 
42 days after removal of acute cadmium exposure, MT-1M protein expression could no 
longer be detected in the urothelium. However, MT-1A and MT-1/2 protein expression 
could both still be observed (n=1). MT-1A protein expression was confined to the nucleus 
post exposure, and could also be detected in the nuclei of stromal cells. This nuclear 
presentation of MT-1A protein was similar to results previously observed after acute (7 
or 14 days) cadmium exposure (Figures 54 and 55). MT-1/2 protein expression was 
observed in both the nucleus and cytoplasm of urothelial cells post-cadmium exposure, 
and some immunolabelling in stromal cells was also visible (also observed previously; 
Figures 53 and 55). However, in contrast to ureter cultures that had undergone 56 days 
continuous exposure, MT-1/2 protein expression once again differed in strength between 
the cell zones. Immunolabelling was observed strongest in the superficial urothelial cells 
and some intermediate cell labelling was present, whereas the basal cell zone was 
negative for MT-1/2 protein expression.  
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Figure 56: Immunohistochemical labelling of MT-1/2, MT-1A and MT-1M protein expression 
in ureter organ culture during and after cadmium exposure. Ureter pieces (Y1644) were 
exposed to 10 µM CdCl2 for 56 days continuously, or exposed for 14 days before removal of 
cadmium and further culture for 42 days (pre-exposure). Scale bar = 25 μm. 
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Table 6: Summary of MT protein expression in urothelium from cadmium-exposed ureter 
organ culture. Normal human ureter was exposed to 10 µM CdCl2 for short (≤ 14 days; ‘Acute’) 
or prolonged (56 days; ‘Chronic’) time periods, or were acutely exposed (14 days) before 
removal of exposure and continued culturing (42 days; ‘Post-’). Immunolabelling for MT-1/2, 
MT-1A and MT-1M proteins was performed on samples and the expression of each is summarised 
in the table below.  
 Cadmium Exposure 
Protein Acute (≤14 d.) Chronic (56 d.) 
Post- (14 d. exposure; 
42 d. post-exposure) 
MT-1/2 
Cytoplasmic and 
nuclear localisation. 
Immunolabelling 
intensity decreased 
with penetration 
through the cell zones. 
Cytoplasmic and 
nuclear localisation. 
Equally intense 
immunolabelling in 
all cell zones. 
Cytoplasmic and 
nuclear localisation. 
Immunolabelling 
intensity decreased 
with penetration 
through the cell zones. 
MT-1A 
Nuclear localisation 
with some 
cytoplasmic. 
Immunolabelling in 
all cell zones. 
Cytoplasmic and 
nuclear localisation.  
Strong 
immunolabelling in 
all cell zones. 
Nuclear localisation. 
Immunolabelling in 
all cell zones. 
MT-1M 
Cytoplasmic 
localisation. Sporadic 
immunolabelling in 
superficial and 
intermediate cell 
zones. 
Cytoplasmic and 
nuclear localisation.  
Strong 
immunolabelling in 
all cell zones. 
None. 
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6.2.3 Protein Expression of other Candidate Targets of Cadmium in Exposued 
Ureter Organ Culture 
CK13 
After 7 days ureter organ culture, the urothelium in control samples showed strong 
immunolabelling for CK13 protein in the basal and intermediate cell zones, although 
protein expression was strongest in basal cells (Figure 57). Superficial urothelial cells 
were mostly negative for CK13 protein expression. These results were as expected for 
normal human urothelium, indicating the presence of a transitional differentiation 
morphology (Southgate et al., 2007).  However, after 7 days continuous cadmium 
exposure, urothelial expression of CK13 protein expression was decreased (n=1). This 
was particularly evident in basal urothelial cells, several of which did not express CK13 
protein, in direct contrast to control results. After 56 days in culture, CK13 protein 
expression was lost in both control and exposed samples, although very weak 
immunolabelling could be sporadically observed in areas of control urothelium.   
FOXA1 
At day 7 strong immunolabelling of FOXA1 was observed in the urothelium from 
control ureter (Figure 58). FOXA1 protein expression was confined to the nucleus and 
observed in the majority of urothelial cells from all cell zones. FOXA1 protein 
expression was also present in most urothelial cells from cadmium-exposed ureter; 
however, there was a distinct decrease in expression in ~50 % of cells. After 56 days in 
culture, strong FOXA1 immunolabelling was still visible in control urothelium, whereas 
chronically exposed urothelium again demonstrated reduced expression, although this 
was less obvious at this time-point. In support of this observation, a small reduction in 
FOXA1 protein expression also occurred in the urothelium of ureters post-acute 
exposure to cadmium.  
CK5 
Strong immunolabelling for CK5 protein expression was observed in both control and 
cadmium-exposed urothelium at day 7 (Figure 59). Expression was mostly confined to 
the basal cell zone, although immunolabelling also occurred in some intermediate 
urothelial cells. By day 56 the results showed that although CK5 protein expression was 
still detectable in control urothelium, it was greatly reduced, and only sporadic cells were 
immunolabelled. By contrast, in ureters post-acute cadmium exposure, CK5 protein 
expression presented more frequently. Moreover, there was strikingly higher CK5 protein 
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expression in the urothelium from chronically cadmium-exposed ureter cultures 
compared to both control and pre-exposed conditions (n=1). Not only was CK5 protein 
expression more intense, but it was also more frequently expressed in urothelial cells. 
Additionally, CK5 protein expression was no longer confined to only the basal and 
intermediate cell zones, as the majority of superficial urothelial cells were also positive 
for protein expression. 
Ki67 
After 7 days in culture, several superficial urothelial cells in both control and cadmium-
exposed urothelium immunolabelled for Ki67 protein expression (Figure 60). At day 56 
however, no urothelial cells were observed to express Ki67 protein in control samples. 
By contrast, a small number of urothelial cells demonstrated Ki67 protein expression in 
both the cadmium post-exposure and chronically exposed ureter organ cultures, 
indicating the presence of cells that were still actively proliferating (n=1). 
H3K27me3 
Strong H3K27me3 protein expression was observed in the nucleus of most urothelial cells 
from all cell zones in both control and cadmium-exposed ureters at day 7 (Figure 61). By 
day 56, H3K27me3 protein expression could only be detected in ~50 % urothelial cells 
from all ureters samples, suggesting expression was lost with time in culture. Despite this, 
it was observed that H3K27me3 protein expression was markedly stronger in chronically 
cadmium-exposed urothelium compared to control and post-exposure organ cultures 
(n=1). Urothelial cells from post-exposure ureter cultures also demonstrated stronger 
immunolabelling compared to controls, although this difference in protein expression was 
less prominent.
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Figure 57: Immunohistochemical labelling of other protein targets potentially affected by cadmium exposure (CK13). Ureter pieces (Y1644) were exposed to 10 
µM CdCl2 for 7 or 56 days continuously, or exposed for 14 days before removal of cadmium and further culture for 42 days (pre-exposure). Immunolabelling was 
performed to determine the protein expression of markers previously identified in the literature as being affected by cadmium exposure. IHC for candidate protein 
target CK13 is shown above. Scale bar = 25 μm. 
  
Chapter 6: Translation of In Vitro Findings to Ex Vivo Organ Culture. 
190 
 
Figure 58: Immunohistochemical labelling of other protein targets potentially affected by cadmium exposure (FOXA1). Ureter pieces (Y1644) were exposed to 10 
µM CdCl2 for 7 or 56 days continuously, or exposed for 14 days before removal of cadmium and further culture for 42 days (pre-exposure). Immunolabelling was 
performed to determine the protein expression of markers previously identified in the literature as being affected by cadmium exposure. IHC for candidate protein 
target FOXA1 is shown above. Scale bar = 25 μm.
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Figure 59: Immunohistochemical labelling of other protein targets potentially affected by cadmium exposure (CK5). Ureter pieces (Y1644) were exposed to 10 µM 
CdCl2 for 7 or 56 days continuously, or exposed for 14 days before removal of cadmium and further culture for 42 days (pre-exposure). Immunolabelling was 
performed to determine the protein expression of markers previously identified in the literature as being affected by cadmium exposure. IHC for candidate protein 
target CK5 is shown above. Scale bar = 25 μm.  
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Figure 60: Immunohistochemical labelling of other protein targets potentially affected by cadmium exposure (Ki67). Ureter pieces (Y1644) were exposed to 10 µM 
CdCl2 for 7 or 56 days continuously, or exposed for 14 days before removal of cadmium and further culture for 42 days (pre-exposure). Immunolabelling was 
performed to determine the protein expression of markers previously identified in the literature as being affected by cadmium exposure. IHC for candidate protein 
target Ki67 is shown above. Scale bar = 25 μm.  
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Figure 61: Immunohistochemical labelling of other protein targets potentially affected by cadmium exposure (H3K27me3). Ureter pieces (Y1644) were exposed to 
10 µM CdCl2 for 7 or 56 days continuously, or exposed for 14 days before removal of cadmium and further culture for 42 days (pre-exposure). Immunolabelling was 
performed to determine the protein expression of markers previously identified in the literature as being affected by cadmium exposure. IHC for candidate protein 
target H3K27me3 is shown above. Scale bar = 25 μm.
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6.3 Key Findings 
• MT-1/2 protein expression was highly induced in the urothelium of ureter organ 
culture acutely and chronically exposed to cadmium. MT-1A and MT-1M protein 
isoforms were specifically found induced, and demonstrated differential expression 
patterns. 
• Cadmium-induced MT-1/2 protein expression was observed to be strongest in 
superficial urothelial cells, and decreased with penetration through the cell zones.  
• MT-1/2 and MT-1A protein expression could still be detected in the urothelium of 
ureter organ cultures up to 6 weeks post exposure to cadmium. 
• Other protein markers also seemed to demonstrate altered expression due to cadmium 
exposure; including apparent increased CK5, Ki67 and H3K27me3 protein 
expression, and decreased CK13 and FOXA1 protein expression.  
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6.4 Discussion 
6.4.1 MT Protein Expression in Cadmium-Exposed Ureter Organ Culture 
Use of human ureter organ culture revealed that MT-1/2, MT-1A and MT-1M proteins 
were all induced in human urothelium acutely exposed to cadmium, supporting the in 
vitro results (Chapters 4, 5 and 6). The isoforms were also observed to exhibit differential 
timing of induction, as well as individual expression patterns, further suggesting 
individual differing roles (section 1.5.5.4). Chronic exposure of human ureter to cadmium 
also resulted in strong induction of all three MT proteins in the urothelium, although the 
isoforms no longer displayed their individual expression patterns (section 6.2.2.1). This 
may have been due to urothelial tissue saturation by cadmium after prolonged exposure 
(Urani et al., 2007), potentially causing an over-abundance of MT protein expression, and 
thereby masking normal individual isoform expression patterns. 
 The MT-1/2 and MT-1A proteins were found to remain expressed up to 6 weeks after 
the removal of cadmium exposure (Figure 56), also supporting the in vitro results (section 
5.2.4.2). MT-1A protein expression relocalised from a nuclear localisation during acute 
cadmium exposure to a perinuclear localisation after cessation of exposure. This finding 
is supported by previous studies, which have demonstrated that MT-1 subfamily 
transcription occurs in the perinuclear cytoplasm, and that transcripts can be specifically 
found bound to cytoskeletal polysomes (Mahon et al., 1997). Moreover, it has been 
suggested that perinuclear localisation and association with the cytoskeleton has the 
physiological role of facilitating efficient shuttling of the MT-1 protein into the nucleus, 
which is its proposed site of function (Levadoux et al., 1999; Chabanon et al., 2004). A 
flaw in these studies however is that they did not discriminate between the MT-1 
subfamily isoforms, and thus it is not clear from their results which isoform(s) may be 
associated with perinuclear localization, although the results in this thesis suggest that it 
may be MT-1A.   
 The strength of MT-1/2 immunolabelling was observed to increase throughout the cell 
zones in an apical direction, both in urothelium acutely exposed to cadmium and post-
exposure, and superficial urothelial cells demonstrated the strongest MT-1/2 protein 
expression. Change in protein expression appeared to occur along a gradient, which has 
not been reported in humans before, and was observed in two ureters derived from 
independent donors. There is the possibility that this change in MT-1/2 protein expression 
may reflect the presence of a cadmium concentration gradient in the urothelium due to 
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exposure. A similar observation has been made in plant crops exposed to cadmium, where 
a declining cadmium concentration gradient was reported in the stem in the direction of 
the developing leafy tissues (Harris and Taylor, 2013). A study using shark testis also 
reported the presence of a cadmium concentration gradient along the developmental 
stages, which are topographically separated (Betka and Callard, 1999). Further, 
accumulation of cadmium along a gradient has been observed in the kidney of brown 
trout, where cadmium concentration was found to increase with progression from the 
posterior kidney tail to the kidney head (Woodling et al., 2001). It has additionally been 
suggested that in metal-exposed marine organisms the metals demonstrate an inward-
directed tissue diffusion gradient, due to the metal ions binding to a variety of ligands 
within the tissue cells, which may also act to slow overall metal efflux from the organism 
(Mason et al., 1988; Neff, 2002).  
 These studies support the hypothesis that the change in MT-1/2 protein expression 
observed in cadmium-exposed urothelium may reflect a cadmium concentration gradient, 
which decreased with penetration into the urothelial tissue. The reasons behind a potential 
concentration gradient are not clear, but may be due to cadmium sequestration by MT as 
it passes through the cells, meaning less cadmium reaches the underlying cells. It may 
also be that transcellular movement becomes more difficult with penetration into the 
urothelium, thus reducing the depth reached by cadmium. Future studies could isolate the 
individual urothelial cell zones after cadmium exposure and determine whether different 
cadmium concentrations are present using ICP-OES. This approach could also be 
combined with western blotting of protein lysates from the individual urothelial cell zones 
in order to determine whether differential MT-1/2 protein expression correlated with 
cadmium concentration changes.   
 Strong immunolabelling of MT-1/2 protein was detected in the stromal cells of control 
ureters. Expression was predominantly nuclear, and occurred in approximately 50 % of 
the stromal cells. The E9 antibody can detect protein expression of any isoform from the 
MT-1 and MT-2 subfamilies, meaning that it is unclear which protein isoform(s) was 
highly expressed within the stromal cells. As explained previously, the MT-2A isoform 
is the most abundant isoform in the human body (section 1.5.2), and it is therefore 
possible that the E9 antibody detected high protein expression of this isoform. Moreover, 
the stromal MT-1/2 immunolabelling was nuclear, and MT-2A has been reported to 
regulate cell cycle progression and proliferation, requiring a nuclear localisation (Studer 
et al., 1997; Jin et al., 2002; Lim et al., 2009; Yap et al., 2009; Kim et al., 2011). 
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6.4.2 Protein Expression Changes in other Potential Targets of Cadmium 
Exposure 
After long-term ureter organ culture, control urothelium was observed to contain a high 
number of apoptotic bodies (indicated by cell shrinkage and chromatin condensation; 
Elmore, 2007) . The cause of cell death was most likely due to prolonged in vitro culture, 
as organ cultures cannot survive indefinitely (Yadav and Tyagi, 2006). However, it has 
been shown that ureter organ culture can be maintained for up to 18 weeks (Scriven et 
al., 1997), and thus extraneous variables affecting cell viability (such as patient donor 
health and sample time in transport medium) cannot be excluded (Resau et al., 1991). 
Chronically cadmium-exposed ureter also contained several apoptotic bodies, although  
to a lesser extent, suggesting increased cellular survival compared to control. This 
observation was supported by Ki67 immunolabelling, which showed protein expression 
in several urothelial cells from chronically cadmium-exposed ureter, whereas no 
expression was detectable in control urothelium (Figure 60). 
 Increased CK5 and decreased CK13/FOXA1 protein expression was observed in 
urothelial cells from cadmium-exposed ureters, inferring a possible loss of differentiation. 
The process by which cadmium may be able to inhibit differentiation is unclear. However, 
it could be related to the reported ability of cadmium to replace zinc in transcription 
factors, altering their physiological function and potentially deregulating important 
cellular pathways such as differentiation (see section 1.4.4.2). A potential approach to 
investigate this hypothesis would be to measure intracellular zinc levels pre-, during and 
post-cadmium exposure, which could be achieved using the labile zinc-specific 
fluorescent probe Zinquin (Nasir et al., 1999). Such as approach has previously been 
performed in the hepatic HepG2 cell line, as the authors reported an approximately 93 % 
increase in free intracellular zinc due to cadmium exposure (Urani et al., 2015). This 
study supports the hypothesis that cadmium may be able to displace zinc from its 
proteome, binding to TFs and altering normal cellular processes. 
 The observed increase in immunolabelling of H3K27me3 protein in chronically 
cadmium-exposed urothelium revealed a potential mechanism of cadmium-induced 
urothelial carcinogenesis. Elevated H3K27me3 protein expression has previously been 
demonstrated in UROtsa cells malignantly transformed by cadmium exposure (Somji et 
al., 2011b). Moreover, increased abundance of the H3K27me3 mark has been specifically 
associated with regions of chromosomal silencing found in a subset of urothelial cancers, 
termed the Multiple Regions of Epigenetic Silencing (MRES) phenotype (Vallot et al., 
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2011). This subset of tumours was observed associated with a CIS-specific gene 
signature, and displayed a more aggressive phenotype. A further study investigating 
H3K27me3 expression in urothelial cancer found upregulated H3K27me3 expression in 
the majority of urothelial cancers analysed (Liu et al., 2013). They also found that 
increased H3K27me3 expression was associated with multifocal tumours and lymph node 
metastases, and was an independent prognostic indicator of cancer-specific survival. A 
more recent study additionally found that elevated expression of H3K27me3 protein may 
predispose urothelial tissue to development of the urothelial cancer (Balsara and Li, 
2017). Taken together, these studies suggest that increased H3K27me3 protein expression 
may be linked with the development of aggressive urothelial cancer, possibly as a result 
of cadmium exposure. 
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Chapter 7: Discussion 
7.1 Main Findings 
The first thesis objective was to perform novel characterisation of MT isoform expression 
in normal human urothelium. To achieve this, baseline and cadmium-induced MT 
isoform transcript expression was investigated for the first time in NHU cells derived 
from patient donors. Novel discrimination between all functional MT isoforms was 
performed in order to conduct a comprehensive characterisation of expression, and it was 
observed that the MT-1 subfamily was highly inducible by cadmium, and that the 
urothelium possessed its own unique MT isoform expressional profile. Further, novel 
iscrimination between MT-1 isoforms at the protein level was completed utilising 
commercially untested antibodies, revealing differential protein expression that 
supported the hypothesis of divergent MT isoform function.  
 Robust induction of the MT-1 subfamily facilitated achievement of the second objective, 
which was to determine whether cadmium could penetrate an intact human urothelial 
barrier. Using induction of MT-1 isoforms as a marker of cadmium exposure, it was 
indicated that cadmium could cross the protective urothelial barrier of differentiated NHU 
cells in culture. This finding was further supported using spectroscopic methods, which 
revealed direct detection of cadmium in exposed differentiated NHU cell cultures, despite 
the continuous presence of a functional urothelial barrier.  
 The third objective was to investigate specificity and longevity of cadmium-induced MT 
isoform expression. Individual MT isoform expression was assessed in NHU cell cultures 
exposed to a broad range of potential inducers, which allowed the identification of two 
MT-1 isoforms (MT-1A and MT-1M) whose induction was highly specific to cadmium. 
Moreover, results demonstrated the importance of discriminating between the MT 
isoforms at both the transcript and protein level, as the isoforms were observed to differ 
in their baseline expression, preferential induction, translational efficiency, 
transcript/protein longevity and protein localization. Bioinformatic analysis revealed that 
differential expression may be regulated by the number and location of MTF-1 binding 
sites within MT genes. It was also observed that while MT isoform transcript induction 
was transient, protein induction was long-lived and persisted for prolonged periods post-
cadmium exposure. 
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 The final objective was to determine whether the in vitro findings of cadmium-induced 
MT-1A and MT-1M protein expression could be translated to ex vivo ureter organ culture. 
Ureter organ culture supported the in vitro results, revealing MT-1A, MT-1M and generic 
MT-1/2 protein induction in the urothelium of cadmium-exposed ureters. Protein 
induction was found to be particularly strong after chronic (≥ 8 weeks) cadmium 
exposure, and MT-1A and MT-1/2 protein expression was observed to persist in the 
urothelium up to six weeks post-exposure. Additional investigation of cadmium-exposed 
ureter resulted in the observation of several other molecular changes, potentially 
indicating a change to a predominantly basal urothelium with increased cellular survival. 
7.1.1 Key Findings 
• The majority of MT-1 isoform transcripts were not expressed in NHU cells under 
baseline conditions; however, they were highly inducible by cadmium exposure  
• Novel discrimination between the MT-1A and MT-1M proteins could be 
performed in cadmium-exposed NHU cells using commercially untested 
antibodies 
• Cadmium appeared able to penetrate an intact urothelial barrier and enter the 
underlying urothelial cells  
• Differential induction of the MT-1 isoforms was observed (including metal-
specific activation), and MT-1A and MT-1M isoform induction appeared highly 
cadmium-specific  
• MT-1 gene isoforms appeared to demonstrate individual spatial arrangements and 
total number of MTF-1 binding sites (MREs) 
• MT-1A, MT-1M and MT-1/2 protein expression was induced in the urothelium 
of human ureters exposed to cadmium, along with other potential molecular 
changes 
• MT-1A and MT-1/2 protein expression was still detectable in human urothelium 
up to 6 weeks post-exposure to cadmium 
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7.2 Discussion Points 
7.2.1 Differential MT Isoform Expression 
MT isoform expression was investigated in normal human urothelium for the first time 
in this thesis, and it was found that urothelial tissue possessed its own unique expressional 
profile (section 3.2.2). This finding was consistent with previous literature, which has 
suggested that MT isoform expression is tissue-specific (section 1.5.5.2). Moreover, the 
MT isoforms showed tissue-specific induction; MT isoforms previously found to be 
induced in other cell types by a specific agent (e.g. dexamethasone) could not be induced 
in NHU cells (section 5.2.1). Even other urothelial cell lines (thereby derived from the 
same source tissue) showed differential MT isoform expression to NHU cells under 
baseline and cadmium-exposed conditions (section 3.2.2.1), suggesting that the processes 
of immortalisation and/or carcinogenesis can also cause differential expression of MT 
isoforms. This observation is supported by previous literature, which has demonstrated 
altered MT-2A expression as a result of immortalisation of human primary cells (Duncan 
and Reddel, 1999; An et al., 2003). Therefore not only must the cell/tissue type be taken 
into consideration when investigating MT isoform expression, but also whether the cell 
has undergone carcinogenesis and/or immortalisation.  
 Novel discrimination of all known MT isoforms was successfully achieved within the 
same cell type. Previously, studies generally assessed combined MT-1 and MT-2 
subfamily expression, or only selected a few specific MT-1 isoforms to analyse (section 
1.5.6.1). However, this approach means that the whole picture is never truly evaluated, 
and changes in individual isoform expression may be missed. The work performed here 
demonstrates the urgent need to assess the MT isoforms individually, as each isoform 
was observed to differ in tissue-specific expression, preferential activation, rate of 
induction/de-induction, and even protein localisation (sections 3.2.2, 5.2.1, 5.2.4 and 
6.2.1 respectively). These findings of differential MT isoform expression are supported 
by the bioinformatic analysis performed for this thesis, which suggested that the MT-1 
isoforms possess different numbers and spatial arrangements of MREs (section 5.2.3). 
This is the first time that isoform-specific MRE localisation has been reported in human 
MT genes, and as well as supporting the observation of differential MT isoform 
expression, also provides a possible mechanism of the same.  
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 The finding that each MT isoform demonstrated unique expressional characteristics 
supports the hypothesis that individual isoforms may perform related yet distinct 
functions (section 1.5.5.4). As discussed in the Introduction (section 1.5.2.1), the MT 
family has recently undergone rapid gene duplication due to a change in selection 
pressure, resulting in several new MT genes having been selected for and maintained. It 
is possible that the shift in selection pressure was due to the increased use and emittance 
of heavy metals in anthropological activity, resulting in the observation that the natural 
bio-geochemical cycle of heavy metals in ecosystems has become overwhelmed (Nriagu, 
1996). De novo MT isoforms may have evolved and adapted in response to historical 
increased exposure, acting to both sequester these toxic metals and regulate cellular 
mechanisms to promote survival in the face of exposure. 
7.2.2 The Metallothioneins as Possible Biomarkers of Cadmium Exposure 
As explored in the Introduction (section 1.5.7.2), the MTs have long been suggested as 
possible biomarkers of cadmium exposure. However, the specificity of MT induction 
remained unclear, which is an essential prerequisite for a biomarker (Mayeux, 2004; 
Humpel, 2011). Research investigating the longevity of MT expression post-exposure in 
humans had also not been published, and is another important biomarker aspect to 
establish as not all exposure is current. For MT expression to qualify as a candidate 
biomarker of cadmium exposure, it would not only need to be specific to cadmium, but 
would also need to persist post-exposure, so that both current and historical cadmium 
exposure could be detected. 
 This thesis employed the use of commercially untested antibodies in order to perform 
novel discrimination between two of the MT-1 isoforms at the protein level (MT-1A and 
MT-1M). Previously, discrimination between MT-1 isoforms had only been attempted 
using spectroscopic techniques (section 1.5.5.4), which can be costly. In this work, 
discrimination between the MT-1A and MT-1M proteins allowed the specificity of their 
induction to be investigated, and therefore the isoforms could be assessed for their 
potential as biomarkers of cadmium exposure. MT-1A protein expression was found to 
be more promiscuous, but clearly showed preferential induction by cadmium, whereas 
MT-1M protein expression was found to be highly specific to cadmium alone (section 
5.2.2). Importantly, ROS did not cause strong induction of either protein, suggesting that 
cadmium itself caused MT protein induction and not ROS as a by-product of exposure 
(sections 5.2.1.2 and 5.2.2).   
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 However, a limitation of the use of these antibodies is that their specificity to the different 
MT-1 isoforms was not tested. It is therefore possible that the antibodies may have 
detected more than one MT-1 protein isoform. In order to confirm their specificity, co-
immunoprecipitation could be performed. This methodology would involve the use of the 
MT-1A antibody to extract ‘MT-1A protein’ from cadmium-exposed NHU cells. The 
resultant protein fraction would then be probed with the MT-1M antibody in order to 
determine whether MT-1M protein was also present. This process could then be repeated 
using the MT-1M antibody to extract protein, and subsequent probing with the MT-1A 
antibody. It should also be noted that although the extent of protein induction was 
observed to vary between MT-1A and MT-1M, there is the possibility that this was due 
to antibody efficiency. Therefore caution should be use when comparing MT-1A and 
MT-1M protein expression.  
 Investigation of the longevity of MT protein expression in ureter organ culture showed 
that cadmium-induced MT-1A and MT-1/2 protein expression persisted up to 6 weeks 
after cessation of exposure (section 6.2.2.2). These findings of long-lived MT protein 
expression post-cadmium exposure were also supported by in vitro results (section 
5.2.4.2). The initial results are promising, suggesting that MT protein expression may 
persist in the body for prolonged periods, and therefore could be utilised to detect both 
current and historical exposure. However, the experiment would need repeating in at least 
two other ureters from independent donors in order to make the results more robust. 
Future experiments would also need to extend the experimentation time, to determine 
whether MT protein expression can persist for longer than found in this thesis.  
 Results demonstrating long-lived protein expression of MT supports its putative role in 
metal sequestration, which has been suggested to occur via the formation of IBs 
(explained in the Introduction; section 1.5.4.2). Immunolabelling of MT-1A protein in 
NHU cells supported a sequestration hypothesis, as the protein was found to localise to 
both the cytoplasm and nucleus, which are the postulated sites of IB formation and 
migration respectively (Sigel et al., 2009). During cadmium exposure the protein 
presented as granular deposits, whereas post-exposure MT-1A protein presented as 
intranuclear circular structures, which suggests an association with the outer portion of 
an IB (section 6.2.2.2). Persistent MT protein expression may also have been caused by 
‘systemic cycling’ of cadmium, which occurs when metal ions are re-released into the 
cell due to protein degradation of the MT-Cd complex (Bebianno and Langston, 1998; 
Sandbichler and Höckner, 2016). Release of free cadmium ions results in de novo 
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synthesis of MT protein and re-sequestration of the metal, meaning that cadmium is not 
only maintained in the cell for prolonged periods, but MT protein expression also persists 
long-term. 
7.2.3 Possible Mechanisms of Cadmium-Induced Urothelial Carcinogenesis 
Chronic cadmium exposure of normal human ureter revealed potential insights into the 
mechanisms by which cadmium can induce urothelial carcinogenesis. Long term ureter 
organ culture resulted in prominent urothelial cell death, the cause of which remains 
unclear, but it was observed that urothelial cells from chronically cadmium-exposed 
ureter demonstrated increased cellular survival. Exposed urothelium was additionally 
much narrower in width, demonstrating a less-differentiated, more basal phenotype and 
indicating a potential loss of the superficial cell zone (as indicated by Ki67, CK5, CK13 
and FOXA1 protein expression; section 6.2.3).  
 Loss of the superficial urothelial cell zone has been reported previously in mouse 
bladders infected with UPEC, leaving the underlying intermediate urothelial cells 
exposed (Mysorekar et al., 2002; Colopy et al., 2014). These studies found that the loss 
of the superficial urothelial cell zone was followed by a rapid proliferation of CK5-
posititive basal cells, supporting the observation of increased basal urothelial cell survival 
after chronic cadmium exposure in this thesis (section 6.4.2). Loss of the superficial 
urothelial cell zone could also explain the narrow urothelial width observed in exposed 
ureters and its apparent loss of differentiation, resulting in a predominantly basal 
phenotype. Loss of tissue differentiation is a characteristic property of malignant cells 
and closely coupled with abnormal proliferation, thereby providing a possible mechanism 
of cadmium-induced carcinogenesis (Cooper, 2000). Loss of the differentiation-
associated marker FOXA1 expression (as observed in chronically cadmium-exposed 
urothelium; Figure 58) has specifically been linked to the development of undifferentiated 
cancers, and silencing of this gene has been demonstrated as sufficient to cause EMT in 
pancreatic ductal adenocarcinoma cell lines (Song et al., 2010). Moreover, loss of 
urothelial FOXA1 expression has specifically been reported to correlate with increased 
stage and histologic grade of urothelial cancers (DeGraff et al., 2012). 
 Although these initial results offer promising insight into cadmium-induced urothelial 
carcinogenesis, it should be noted that this was a preliminary study and only performed 
in ureter from one individual donor. Future experiments using ureters from two or more 
individual donors should therefore be performed in order to verify these observed protein 
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expression changes. To further determine whether chronic cadmium exposure can 
increase urothelial cell survival, experiments analysing expression of anti- and pro-
apoptotic markers such as Bcl-2 and Bax (respectively) should be conducted (Adams and 
Cory, 1998; Pfister et al., 1999; Singh et al., 2009), perhaps in conjunction with the 
analysis of multiple markers of proliferation (Whitfield et al., 2006). 
 It is currently unclear whether the apparent increase in cellular survival could have been 
as a result of cadmium exposure, increased MT protein expression, or a combination of 
both. As explained in the Introduction, cadmium exposure has been demonstrated to 
induce malignant cellular transformation in a number of cell types (section 1.4.3). 
Transformation was characterised by reduced apoptosis and increased proliferation, 
which together may have contributed to the apparent increased cellular survival observed 
in this thesis (section 6.2.3). There is the additional possibility that elevated MT protein 
levels could have played a role, as MT protein expression has also been reported to 
directly increase cell survival by both promoting cell proliferation and inhibiting 
apoptosis (section 1.5.7.1). However, these results are so far only correlative. To 
determine whether MT protein does play a role increased cellular survival, functional 
analyses could be utilised. For example, if MT protein were to be knocked down in 
cadmium-exposed NHU cells and cellular survival remain unaffected, this would suggest 
that elevated MT protein expression does not play a role in cellular survival.  
7.2.4 Thesis Implications  
Comprehensive analysis of MT isoform expression revealed the extent to which the 
individual isoforms may differ in their expression, demonstrating the importance of 
discriminating not just between MT subfamilies, but also between all known MT 
subfamily isoforms. Important changes in individual isoform expression may otherwise 
be missed and/or masked by changes in other subfamily members. The results also show 
the need to establish MT isoform expression specifically in the target tissue being 
investigated, as normal human urothelium was observed to express its own unique MT 
isoform profile under both baseline and cadmium-induced conditions. This suggests that 
findings of altered MT expression from studies using other cell/tissue types are not cross-
applicable, and individual investigation of target tissues must be performed. Moreover, 
this work also demonstrated the importance of using normal human primary cells, as both 
the processes of immortalisation and carcinogenesis may be able to alter MT isoform 
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expression. Isoform expression in cells that have undergone these processes may 
therefore not accurately reflect in vivo expression, reducing the validity of results. 
 The extent to which the MT isoforms differ in their expression is supportive of the theory 
that each individual may perform related but distinct roles in the cell (discussed in the 
Introduction; section 1.5.5.4). The results showed not only preferential induction of 
different isoforms by specific inducers, but also different rates of induction/de-induction, 
individual protein localisation, and isoform-specific number and spatial arrangement of 
MREs in the non-coding DNA; all of which are suggestive of divergent functions. 
Previous investigation of the MT-1G isoform supports such a hypothesis. This thesis and 
other studies have found strong preferential induction of MT-1G by zinc, potentially 
suggesting that the isoform’s expression may be dependent upon intracellular zinc levels 
(Rahman and De Ley, 2001; Arriaga et al., 2014; section 5.2.1.5). Another study found 
that MT-1G transcript expression strongly correlated with cellular zinc levels in human 
Sertoli cells, leading the authors to propose that MT-1G has a predominant role in zinc 
homeostasis (Kheradmand et al., 2010). This was the first report of a MT isoform-specific 
function, and paves the way for future studies to elucidate such individual functions of 
the other isoforms. Functional analyses of the MT isoforms need to be performed, in order 
to observe the effects of under- and/or over-expression on the cell. Spectroscopic analysis 
could also be utilised, potentially combining the methods developed by Mehus et al. 
(2014) with those from Van Campenhout et al. (2004) and Wolf et al. (2009). Use of these 
methods would allow separation of the individual MT isoforms, and the identification of 
which specific metals they may be bound to, potentially providing novel insight into their 
individual functions within the cell.  
 A further implication of the research performed is that cadmium appears able to penetrate 
an intact urothelial barrier (Chapter 5). This is the first time that such a report has been 
made, as it was previously unclear whether cadmium may first damage the urothelium, 
thereby faciliating entry. The finding that cadmium appears able to cross one of the 
tightest epithelial barriers in the human body (section 1.1.3) and gain access to underlying 
tissue is of great public concern, and implies that the human body is not well-equipped to 
deal with this relatively recent health threat (section 1.4.1). The mechanisms that facilitate 
cadmium penetration of the urothelial barrier are unclear, but one possible explanation is 
that it can substitute for zinc in biological systems (see Introduction section 1.4.4.2). It is 
therefore possible that cadmium can utilise the same mechanisms as zinc to enter 
urothelial cells. This hypothesis is supported by several studies which have identified the 
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zinc importer protein (ZIP) 8 as a major facilitator of cadmium entrance into the cell, due 
to its high expression in cadmium-sensitive murine cells but minimal expression in 
cadmium-resistant cells (Fujishiro et al., 2009; He et al., 2009). ZIP8 expression has also 
been identified in normal human urothelium and in the UROtsa cell line (Ajjimaporn et 
al., 2012), further supporting the hypothesis that cadmium may enter urothelial cells by 
hijacking the use of zinc transporters.  
 Long term ureter organ culture revealed that chronic cadmium exposure may result in 
increased cellular survival, possibly via increased apoptotic-resistance induced by 
cadmium exposure and/or increased MT protein expression (section 6.4.2). This has 
implications not only for cadmium-induced carcinogenesis, but also for the development 
of chemotherapeutic resistance in cadmium-related malignancies. These cancers may be 
highly resistant to apoptosis and demonstrate increased proliferation (see Introduction; 
section 1.2.6.3), making them difficult to target using traditional apoptosis-inducing 
therapies, as well as potentially promoting the survival of highly aggressive malignant 
cells (Hart, 2000). Chemotherapeutic resistance in cadmium-related malignancies has 
already been observed, with Hatcher (1997) finding that cadmium exposure induced 
various forms of resistance in human lung carcinoma cell lines, including resistance 
against anti-neoplastic agents.  
 Whether increased treatment resistance was directly due to cadmium exposure, or 
increased MT expression as a result of exposure, is not yet clear. As explored in the 
Introduction, increased MT expression has also been postulated to cause increased 
cellular proliferation and resistance to apoptosis, and has also been linked to 
chemotherapeutic resistance (section 1.5.7.1). MT-induced resistance is potentially 
supported by the results in this thesis, which demonstrated high MT protein expression 
correlating with increased cellular survival (Chapter 7). Moreover, a previous study found 
that human ovarian cancer cells with acquired resistance to the anti-neoplastic cisplatin 
were also highly resistant to cadmium exposure, suggesting that another mechanism (such 
as MT expression) may be responsible for the acquired resistance (Lee et al., 1995). 
Further studies are needed to verify whether MT protein expression may directly 
influence chemotherapeutic resistance, as the proteins could potentially be targeted by 
future treatments with the aim of increasing tumour sensitivity to chemotherapy.  
 The work conducted here suggests that the MT isoforms MT-1A and MT-1M may 
potentially be utilised as specific biomarkers of cadmium exposure. Such markers would 
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be useful for monitoring both environmental and occupational exposure, with the aim of 
informing policy decisions and ultimately reducing human health risks. However, a non-
invasive method of determining urothelial MT expression would be required, instead of 
basing analysis on invasive urothelial patient biopsies. An ideal patient sample source 
would be urine, which often contains sloughed off urothelial cells, and has already been 
used to determine MT protein concentration in exposed individuals (see Introduction; 
section 1.5.6.3). Protocols would need to be further developed in order to detect 
individual MT isoform expression for the test to be cadmium-specific, but this could 
potentially be achieved using a combination of the previously described spectroscopic 
methods (section 1.5.5.4). 
 Lastly, biomarkers of cadmium exposure would allow the stratification of urothelial 
cancers into a subgroup specifically linked to exposure, providing novel insights into 
cadmium-induced urothelial carcinogenesis. Gene expression profiles could be compared 
from non- and cadmium-induced urothelial samples, which may allow the identification 
of genes specifically altered in the exposed samples. This would not only elucidate the 
mechanisms by which cadmium may cause carcinogenesis, but also provide novel targets 
for treatment.  
7.2.5 Future Work 
A number of suggested experiments for future work have been suggested throughout the 
thesis, within discussion sections. However, there are a number of experiments which 
would be important next steps in order to verify and extend the current research. First 
and foremost, as explored in section 7.2.2, it would be essential to confirm the 
specificity of the MT-1A and MT-1M antibodies. This could be achieved not only via 
co-immunoprecipitation, but also by knocking out isoform gene expression in NHU 
cells and subsequent probing for protein expression. A knock-out NHU cell model 
could be further used for functional studies, aimed at determining whether the MT-1 
isoforms may perform differential roles (section 7.2.3). 
 To further eludicate the mechanisms by which cadmium may enter and perturb NHU 
cellular function, future research should focus upon cellular zinc kinetics. 
Determination of zinc transporter presence and expression on NHU cells could reveal 
the mechanisms by which cadmium ions enter the cell, and possibly reflect alterations 
to intracellular zinc concentration (section 1.5.4.1). Experiments using the labile zinc-
binding fluorescent probe Zinquin could additionally be utilised in order to directly 
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assess intracellular zinc levels during and after cadmium exposure (section 6.4.2), as 
increased labile zinc has been well-reported as a possible mechanism of cadmium-
induced carcinogenesis (section 1.4.4.2)  
 The protein changes observed in ureter organ culture after chronic exposure to 
cadmium revealed insights into other potential mechanisms of cadmium-induced 
carcinogenesis, inferring increased cellular survival and loss of differentiation in 
exposed urothelium (sections 6.2.3 and 6.4.2). However, as this experiment was only 
performed in ureter from one donor, the experiment needs to be repeated using ureters 
from at least another two individual donors to verify the initial results. Experiments 
should not only aim to assess initial target protein expression, but include additional 
targets indicative of cellular apoptosis, such as Bcl-2 (section 7.2.3).  
 Lastly, as mentioned above (section 7.2.4), further work should aim to determine 
whether MT-1A and/or MT-1M could be used as biomarkers of cadmium exposure in 
vivo. This would allow the stratification of a subset of urothelial carcinoma specimens 
associated with cadmium exposure, facilitating identification of cadmium-specific gene 
signatures and potentially revealing mechanisms of cadmium-induced urothelial 
carcinogenesis. To determine whether such stratification may be possible, future 
experiments should aim to determine whether MT-1A/MT-1M protein expression can 
be detected in malignant urothelial samples obtained from patients who have been 
identified as being occupationally exposed to cadmium. Determination of exposure 
could be achieved using a questionnaire, aimed at determining current and historical 
occupations, as well as smoking habits (to control for extraneous variables). 
Immunolabelling of samples for MT-1A and MT-1M protein expression would then 
reveal whether a correlation could be found between cadmium exposure and MT protein 
expression, allowing the novel stratification of a subgroup of cadmium-related 
urothelial cancers.   
  
Chapter 8: Appendices 
210 
Chapter 8: Appendices 
8.1 NHU Cell Lines Used 
All NHU cell lines used in experiments for this thesis are detailed in the table below. 
Table 7: Summary of NHU cell lines used in thesis. All NHU cell lines were obtained from 
independent donors. Detailed in the table is their unique Y-number, their tissue of origin and the 
surgical procedure the patient underwent which allowed the tissue to be obtained. 
Y Number Tissue of Origin Surgical Procedure 
1089 Renal Pelvis Pyeloplasty 
1097 Ureter Nephrectomy 
1234 Renal Pelvis Pyeloplasty 
1270 Ureter Nephrectomy 
1277 Renal Pelvis Pyeloplasty 
1342 Ureter Nephrectomy 
1344 Ureter Nephrectomy 
1387 Ureter Renal Transplant 
1426 Ureter Renal Transplant 
1456 Ureter Renal Transplant 
1470 Ureter Renal Transplant 
1483 Ureter Renal Transplant 
1493 Ureter Renal Transplant 
1497 Ureter Renal Transplant 
1526 Ureter Renal Transplant 
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1531 Ureter Renal Transplant 
1566 Ureter Nephrectomy 
1594 Ureter Renal Transplant 
1644 Ureter Renal Transplant 
1705 Ureter Renal Transplant 
1770 Ureter Renal Transplant 
1089 Renal Pelvis Pyeloplasty 
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8.2 List of Suppliers 
• Abnova  - http://www.abnova.com/ 
• Bioline - http://www.bioline.com/ 
• Bio-Rad - http://www.bio-rad.com/ 
• CellPath - http://www.cellpath.co.uk/ 
• Dako - http://www.dako.com/ 
• Dynex Technologies - http://www.dynextechnologies.com/ 
• Elga - http://www.elgalabwater.com/en-gb/ 
• Eurofins - http://www.eurofins.co.uk/ 
• Fisher Scientific - https://www.fishersci.com/us/en/home.html 
• Fumetec Limited - http://www.fumetec.co.uk/ 
• Greiner Bio-one - http://www.greinerbioone.com/en/start/ 
• Hendley-Essex - http://www.hendley-essex.com/ 
• Hettic - http://www.hettichlab.com/ 
• Jencos - https://uk.vwr.com/store/ 
• Leica Microsystems - http://www.leica-microsystems.com/home/ 
• Li-Cor- https://www.licor.com/ 
• Media Cybernetics - http://www.mediacy.com/ 
• Medical Air Technology - http://www.medicalairtechnology.com/ 
• Millipore - http://www.emdmillipore.com/ 
• Ohaus - http://europe.ohaus.com/europe/en/home.aspx 
• Olympus - http://www.olympus.co.uk/ 
• Philip Harris - http://www.philipharris.co.uk/ 
• Promega - http://www.promega.co.uk/ 
• ProteinTech - http://www.ptglab.com/ 
• Sarsedt - https://www.sarstedt.com/en/home/ 
• Scientific Laboratory Supples - http://www.scientificlabs.co.uk/ 
• Seralab - http://www.seralab.co.uk/ 
• Serotec - https://www.abdserotec.com/ 
• Sigma-Aldrich - https://www.sigmaaldrich.com/ 
• Source Bioscience - http://www.sourcebioscience.com/ 
• Starlab - http://www.starlab.de/int/?l=3 
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• Syngene - http://www.syngene.com/ 
• Thermo Scientific - http://www.thermoscientific.com/en/home.html 
• Vector Laboratories - http://vectorlabs.com/ 
• VWR - https://uk.vwr.com/store/ 
• World Precision Instruments - https://www.wpiinc.com/ 
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8.3 Stock Solutions 
8.3.1 General Lab Solutions 
8.3.1.2 Phosphate Buffered Saline (PBS) 
5 PBS tablets (Sigma) were dissolved in 1 L of dH2O. The solution was then autoclaved 
at 121° for 20 minutes, and cooled to room temperature before use. 
8.3.2 Cell Culture Solutions 
8.3.2.1 Transport Medium 
500 mL Hanks Balanced Salt Solution (HBSS; Gibco, Life Technologies) containing 140 
mg/L CaCl2, 100 mg/L MgCl2, 10 mM hydroxyethyl-piperazineethanesulfonic acid 
(HEPES) buffer (Gibco, Life Technologies) and 500 000 kallikrein inactivating units 
(KIU) Trasylol (Nordic Pharma). 
8.3.2.3 Stripper Medium 
500 mL HBSS (-Ca2+, -Mg2+; Gibco, Life Technologies) containing 0.1 % (w/v) EDTA, 
500 000 KIU Trasylol and 10 mM HEPES buffer (Gibco, Life Technologies).  
8.3.2.4 Cholera Toxin 
34.3 mL KSFM (keratinocyte serum-free medium; Gibco, Life Technologies) containing 
cholera toxin powder (Sigma Aldrich) was stored at 4°C until use. When diluted in 500 
mL KSFM-complete (KSFM with supplements) for use the final cholera toxin 
concentration was 30 ng/mL.  
8.3.2.5 0.1 % EDTA Solution 
1 L dPBS containing 1 g EDTA (Fisher Scientific) was autoclaved at 120°C for a duration 
of 20 minutes. The solution was then cooled before use. 
8.3.2.6 Collagenase IV Solution 
10 000 units of Collagenase IV powder (Sigma Aldrich) was dissolved in 100 mL HBSS 
(+Ca2+, +Mg2+) containing 10 mM HEPES buffer (Gibco, Life Technologies). The 
solution was then filter-sterilised using a 0.2 µM low protein-binding filter syringe 
(Gelman, Sigma Aldrich) before storage at -20°C.  
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8.3.2.7 Dispase II Solution 
dPBS was pre-warmed to 37°C before addition of dispase II powder to a final 
concentration of 0.5 % (w/v). The solution was then vortexed thoroughly, passed through 
Whatman 0 filter paper and filter sterilised using a 0.2 µM low protein-binding filter 
syringe (Gelman, Sigma Aldrich). The final solution was then aliquoted and stored at -
20°C until use.  
8.3.2.8 Trypsin Versene 
4 mL 1 % EDTA was combined with 20 mL 10x Trypsin (Sigma Aldrich) and then made 
up to 200 mL with HBSS (-Ca2+, -Mg2+; Gibco, Life Technologies). The solution was 
aliquoted and then stored at -20°C until use. 
8.3.2.9 Trypsin Inhibitor 
100 mg Trypsin inhibitor (Sigma) was dissolved in 5 mL dPBS, filter sterilised using a 
0.2 µM low protein-binding filter syringe (Gelman, Sigma Aldrich), aliquoted and stored 
at -20°C.  
8.3.3 Histology Solutions 
8.3.3.1 Haemotoxylin 
850 mL dH2O containing 0.3 g sodium iodate, 1 g citric acid and 50 g aluminium 
potassium sulphate was combined with 20 mL 100 % ethanol containing 3 g 
haemotoxylin. Once thoroughly mixed 120 mL glycerol was added.  
8.3.3.2 Scott’s Tap Water 
0.35 % (w/v) NaHCO3 and 2 % (w/v) MgSO4 in dH2O. 
8.3.3.3 10% Formalin  
900 mL PBS containing 0.9 mM CaCl2and 0.5 mM MgCl2 was added to 100 mL 37 % 
(v/v) formaldehyde.  
8.3.3.4 Tris-Buffered Saline (TBS) 
1 L dH2O containing 0.5 M Tris-HCL (Sigma Aldrich) and 0.15 M NaCl (SLS), pH 
adjusted to 7.6. 
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8.3.3.5 Tris-Buffered Saline plus Tween®20 (TBST) 
1 L dH2O containing 0.5 M Tris-HCL (Sigma Aldrich), 0.15 M NaCl (SLS) and 0.1 % 
Tween®20 (Sigma Aldrich), pH adjusted to 7.6. 
8.3.4 PCR Electrophoresis 
8.3.4.1 10x Tris-Borate-EDTA (TBE) Buffer 
1 L dH2O containing 0.9 M Tris, 0.9 M Boric acid and 25 mM EDTA. The solution was 
diluted to 1x using dH2O prior to use.  
8.3.5 Western Blotting 
8.3.5.1 2x Sodium Dodecyl Sulphate (SDS) Lysis Buffer 
20 % (v/v) glycerol, 2 % (w/v) sodium dodecyl sulphate (SDS), 18.4 mg sodium 
orthovanadate, 0.42 g sodium fluoride, 0.446 tetra-sodium pyrophosphate and 125 mM 
Tris-HCL (pH 6.8) made up to 50 mL with dH2O. The solution was then stored at -20°C.  
8.3.5.2 Transfer Buffer 
1 L dH2O containing 12 mM Tris, 96 mM glycine and 20 % (v/v) methanol. 
8.3.5.3 Tris-Buffered Saline (TBS) 
1 L dH2O containing 10 mM Tris and 140 mM NaCl, pH adjusted to 7.4. 
8.3.5.4 Tris-Buffered Saline plus Tween®20 (TBST) 
1 L dH2O containing 10 mM Tris, 140 mM NaCl and 0.1 % Tween®20 (Sigma Aldrich), 
pH adjusted to 7.4. 
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8.4 Primer Table 
Table 8: Details of primers used for experiments. 
Target Gene Forward or Reverse Sequence (5´-3´) Product Size (bp) 
GAPDH Forward CAAGGTCATCCATGACAACTTTG 90 
GAPDH Reverse GGGCCATCCACAGTCTTCTG 90 
HIF-1α Forward GCAGGGTCAGCACTACTTCG 684 
HIF-1α Reverse TTTCCTCAGTCGACACAGCC 684 
IRF-1 Forward CCTGCAGCAGAGCCAACATG 280 
IRF-1 Reverse AGGGAGTTCATGGCACAGCG 280 
MT-1A Forward CTCGAAATGGACCCCAACT 219 
MT-1A Reverse ATATCTTCGAGCAGGGCTGTC 219 
MT-1B Forward GGAACTCCAGGCTTGTCTTGG 77 
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MT-1B Reverse TTGCAGGAGGTACATTTG 77 
MT-1E Forward TGCGCCGGCTCCTGCAAGTC 118 
MT-1E Reverse ATGCCCCTTTGCAGACGCAGC 118 
MT-1F Forward CCTGCACCTGCGCTGGTTCC 110 
MT-1F Reverse ACAGCCCTGGGCACACTTGC 110 
MT-1G Forward CTTCTCGCTTGGGAACTCTA 309 
MT-1G Reverse AGGGGTCAAGATTGTAGCAAA 309 
MT-1H Forward CCTCTTCTCTTCTCGCTTGG 317 
MT-1H Reverse GCAAATGAGTCGGAGTTGTAG 317 
MT-1M Forward CTAGCAGTCGCTCCATTTATCG 180 
MT-1M Reverse CAGCTGCAGTTCTCCAACGT 180 
MT-1X Forward GGACCCAACTGCTCCTGCTC 151 
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MT-1X Reverse TTTGCAGATGCAGCCCTGGGC 151 
MT-2A Forward CCGACTCTAGCCGCCTCTT 259 
MT-2A Reverse GTGGAAGTCGCGTTCTTTACA 259 
MT-3 Forward AGTGCGAGGGATGCAAATG 98 
MT-3 Reverse GCCTTTGCACACACAGTCCTT 98 
MT-4 Forward CATGGACCCCAGGGAATGTGT 213 
MT-4 Reverse GGGGTGGGCACGATGGA 213 
TGF-β2 Forward GCGCTACATCGACAGCAAAG 381 
TGF-β2 Reverse CAATAGGCCGCATCCAAAGC 381 
ZO-1 Forward GTGTCTTCCCGGAGATCCAA 292 
ZO-1 Reverse GCCAATACCAACAGTCCCGT 292 
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8.5 Antibody Table 
Table 9: Primary antibodies used for research. *denotes antibodies that required use of the Impress IHC kit (see methods). 
Antigen Clone Host Supplier Dilution Molecular Weight 
(kDa) 
Beta-actin A5441 Mouse Sigma Aldrich 1:10 000 (WB) 42  
Claudin 7 34-9100 Rabbit Zymed 1:100 (IHC) - 
Cytokeratin 5 Ab53121 Rabbit Abcam 1:200 (IHC)  
Cytokeratin 7 LP1K Mouse CRUK 1:1000 (IHC) - 
Cytokertain 13 IHC: KS13.1 IHC: Mouse IHC: MP Biomedicals IHC: 1:10 - 
*FOXA1 HF3α Mouse Santa Cruz 1:250 - 
H3K27me3 C36B11 Rabbit Cell Signalling 1:400 - 
Ki67 MM1 Mouse Leica 1:200 - 
*Metallothionein 1A B01P Mouse Abnova 1:750 (WB) 6  
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1:500 (IHC)* 
*Metallothionein 1M 17281-AP Rabbit ProteinTech 1 µg/mL (WB) 
1:16 000 (IHC)* 
6 
Metallothionein 1/2 E9 Mouse Dako 1:800 (IHC) - 
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Table 10: Secondary antibodies used for research. 
Antigen Conjugate Host Supplier Application 
Anti-mouse IgG Alexa 680 Goat Life Technologies WB 
Anti-rabbit IgG Alexa 800 Goat Life Technologies WB 
Anti-mouse IgG Biotin Rabbit Dako IHC 
Anti-rabbit IgG Biotin Goat Dako IHC 
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8.6 Experimental Controls 
8.6.1 Cell Culture 
Induction of target gene expression was used as a positive control to ensure that treatment 
of cells with various compounds had been successful.  
 
Figure 622: Use of gene expression to ensure successful treatment of cells with a specific 
compound. In this case, CK13 gene expression was used in order to confirm differentiation of 
NHU cells treated with ABS and calcium.  
8.6.2 Treatment Titrations 
For treatments used in cell culture optimal doses were determined using concentration 
titrations and target gene expression changes.  
 
Figure 633: RT-PCR showing Sulforaphane (SF) titration to determine an optimal dose for 
inducing reactive oxygen species (ROS). Proliferating NHU cells (Y1344) were treated with a 
range of concentrations of the ROS-inducing agent SF for 12 hours, and the effect on the target 
gene HMOX1 transcript expression assessed in comparison to exposure to 10 µM CdCl2. The 
concentration of SF that induced expression of HMOX1 to a comparable extent to cadmium was 
selected. 
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Figure 64: RT-PCR showing ascorbic acid titration to determine an optimal dose for inhibiting 
production of reactive oxygen species (ROS). Proliferating NHU cells (Y1594) were treated with 
10 µM CdCl2 in combination with a range of concentrations of the ROS inhibitor ascorbic acid 
for 12 hours. HMOX1 transcript expression was used to infer levels of ROS. A reduction in 
transcript expression was therefore indicative of inhibition of ROS production. 
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8.7 Biological Experimental Replicates 
Below are supplementary figures detailing results from biological replicates of 
experiments shown in the main results chapters. The representative figure number is 
given, followed by the supplementary images from biological replicates. 
 
8.7.1 Biological Replicates from Representative Figure 22 
 
Figure 65: Phase contrast images of NHU cells cultured in the presence of cadmium for 48 
hours. Proliferating NHU cells (n=1; Y1270) were seeded at a density of 6x104 cells/cm2 and 
exposed to 10 µM CdCl2 for up to 48 hours. Arrows indicate formation of extended processes 
between the cells. Scale bar = 50 µm. 
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Figure 66: Phase contrast images of NHU cells cultured in the presence of cadmium for up to 
24 hours. Proliferating NHU cells (n=1; Y1426) were seeded at a density of 6x104 cells/cm2 and 
exposed to 10 µM CdCl2 for up to 48 hours. Arrows indicate formation of extended processes 
between the cells. Scale bar = 50 µm. 
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8.7.2 Biological Replicates from Representative Figure 25 
 
Figure 67: RT-PCR showing MT isoform transcript expression in proliferating NHU cells 
exposed to cadmium. Proliferating NHU cells (n=1; Y1426) were exposed to 10 µM CdCl2 for 
up to 12 hours, RNA was then extracted and MT isoform transcript expression assessed. PCR 
controls included genomic DNA as a positive control and dH2O as a negative control. GAPDH 
transcript expression was used as a loading control, and RT-ve samples confirmed the absence 
of genomic contamination.  
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Figure 68: RT-PCR showing MT isoform transcript expression in proliferating NHU cells 
exposed to cadmium. Proliferating NHU cells (n=1; Y1344) were exposed to 10 µM CdCl2 for 
up to 48 hours, RNA extracted and MT isoform transcript expression assessed. PCR controls 
included genomic DNA as a positive control and dH2O as a negative control. GAPDH transcript 
expression was used as a loading control, and RT-ve samples confirmed the absence of genomic 
contamination.  
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8.7.3 Biological Replicates from Representative Figure 32 
 
Figure 69: RT-PCR showing MT isoform transcript expression in cadmium-exposed 
differentiated NHU cell sheets that demonstrated a functional barrier. NHU cells (n=1; Y1493) 
were terminally differentiated and exposed to 10 µM CdCl2 for up to 72 hours. Differentiation 
was confirmed using TER readings and expression of KRT13. PCR controls included genomic 
DNA as a positive control and dH2O as a negative control. GAPDH transcript expression was 
used as a loading control, and RT-ve samples confirmed the absence of genomic contamination. 
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Figure 70: RT-PCR showing MT isoform transcript expression in cadmium-exposed 
differentiated NHU cell sheets that demonstrated a functional barrier. NHU cells (n=1; Y1531) 
were terminally differentiated and exposed to 10 µM CdCl2 for up to 72 hours. Differentiation 
was confirmed using TER readings and expression of ZO-1. PCR controls included genomic DNA 
as a positive control and dH2O as a negative control. GAPDH transcript expression was used as 
a loading control, and RT-ve samples confirmed the absence of genomic contamination. 
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8.7.4 Biological Replicates from Representative Figure 39 
 
Figure 71: RT-PCR showing the effects of ROS on MT isoform transcript expression in NHU 
cells. The chemical Sulforaphane (SF) was used to induce ROS, having been titrated to a 
concentration that mimicked the levels of cadmium-induced ROS. Proliferating NHU cells (n=1; 
Y1344) were treated with either 10 µM CdCl2 or 5 µM Sulforaphane for 12 hours and RNA 
extracted for analysis. The production of ROS was inferred using the ROS-sensitive HMOX1 gene 
transcript expression. PCR controls included genomic DNA as a positive control and dH2O as a 
negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
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samples confirmed the absence of genomic contamination. A positive genomic DNA control for 
HMOX1 expression was not possible due to intron-spanning primers (N/A; not applicable).  
 
 
Figure 72: RT-PCR showing the effects of ROS on MT isoform transcript expression in NHU 
cells. The chemical Sulforaphane (SF) was used to induce ROS, having been titrated to a 
concentration that mimicked the levels of cadmium-induced ROS. Proliferating NHU cells (n=1; 
Y1526) were treated with 5 µM Sulforaphane for 12 hours and RNA extracted for analysis. The 
production of ROS was inferred using the ROS-sensitive HMOX1 gene transcript expression. 
PCR controls included genomic DNA as a positive control and dH2O as a negative control. 
GAPDH transcript expression was used as a loading control, and RT-ve samples confirmed the 
absence of genomic contamination. A positive genomic DNA control for HMOX1 expression was 
not possible due to intron-spanning primers (N/A; not applicable).  
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8.7.5 Biological Replicates from Representative Figure 44 
 
Figure 73: RT-PCR showing the effects of exposure to the carcinogenic metals arsenite and 
nickel on MT-1 isoform transcript expression in NHU cells. Proliferating NHU cells (n=1; 
Y1526) were exposed to 2 µM NaAsO2 or 200 µM NiCl2 for 12 hours and MT-1 isoform transcript 
expression assessed. PCR controls included genomic DNA as a positive control and dH2O as a 
negative control. GAPDH transcript expression was used as a loading control, and RT-ve 
samples confirmed the absence of genomic contamination. 
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8.8 SOP for the Handling and Use of Cadmium Chloride 
8.8.1 Safety Protocol for the handling and use of Cadmium Chloride (Hazard Level 
Code: 4) 
General 
Cadmium chloride is a known human non-genotoxic carcinogen that causes cancer 
following inhalation or ingestion, targeting the lung and prostate, with evidence to 
suggest that bladder and kidney cancers are linked to cadmium. It is toxic if inhaled or 
swallowed and is an irritant to skin. It can also cause sensitization by inhalation and skin 
contact. Cadmium chloride is also very toxic to aquatic organisms and may cause long 
term adverse effects in the aquatic environment.  Inhalation of cadmium can be fatal. 
Precautions for safe handling are to avoid inhalation and contact with skin, eyes and 
clothing. Hands should always be washed after working with cadmium chloride. 
8.9.1.1 Personal Protective Equipment 
Nitrile gloves and lab coat are essential. The safety cabinet shield on the fume hood and 
tissue culture hood will provide adequate protection for eyes and inhalation risk. 
8.9.1.2 Storage 
The cadmium chloride powder stock container should be tightly closed, contain silica gel 
beads for removal of air moisture, and be stored in the lockable dangerous chemicals 
cabinet. The contained should be labelled with researcher name and date of opening.  
8.9.1.3 Weighing  
The transfer of cadmium chloride powder from the original container to a bijou/universal 
tube should take place in the fume hood. Place a tray lined with damp blue roll into the 
fume hood to collect any powder spillages. Predetermine if the air flow in the hood is too 
strong by testing whether a non-harmful powder gets blown off a spatula. If this does 
occur turn off the fume hood while dispensing the cadmium chloride and then turn on 
again once the cadmium chloride has been put in bijou/universal tube. 
 Using a disposable spatula carefully dispense a small amount of cadmium chloride 
powder into a pre-weighed bijou/universal in the fume hood over the lined tray. Once the 
cadmium chloride is in the bijou, seal up the bijou/universal and cadmium chloride 
containers and replace the latter in the dangerous chemicals cabinet. Take the 
bijou/universal containing the cadmium chloride powder to the balance and weigh it. 
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Calculate the correct volume of purified H20 needed for your stock solution based on the 
amount of cadmium chloride present in the bijou. Put any damp blue roll and disposable 
spatulas into a yellow clinical waste bag for incineration.   
8.9.1.4 Making up stock solution 
Where possible use the middle (externally vented) flow cabinet in the cell culture 
laboratory. Make up your stock solution in a tissue culture hood with the calculated 
amount of purified H20 needed. Sterilize by passing through a 0.2 µm filter, aliquot into 
microfuge tubes, label clearly and store in the -20 ºC freezer until use. 
8.9.1.5 Treatment of Cells  
Thaw aliquot. In the tissue culture hood dilute the cadmium chloride solution in medium 
to the desired treatment concentration. Apply this medium to the cells, changing medium 
every 2-3 days.  Aspiration of cadmium from cells should be performed using disposable 
serological pipettes taking care not to suck liquid into the filter of the pipette buoy.  Liquid 
waste should then be dispensed into a bottle containing 10 % (w/v) Virkon™ (ensuring 
that this remains pink).  Do not suck medium containing cadmium into the Virkon™ 
traps.   
8.9.1.6 Disposal 
Used filters, syringes, universal tubes, flasks, dishes, gloves, spatulas, blue roll etc. should 
be collected in small bags containing enough absorbent material to contain any leakage 
of excess liquids, sealed and then placed in a double-bagged clinical waste bag for 
disposal by incineration (take these bags to stores when half full).   Pipette tips and 
serological pipettes shouldn’t be placed in bags due to puncture risk; they should instead 
be placed in designated puncture-resistant ‘cin’ bins. 
 Stock powder should be either dissolved or mixed with a combustible solvent and put 
into Winchester bottles or retained in the original container and disposed of through the 
Biology Department internal chemical waste. Fill out an internal waste transfer note and 
take down to Biology Stores. 
 Liquid waste should be stored in a clearly labelled bottle, containing 10 % (w/v) 
Virkon™ if containing cell culture waste.  This bottle should be stored in the lockable 
dangerous chemicals cupboard and taken to biology stores with the appropriate 
paperwork when 90 % full.  Do not allow these bottles to sit long term in the dangerous 
chemicals cupboard. Take care to ensure that cadmium never enters the water system.   
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8.9.1.7 Spillage  
Spillage <1 g of stock powder should be wiped up immediately with damp blue roll, put 
in a container and disposed of in yellow clinical waste bag. Spillage >1 g of stock powder 
in the open lab requires the lab members to be evacuated from the lab and cadmium to be 
contained and collected into a container for disposal whilst wearing a respiratory face 
mask (ie. a FFP2 type face mask which is available from Biology Stores). Spillage >1 g 
of stock powder in fume hood requires the shield of the hood to be closed down and the 
hood to be left running for a few minutes to allow removal of any air-borne material. Any 
spilled material should then be collected onto damp blue roll and placed into a container 
for disposal. Liquid spillages should be mopped up with blue roll, put in a container and 
disposed of in a yellow clinical waste bag. 
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